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Effects of Adoptive Transfer of Beta-Amyloid Sensitive Immune Cells in a Mouse 
Model for Alzheimer’s Disease  
Daniel Shippy 
ABSTRACT 
 
One major therapeutic target for preventing and treating Alzheimer’s Disease (AD) is removal 
of excess β-amyloid (Aβ) from the brain.  Both active and passive immunotherapies targeting Aβ 
have proven effective in reducing brain Aβ levels and improving cognitive function in mouse 
transgenic models of AD.  However, these approaches can induce adverse neuropathologic effects 
and immunologic over-activation.  Indeed, clinical trials of active Aβ immunotherapy in AD patients 
were halted due to development of meningoencephalitis, apparently resulting from wide-spread 
neuroinflammation. Here we show that a more restricted and specific immune re-activation through 
a single adoptive transfer of Aβ-specific T cells can provide long-term benefits to APPsw+PS1 
transgenic mice that last at least 1½ months. Aβ-sensitive splenocytes and lymphocytes were 
generated in normal mice, re-stimulated with Aβ in vitro, and then adoptively transferred into 
cognitively-impaired APPsw+PS1 mice.  Compared to control transgenic mice through 1½ month 
post-infusion, those mice that received Aβ-sensitive T cells exhibited a reversal of pre-infusion 
working memory impairment and demonstrated superior basic mnemonic processing. Step-wise 
forward Discriminant Function Analysis of behavioral results clearly demonstrated that T cell 
infused mice performed comparably to wild-type non-transgenics, further emphasizing the extent of 
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cognitive benefit this therapeutic technique afforded.  Importantly, a global inflammatory response 
did not accompany these benefits.  Though no overall reductions in Aβ deposition were noted for T 
cell recipient mice, a subset of T cell infused mice that benefited most in cognitive function had 
reduced hippocampal burdens, suggesting that hippocampal Aβ burdes did play a role in determining 
performance capabilities of these mice.  Since chronically high levels of Aβ such as those found in 
APPsw+PS1 mice cause immune hypo-responsive/tolerance to Aβ, our results indicate that adoptive 
transfer of Aβ-sensitive T-cells can supercede such immune tolerance to Aβ, and may provide a safe, 
long-lasting therapy for AD. 
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Alzheimer’s Disease 
 
Alzheimer’s Disease Background 
 It is estimated that by the year 2050, 13.2 million individuals in the United 
States will be living with a diagnosis of Alzheimer’s Disease, further reinforcing its 
position as the most common neurodegenerative disorder and leading cause of 
dementia therein (Hebert et al. 2003).  Alzheimer’s is characterized by a progressive 
loss of cognition and retention accompanied by varied disruptions in behavior and in 
many cases extreme psychological disturbances.  These symptoms lead to eventual 
loss of social integration while at the same time stripping the affected individual of 
the ability to care for his or her self.  Death is the eventual end result of the disease, 
though it is often preceded by an extensive period of complete mobility loss and a 
comatose state.  The resulting widespread social and economic impact of caring for 
such afflicted individuals, already devastating today for many families affected by the 
disease, will undoubtedly continue to grow as Alzheimer’s becomes more prevalent.   
 Though treatments for Alzheimer’s have been approved by the FDA, none 
provide long-term reversal or delay of the disease and none serve as a cure (Doody et 
al. 2001, Areosa et al. 2005).  This, despite the fact that the disease was characterized 
nearly a century ago in 1907 by Dr. Alois Alzheimer, who correlated some of the 
behavioral impacts of the disease to the most noteworthy aspects of its pathology, 
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including dramatic loss of brain mass and development of both neuritic plaques and 
neurofibrillary tangles as well as gliosis (Alzheimer et al. 1995).  Even with the surge 
of research activity which has occurred within this field over the past several decades 
resulting from both its increased prevalence and from increased exposure due to 
diagnosis of Alzheimer’s Disease in such noteworthy figures as President Ronald 
Reagan, progress in developing treatments and determining preventative measures 
has been slow at best.  Recent innovative studies involving varied immunotherapeutic 
approaches have explored outside the field of typical pharmacological treatments and 
have shown promise, however have at the same time been a source of major 
disappointment in human applications.  With increased understanding of the faults of 
such treatments, it is possible that alternate immunological approaches may lead to 
valid treatments for Alzheimer’s. 
Behavioral Characterization of AD 
 Due to the progressive nature of Alzheimer’s Disease and to the incomplete 
understanding of its development, it has proven useful for clinicians to establish a 
staging sequence for Alzheimer’s behavioral impacts.  Prior to development of 
dementia, it is thought that most individuals enter a transition state termed Mild 
Cognitive Impairment (MCI).  It is estimated that up to 15% of individuals diagnosed 
with MCI proceed to Alzheimer’s development each year, though many are 
diagnosed with AD without a prior MCI diagnosis (Feldman et al. 2004).  Using 
mainly the extent of cognitive impairment present, Alzheimer’s patients can then be 
grouped as early, moderate, or advanced phase.  Only after death can a true 
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verification of AD diagnosis occur via correlation with specific Alzheimer’s 
pathology. 
 A diagnosis of Mild Cognitive Impairment does not always correlate to 
development of AD, though the term was specifically developed to describe a state of 
lesser impairment preceding Alzheimer’s.  It is thought that some limitations of MCI 
application may be due to variations in symptom sets used to define it and reliance on 
the testimonies of patients and relatives for establishing a history of memory 
disruption (Davis and Rockwood 2003).  Still, MCI is considered a strong risk factor 
for AD development and is therefore clinically relevant.  MCI is characterized by 
reported working memory deficits, verified to be more significant than is normal for a 
patient’s age, with no loss of other functions.  Recent studies have also found that 
certain patterns of neuropsychiatric symptoms are present in up to 59% of subjects 
diagnosed with MCI, including various mood abnormalities and psychosis.  In fact, 
there appears to be a correlation between presence of neuropsychiatric symptoms 
common in AD and progression from MCI to early Alzheimer’s (Feldman et al 2004, 
Hwang et al 2004).       
 During the initial phase of AD, mild to moderate cognitive impairment with 
respect to short-term memory is present and is definitive for diagnosis during the life 
of the patient (McKhann et al. 1984).  Specific behavioral deficits and abnormalities 
are present throughout AD and may show some correlation to staging determined by 
working memory deficits, though it should be noted that many of these symptoms are 
not consistently present on an individual basis.  Other major clinical features often 
associated with the disease include language and visuospatial deficits, though the 
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former may not appear until mid or often late phase AD.  Behavioral symptoms such 
as depression, agitation, anxiety, aggression, and insomnia, as well as psychological 
symptoms such as delusions and hallucinations have been found to accompany these 
deficits during early phase AD, though again these symptom sets are more prevalent 
in later AD phases (Moran et al. 2003).  These symptoms are often coupled with 
functional behavioral impacts such as errors in judgment, untidiness, and transient 
confusion as the disease progresses.  Not all symptoms are present in all patients, they 
occur in widely varied percentages of individuals in this phase of the disease.  Moran 
et al. recently described three classes of early phase AD patients based on observed 
symptom sets, the first with little to no symptoms outside of memory deficits, the 
second with additional symptoms related mostly to anxiety and depression, and the 
third with additional aggression-based symptoms.  Such grouping methodologies 
could prove useful in understanding the basis of these symptoms if correlation to 
neuropathology can be made. 
 Entry into moderate phase AD is established based on continued loss of short-
term memory coupled with new, progressive loss of long-term memory.  Other 
symptoms described for MCI and early phase AD are common to moderate phase AD 
as well. Language deficits, which tend to develop later than visuospatial disruptions, 
become especially prevalent by the time a patient enters moderate AD.  Finally, it is 
not uncommon for both behavioral and psychological disturbances developed during 
MCI or early phase AD to become even more severe before being lost to immobility 
and stupor common to advanced phase AD (Hart et al. 2003).  Advanced phase AD 
involves an almost complete loss of all memory forms and entry into a vegetative 
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state which continues until death due to illness or systemic loss of bodily functions 
occurs.   
 In a retrospective study, Hart et al. showed that depression, delusions, and 
anxiety are the most prevalent of the psychological symptoms present throughout AD, 
although hallucinations, elation, and disinhibition may also occur.  Numerous studies 
have also shown that apathy, motor disturbance, aggression, irritability, appetite 
changes, and sleep disturbances are all relatively common behavioral symptoms for 
AD (Hart et al 2003, Moran et al 2003, Lyketsos et al 2001).  Of these, apathy 
appears to be the most prevalent form of behavioral change which occurs.  
 From the time of diagnosis of AD, an individual may often live as long as 
twenty years.  With further development of correlations between certain forms of 
MCI and progression to AD, the time with which an individual and his or her family 
may live with such a diagnosis is ever increasing, further reinforcing the importance 
of developing a treatment for the disease. 
Pathological Characterization of AD 
 Although it was Dr. Alois Alzheimer who first described the general 
pathological characteristics of AD, an understanding of the true molecular nature of 
these markers could not be gained until the 1960s when electron microscopy allowed 
for more detailed analysis of neuritic plaques and neurofibrillary tangles (NFT’s), the 
two hallmark brain pathologies of the disease (Kidd 1964).  In the decades since, 
numerous hypotheses regarding the cause of this pathology and its correlation to 
behavioral impacts as well as other AD pathological characteristics have been 
formulated.  Perhaps the most widely acknowledged of these focuses on the presence 
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of a particular protein fragment, Beta-amyloid (Aβ), in the brain and has thus been 
termed the amyloid hypothesis.  Other AD pathologies such as brain atrophy, 
neuronal dystrophy, synaptic loss, and NFT formation are thought to be tied in some 
way to Aβ peptide formation in the CNS under this hypothesis. 
 Aβ is formed from proteolytic processing of the Amyloid Precursor Protein 
(APP), a 695-770 amino acid protein typically found in membranes of many cell 
types throughout the body.  APP contains three relevant cleavage sites which are 
discriminately cleaved by the α, β, and γ-secretase complexes.  α-Secretase cleaves 
within the Aβ domain of the APP molecule, preventing formation of Aβ, while 
sequential cleavage by β and γ secretases is needed for amyloidogenesis.  The activity 
of these latter two enzymatic complexes appears to be increased in later life and even 
more so in AD (Canevari et al. 2004).  While Aβ is produced in and can be found in 
fairly low concentrations throughout the body, it is its activity within the CNS which 
appears to be relevant to AD, both in regards to formation of neuritic plaques as well 
as through its presence in a soluble form.  This is not to suggest that peripheral Aβ is 
not relevant to the disease, however, as it has been shown that Aβ is capable of 
passing through the blood brain barrier (BBB) (Zlokovic 2004).  Some studies in 
animal models have even suggested that Aβ may be able to trigger disruptions in the 
BBB, which is commonly disrupted in AD patients (Farkas et al. 2003). 
 Two isoforms of the Aβ peptide can be found within neuritic plaques.  Most 
contain the 42 amino acid isoform (Aβ1-42), though this isoform is actually less 
common elsewhere in the CNS than the second Aβ1-40 peptide.  The Aβ1-42 peptide is 
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thought to be one of the initiating factors for neuritic plaque formation, originally 
aggregating to form what are known as low density or diffuse plaques (Lemere et al. 
1996).  Inflammatory proteins such as APOE and α-ACT, along with a number of 
other proteins produced by various cells of the CNS, are also thought to contribute to 
formation of these plaques (Nilsson et al. 2004).   
 Though the exact nature of plaque formation progression is not understood, it 
appears that these diffuse plaques are precursors to the compact plaques noted by Dr. 
Alois Alzheimer.  It is further acknowledged that as these plaques form there is an 
activation of microglial cells which, via secretion of various cytokines, induce 
activation of adjacent astrocytic cells, resulting in a co-stimulatory inflammatory 
response which may accelerate plaque maturation (D’Andrea et al. 2004).  Other 
immune cells such as B and T-cells appear to be involved in regulation of this 
response.  Cytokines such as IL-1 and TNF-α also act by inducing APP messenger 
RNA translation, resulting in further increase in Aβ production (Rogers et al 1999).  
Inflammatory proteins such as APOE and α-ACT are produced as part of the 
response and may be involved in further Aβ deposition by catalyzing conversion of 
Aβ to a β-pleated sheet form which is prone to aggregation (Nilsson 2001).  
Degradation of adjacent neuronal dendritic and axonal processes further increases the 
local inflammatory response via release of intercellular inflammatory factors as well 
as additional degrading lysosomal and cytoplasmic enzymes, resulting in even further 
damage to surrounding cells.  This form of damage elicited by Aβ plaques has caused 
this peptide to be termed “neurotoxic”.  During this process, Aβ1-42 deposition 
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continues coupled with Aβ1-40 incorporation, finally resulting in formation of compact 
(mature) neuritic plaques, each of which is composed of a dense Aβ core surrounded 
by reactive microglia and astrocytes and associated with inflammatory proteins such 
as APOE and α-ACT. (Selkoe 2001, Nilsson et al. 2004). 
 Diffuse versions of the neuritic plaque can be found in various regions of the 
brain, both inside and outside of the hippocampus and association cortices, which are 
the regions most affected with regard to neuronal loss and NFT formation as well as 
neuritic dystrophy associated with Aβ pathology.  Neuronal loss and other AD 
pathologies, including various forms of neuroarchitectural rearrangements in these 
regions, are thought to correlate to the losses in working memory noted in AD.   It is 
primarily in these regions that high levels of compact neuritic plaques can be found, 
further reinforcing the importance of these plaques with regards to AD pathology.   
 It is important to note that Cerebral Amyloid Angiopathy (CAA) is a 
pathological feature common in AD which is also directly caused by deposition of 
Aβ, this time within the vasculature.  Amyloid plaques formed within blood vessels 
can lead to microhemmorages and in some cases instigate a stroke.  Approximately 
80% of individuals over the age of 65 diagnosed with AD are thought to develop 
CAA. 
 Other aspects of this pathology have been linked to Aβ presence, though not 
necessarily in compact, aggregated form.  Aggregation is thought to begin 
intracellularly, with Aβ1-42 fragments twisting together to form first dimmers and then 
various oligomeric isoforms (Selkoe 2001).  Such intracellular Aβ is thought to 
   
16 
influence phosphorylation of tau proteins (Cummings 2004).  This phosphorylation 
event is known to be linked to imbalances in cellular kinases and phosphatases.  Tau 
proteins are microtubule components that, when phosphorylated, can twist together in 
α-helical pairs to form Paired Helical Filaments (PHFs).  These accumulate to form 
true NFTs, resulting in disruption of neuronal function and eventually cell death 
(Canevari et al. 2004 and Sobow et al.2004).   
 Loss of cholinergic system functions is another major hallmark of AD, and 
this too has been linked to Aβ activity.  Aβ is thought to interact with nicotinic 
receptors of cholinergic neurons, specifically by binding to α7 nACh Receptors 
(Kihara and Shimohama 2004).  This interaction is thought to result in inhibition of 
calcium activation and acetylcholine release in these neurons, indicating a mechanism 
for loss of function in cholinergic pathways.  Aβ is also thought to enhance glutamate 
excitotoxicity via NMDA receptor interactions.  These specific interactions between 
Aβ and neurons prone to dysfunction in AD strongly reinforce the importance of the 
peptide in the progression of AD, as loss of memory and cognitive functions have 
been linked to disruption of these pathways (Kihara and Shimohama 2004).   
 Further Aβ involvement via activation of caspases has also been proposed, 
indicating a mechanism by which cellular apoptosis, a widespread occurrence within 
the CNS in AD, may be induced (Eckert et al. 2003).  Interactions between Aβ and 
mitochondrial membrane transporters along with mitochondrial enzymes are thought 
to be involved in decreased mitochondrial activity.  This has been proposed as one 
mechanism for high levels of oxidative stress found in AD (Canevari et al. 2004, 
Marlatt et al. 2004).   
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 Aβ is also though to disrupt Ca++ transport in neurons, astrocytes, and 
microglia.  Alteration of Ca++ transport functionality has been linked to alterations in 
neuronal signal processing, increased neuronal vulnerability to excitotoxicity, and 
activation of both microglia and astrocytes (Cavevari et al. 2004).  Aβ can also be 
linked to production of oxygen free radical species, which occurs during oxygen 
dependent formation of Aβ β-pleated sheets.  Free radicals are also formed by 
microglia upon activation by Aβ.  These reactive species are thought to play a 
substantiative role in triggering oxidative damage prevalent in AD.  This damage 
tends to affect mainly lipids and DNA, and is 3 times more prevalent in AD than in 
normal elderly individuals (Hensley et al. 1996, Selkoe 2001).  Thus, many of AD’s 
pathological features can be attributed to abnormal production and function of Aβ 
within the brain.  However, it should be noted that there are also several lines of 
evidence which suggest that the amyloid hypothesis described above may be incorrect 
or at the very least incomplete.   
 Those malcontent with the amyloid hypothesis have emphasized an inability 
of the hypothesis to explain early neurophysiological developments such as synaptic 
dysfunction, neuronal loss, and decreased LTP, which occur in varying extents before 
formation of Aβ plaques in AD.   It has been suggested that Aβ accumulation, like 
NFT formation, is truly more a consequence of a separate cellular dysfunction, not 
yet entirely elucidated, which occurs before overproduction and aggregation of the 
peptide.  This is supported by findings in transgenic mice which indicate that synaptic 
dysfunction may occur before formation of diffuse or compact amyloid plaques (Lee 
et al. 2004).  It has even been shown that Aβ may be involved in regulation of long-
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term potentiation, indicating that the peptide is not simply a neurotoxic by-product 
and that its presence in AD may be an attempt at compensating for neuronal loss, not 
necessarily the cause of it (Koudinov and Berezov, 2004).  It should be noted that 
other studies have shown the opposite effect of the peptide in lowering capacity for 
LTP (Selkoe 2002).   
 Other hypothesis for the actual mechanisms underlying AD focus on cell 
cycling and mitochondrial enzymatic disruptions which result in oxidative stress and 
neuronal loss and on abnormal levels of enzymes involved in acetylcholine synthesis 
and degradation (Raina et al. 2004, Zhu et al. 2004). While it is necessary to consider 
these possibilities in seeking an understanding of, and a treatment for, Alzheimer’s, it 
is also important to consider in the present that previous studies have shown 
correlation between Aβ levels within the CNS and extent of demetia in early stages of 
AD (Bussiere et al., 2002), though Aβ load does not correlate directly to cognitive 
disturbances as the disease progresses (Terry et al. 1991).  Similar correlation can be 
made between Aβ plaque loads and cognitive impairment in transgenic mouse models 
of AD (Gordon et al. 2001).  Synapse loss and neurodegeneration induced by 
neurofibrillary tangles serve as better correlates to cognitive impairment (Terry et al. 
1991, Arriagada et al. 1992).  However, as has been shown above, these pathological 
findings may be tied to and perhaps even directly caused by the presence of Aβ.  
Also, as elicited above, there are numerous studies which have shown mechanisms by 
which Aβ can be neurotoxic and/or can have other negative physiological impacts 
within the CNS even in soluble form.  Therefore, regardless of other mechanisms 
involved in development of AD, there remains definite validity in searching for a 
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means to elicit Aβ clearance as a means of treatment for the disease or for preventing 
Aβ formation/aggregation as a means of prevention. 
Genetics of AD 
 Further support for the amyloid hypothesis is provided by analysis of known 
genetic mutations linked to Familial Azheimer’s Disease (FAD).  FAD typically 
follows a similar time course to sporadic AD, which has no known genetic basis, and 
differs only with regards to age of onset.  FAD diagnosis typically occurs at a much 
younger age, as early as 40, than sporadic AD.  Each mutation linked to FAD, which 
by definition is congenital and runs within families, has an in vivo effect of increasing 
Aβ peptide formation, and is an autosomal dominant trait.  However, only as few as 
one percent of reported AD cases are currently attributed to FAD.  The mutations 
linked to FAD thus far include those of the APP gene itself, along with those of the 
presenilin genes (PS1 and PS2) (Zekanowski et al. 2004, Selkoe 2001). 
 In 1984, Glenner and Wong proposed that genetic defects in Alzheimer’s 
disease would be found on chromosome 21 after discovering that the amyloid protein 
prevelant in both Alzheimer’s disease and Down’s syndrome pathology were 
homologous (Glenner and Wong, 1984).  Indeed, it has been found that mutations of 
the APP gene which have been linked to FAD are located at either end of the Aβ 
coding domain on chromosome 21p21.  There are 16 unique mutations of the gene 
which promote AD pathology and 4 which do not, though only 4-6% of FAD cases 
are attributed to APP mutations.  The result of each mutation is increased Aβ peptide 
formation, most likely through increased processing of the APP molecule by β or γ 
secretases.  With regards to current research in transgenic models, two of the most 
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relevant of these are the Swedish and London APP mutations.  The Swedish mutation 
is located at positions 670 and 671 of the APP molecule and involves a double 
missense mutation, while the London mutation, which is a single missense mutation, 
is located at position 717.  These correlate to the domains cleaved by the β and γ 
secretases.  Both mutations result in dramatic increases in overall Aβ production, with 
varying ratios of Aβ1-40 to Aβ1-42 produced.  Specifically, the London mutation results 
in an increased ratio of Aβ1-42 to Aβ1-40 while raising levels of both isoform overall, 
whereas the Swedish mutation results in approximately equal increases in the levels 
of both isoform (Eckman et al. 1997, Suzuki et al. 1994). 
 As with the London mutation, it is production of the Aβ1-42 peptide which is 
most increased as a result of the presenilin (PS) mutations.  It is thought that both the 
PS1 and PS2 molecules are incorporated into the γ secretase complex and serve as 
part or all of the active site for this complex (Farmery et al. 2003).  The proteins are 
generally found in endoplasmic reticulum of cells and most likely act on APP during 
its processing via this organelle.  The result of the presenilin mutations is increased 
activity of the γ secretase complex, resulting in increased amyloidogenic processing 
of APP.  The PS1 gene codes for a 467aa protein and is located on chromosome 
14q23.3, while the PS2 gene codes for a 448aa protein and is located on chromosome 
1q31-42.  The genes are highly homologous in their sequences, indicating a similar 
function.  PS1 mutations are the most common cause of FAD based on current data, 
and more than 100 of these mutations have been identified, most of which are 
missense.  Only 9 PS2 mutations have been identified, all of which are missense, and 
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the prevelance of these mutations is significantly lower than those of PS1 (Kimberly 
and Wolfe 2003, Gaskell and Vance 2004). 
Diagnosis of AD 
 The predominant criteria used for the diagnosis of Alzheimer’s comes from 
the National Institute for Neurologic and Communicative Disorders and Stroke-
Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA), which 
specifies diagnosis as being either definite, probable, or possible based on the extent 
of confirmation available.  If a histological confirmation, preceded by clinical 
diagnosis, is obtained, then a definitive diagnosis for AD is established.  Clinical 
diagnosis without histological confirmation is deemed as a probable AD case, while a 
case with clinical abnormalities but no other diagnostic approaches available is 
considered possible AD (Cummings 2004). 
 The specific clinical features looked for in diagnosing AD are the three major 
behavioral hallmarks of the disease; episodic and working memory impairment and 
both language and visuospatial deficits.  Episodic memory is based on retrieval of 
memories of one’s specific past events, typically with events which have occurred 
recently being most easily forgotten (Cummings 2004, Greene et al. 1996).  Working 
memory, or short-term memory, is typically associated only with the ability to recall 
occurrences from within minutes of the present.  Loss of both episodic and working 
memory, which largely correlates to general anterograde amnesia, is perhaps the 
easiest of the behavioral hallmarks of AD to identify and the most important for 
establishing clinical diagnosis (Welsh et al. 1992, Greene et al. 1996).  There are 
many tests which can be administered by clinicians in able to determine if such 
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memory loss is present and extent of impairment, including the most common, the 
Mini-Mental State Exam (MMSE), which involves giving a patient number of words 
to remember followed by a series of questions which serve as a distraction.  An 
individual’s lack of ability to retain the words given to them at the beginning of the 
task (registration-recall) is an indicator of short-term memory impairment.  Other 
tools for evaluating mental state of potential AD patients include the 7-Minute Screen 
and Geriatric Depression Scale (Langbart 2002). 
 Basic histological measurements which may be correlated to memory 
impairment to help strengthen a diagnosis of AD include cerebro-spinal fluid (CSF) 
levels of Aβ1-42 and both tau and phospho-tau (p-tau) proteins.  Numerous studies 
have shown that a dramatic decrease in CSF Aβ1-42 is prevalent in AD (Sobow et al., 
2004; Andreasen et al., 2003).  This is thought to correlate to trapping and 
aggregation of the peptide in insoluble forms within the CNS, allowing the brain to 
act as an Aβ1-42 “sink”. At the same time, levels of both tau and p-tau in the CSF 
increase significantly in most cases of AD (Sobow et al., 2004; Andreasen et al., 
2003).  Unfortunately, CSF sample collecting is a highly invasive process, making 
widespreade clinical application of these histological markers difficult.  Current 
research studies in the area of Aβ and tau levels in the plasma or other more 
accessible fluids are ongoing (Sobow et al. 2004). 
 Several brain imaging techniques also serves as diagnostic tool for AD.  
Computed tomography (CT) and magnetic resonance imaging (MRI) have proven to 
be useful as multiple scans over time can show overall brain atrophy and localized 
atrophy of the hippocampus and entorrhinal cortex (Barnes et al., 2004; Pennanen et 
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al., 2004; de Leon et al., 1997).  This form of atrophy is specific to AD, allowing for 
exclusion of other dementia types, and can also be used to monitor the progress of the 
disease.  In some cases it is possible to detect this atrophy during MCI, allowing for 
anticipation of an imminent diagnosis of AD.  Importantly, studies of AD patients 
have shown direct correlation between hippocampal atrophy and memory 
impairment, specifically short-term memory (Grundman et al. 2003).  Similarly, 
overall atrophy of the cerebral cortices has been correlated to long-term memory and 
memory retrieval impairment in AD (Bilgler et al. 2004).  As discussed above, this 
atrophy is likely caused by neuronal loss and restructuring common in these areas 
during AD progression.  More recently, positron-emmision tomogrogphy (PET) and 
single-photon-emission CT scans have been applied to diagnosis of Alzheimer’s.  
These scans allow for analysis of regional brain activities, and can target deficits in 
activity in regions affected by AD (Cummings 2004, Minoshima 2003).  Recently, 
the possibility of a technique for imaging of amyloid plaques using a modified 
version of the PET scan has been explored which may prove to be a very useful 
diagnostic tool in the future (Klunk et al. 2003). 
 A diagnosis of AD, whether it be definitive, probable, or possible, in a family 
with a strong history of the disease with early onset is sufficient cause for genetic 
testing for FAD.  Tests are clinically available for presenilin mutations, however their 
application is limited and no such tests are available for APP mutations.  Since there 
are numerous mutations which may be present in these genes which do not result in 
FAD, it is important that both physician and patient be well informed before genetic 
testing results are reviewed.  Extensive Genetic counseling is an important aspect of 
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this education, meaning that genetic testing for FAD must typically occur through a 
hospital with trained genetic counseling staff and should not be performed at a 
standard physician’s office.  As more FAD mutations and their resulting phenotypes 
become better understood, it is likely that the availability of genetic testing will 
spread.  In the present, the results of genetic testing for FAD are not definitive for 
diagnosis but can confirm the presence of a FAD mutation in a family, which may 
prove useful for such families in preparing for the disease financially and via 
preventative measures (Gaskell and Vance 2004, Zekanowski et al. 2004). 
Risk Factors for AD 
 Certain risk factors for AD such as the most significant one, aging, are in no 
way preventable.  Other examples of these include sex (females run a higher risk of 
developing AD than do males), having a first degree relative with AD, and carrying 
the ApoE4 allele of the ApoE gene.  The ApoE allele is an extremely important risk 
factor for AD, with each ApoE4 allele carried resulting in a sizable increase in AD 
risk and typically earlier onset of the disease if developed (Selkoe 2001, Yao et al. 
2004).  Other risk factors for Alzheimer’s may be prevented or treated, making them 
particularly important for individuals already at a high risk for AD. 
 Preventable AD risk factors include head trauma (especially in young 
adulthood), high blood pressure in midlife, high cholesterol levels in midlife, high 
blood homocysteine levels, and a number of factors related directly to diet (Fleminger 
et al. 2003, Wellington 2004, Ellinson et al. 2004).  High levels of social interaction, 
mental engagement, and exercise are thought to be related to lowering risk for 
developing AD as well via cognitive stimulation.  Diet and exercise are also indirectly 
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important for regulation of blood pressure and cholesterol levels (Wang et al. 2004).  
Reduction of cholesterol by use of statins has also been strongly linked to a decreased 
risk for AD (Miller and Chacko 2004).  Blood homocysteine levels can be regulated 
by intake of vitamins B6, B12, and folic acid, which are involved in metabolism of 
the molecule (Ellinson et al. 2004).   
 Other dietary considerations for preventing AD include decreasing caloric 
intake, increasing intake of Tocopherol (Vitamin E) and other antioxidants, and/or 
increasing dietary levels of Omega-3 fatty acids (Berman and Brodaty 2004, Bourre 
2004).  Antioxidants are important for defending the brain against oxidative damage, 
and some epidemiological studies looking at dietary antioxidant levels, especially 
Vitamin E levels, have shown a negative correlation between intake levels and risk 
for AD development, though clinical trials have elicited mixed results (Berman and 
Brodaty 2004, Sobow and Kloszewska 2003).  The antioxidant properties of Vitamin 
E are important in AD largely because they prevent membrane lipid peroxidation, 
reducing oxidative damage in the brain.   
 It is thought that Omega-3 fatty acids such as Docosahexaenoic acid (DHA) 
are important for neuronal health and may directly impact APP processing.  
Epidemiological studies indicate that decreased dietary levels of fish, which contain 
high levels of DHA and other fatty acids, can be considered a risk factor for AD 
(Bourre 2004, Kalmijn et al. 1997).  A diet high in fruits and vegetables along with 
fish results in increased uptake of various antioxidants and n-3 fatty acids, and 
patients at risk for Alzheimer’s are often encouraged by doctors to pursue such diets 
both because of the direct impact of these molecular components and the indirect 
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impact of such diets on cholesterol levels.  Other dietetic factors which have been 
linked to decreased AD risk include regular intake of nicotine, caffeine, and alcohol, 
though for each of these it has yet to be determined if possible preventative 
capabilities of these drugs outweigh risks associated with their use or abuse (Dall'Igna 
et al. 2004, Teaktong et al. 2004, Letenneur et al. 2004). 
 Recently, the importance of environment with respect to AD risk has been a 
major point of emphasis in Alzheimer’ research.  It is becoming apparent that 
education level, social integration throughout life, and engagement in mentally 
stimulating activities such as writing and working puzzles has some level of 
protection against AD development (Fratiglioni et al. 2004).  Most risk factors for AD 
have been determined through epidemiological studies, so their exact role and 
mechanism of protection are difficult to define and are often tied to those of other risk 
factors, such as with cholesterol, diet, and exercise.  Fortunately, most actions that 
individuals can take to help in prevention of AD are generally encouraged as part of a 
standard healthy lifestyle and can be undertaken without a full understanding of their 
effectiveness. 
Current Treatments of AD 
 There are currently five pharmacological treatments for AD which have been 
approved by the FDA.  Tacrine (which is no longer used clinically due to its negative 
impact on the liver), donepezil, rivastigmine, and galantamine are all 
acetylcholinesterase inhibitors, while the fifth drug, memantine, is an antagonist for 
NMDA-receptors (Cummings et al. 2004).  Acetylcholinesterase inhibitors have been 
applied clinically in the United States for many years, and are directed against lost of 
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cholinergic function in AD.  By inhibiting acetylcholinesterase, which breaks down 
acetylcholine, cholinergic transmissions are increased due to raised levels of the 
neurotransmitter in the synaptic cleft.  Galantamine also acts as an allosteric ligand at 
nicotinic acetylcholine receptors, further improving cholinergic function.  
Rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase, which is 
another cholinesterase largely associated with glial cells (Scarpini et al. 2004).  
Treatment with these drugs brings about improvement or stabilization in cognitive 
symptoms of mild to moderate AD, however these improvements are small and do 
not typically last for more than 1-2 years.  Studies are ongoing to determine whether 
long-term use is at all beneficial (Scarpini et al. 2004, Sonkusare et al. 2005). 
 Memantine was only recently approved for treatment of AD by the FDA.  By 
acting as a partial NMDA-receptor agonist, this drug helps to prevent excitotoxic over 
activation of these receptors by glutamate, which is thought to be present in elevated 
levels in AD (Sonkusare et al. 2005).  Normal levels of NMDA-receptor activation 
are desirable due to their importance in long-term potentiation, however, since these 
receptors allow long periods of Ca2+ influx into cells upon activation, having too 
many receptors open for extended periods may lead to Ca2+ mediated neuronal 
degeneration.  Proper administration of memantine appears to be able to prevent this 
type of excitotoxicity while allowing for normal levels of receptor activation.  This 
treatment leads to improved cognitive and behavioral functions in the short term over 
placebo.  Studies combining memantine and donepezil treatments have shown great  
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promise in short term treatment of moderate to severe AD (Tariot et al. 2004).  Still, 
as with the other approved treatments for AD, memantine’s effects are relatively 
small and short lived, emphasizing the importance of continued research in the field 
of alternative AD treatments (Scarpini et al. 2004). 
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Animal Models of Alzheimer’s Disease 
 
 Various animal models for Alzheimer’s Disease have been developed based 
on a persistent need for an easily reproduced and cost effective means for studying 
behavioral and pathological progression of the disease.  These models have since 
become invaluable in evaluating potential therapeutics and preventatives.  The most 
commonly used method for producing these models in mice is through random 
insertion of the desired gene into a fertilized mouse egg genome via microinjection or 
electroporation.  Mice models are desirable because they age quickly for a 
mammalian animal, and are relatively easy and cheap to maintain as colonies.  The 
genes inserted to create these mice are mutant-type human transgenes which are 
either linked to FAD, such as mutant APP and presenilin alleles, or which are known 
risk factors for AD, such as the ApoE4 allele.  In order for these inserted mutations to 
exhibit profound effects in subsequent generations of transgenic mice, they are 
inserted with strong promoters specifically activated in the mouse brain.  For FAD 
APP transgenes, the result is massive production of Aβ in the brains of the resulting 
transgenic animals which then leads to progressive deposition of this protein fragment 
to form neuritic plaques in the CNS.  Models based on these mutations include the 
PD-APP, Psw (APP23), and APPsw transgenic mice.  Other mutations work in 
conjunction with these in double transgenic models to further enhance Aβ production 
   
30 
and/or deposition, but are not sufficient to induce neuritic plaque formation in single 
transgenic models.  An important example of this type of double transgenic model is 
the APPsw+PS1 mouse. 
PDAPP Model 
 Mice transgenic for the “London mutation” human allele of the APP gene 
were initially described in 1995 and have since been termed PD-APP mice due to use 
of a platelet-derived growth factor promoter for driving expression of the gene.  As a 
result of using this promoter, PD-APP mice express human APP (hAPP) at levels 
approximately 10 times greater than expression levels in human AD brains. This 
allows for pathology development during the relatively short lifetime of the mice.  
mRNA expression consists of three major variants due to alternative splicing of exons 
7 and 8 of the APP gene construct.  Over-expression of hAPP containing the 717 
single point mutation of Valine to Leucine in the PD-APP mouse brain leads to 
development of pathology and behavior which correlates in many ways with that of 
Alzheimer’s Disease (Games et al. 1995). 
Pathological Characterization of the PDAPP Model 
 AD-type pathology begins to exhibit itself in PD-APP mice between 6 and 9 
months when deposits of Aβ can be detected in plaques formed solely in the 
hippocampus, corpus callosum, and cerebral cortex.  Deposition continues past this 
timepoint until plaque levels parallel or exceed those found in AD.  The plaques 
noted in PD-APP mice brains range from diffuse to compact, and compact plaques 
consist of an Aβ core surrounded by activated astrocytes and microglia, just as is 
typical for AD neuritic plaques (Games et al. 1995).  While these mice do not exhibit 
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cerebral atrophy or widespread neuronal loss, key features of Alzheimer’s pathology 
in humans, they do exhibit a loss of both synapses and dendrites in the hippocampal 
dentate gyrus coupled with overall hippocampal atrophy (Irizarry et al. 1997).  This 
correlates to a similar loss in this area of the human AD brain, which is thought to 
contribute to short-term memory loss.  Further studies of synaptic transmission in the 
hippocampus of these mice have shown that there is a reduction of neurotransmission 
and LTP which precedes Aβ deposition (Giacchino et al. 2000).  This reduction is 
also thought to play an important role in affecting behavioral impairment of these 
mice. 
Behavioral Characterization of the PDAPP Model 
 In 1999, Dodart et al. reported that PD-APP transgenic mice show age-
independent impairment in the radial arm maze task as early as 3 months of age 
despite no deficit in overall motor activity.    By 6 months they were shown to be 
impaired in object recognition tasks (Dodart et al. 1999).  In 2000, a correlation 
between object recognition and Aβ plaque loads was reported along with data 
correlating deficits in both spatial and working memory to changes in synaptic 
density and hippocampal atrophy (Dodart et al. 2000).  That same year, Chen et al. 
(2000) reported an age related deficit in working memory using a modified version of 
the water maze which included use of a shifting assortment of visual cues and escape 
platform locations.  Alterations in platform locations after several trials required that 
the mice tested learn each new location, forcing them to rely on working memory.  
For all age time points, PDAPP mice took longer to learn the location of the hidden 
platform than non-transgenic controls in an age-independent manner.  However, 
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based on last day performance at each time point, impairment was not present at a 6-9 
month time point but became apparent at a 13-15 month time point and became even 
more prominent at a final 18-21 month time point (Chen et al. 2000).  In 2004, 
Nilsson et al. tested PDAPP mice and non-transgenic controls in a full 6 week battery 
of sensorimotor and cognitive based tasks starting at 2 months and 16 months for 
separate groups of animals.  While no differences were noted between groups at the 
earlier time point, aged PDAPP animals showed impairment in the final block of 
Morris water maze and in overall RAWM performance (Nilsson et al. 2004).  That 
same year, Leighty et al. reported a significant statistical correlation between 
impairment in Morris water maze, platform recognition, and RAWM performance 
and deposition of Aβ (diffuse and/or compact) in the hippocampus and parietal cortex 
in 15-16 month old PDAPP mice.  A correlation was also made between circular 
platform escape latency and diffuse Aβ deposition in the cerebral cortex.  These 
patterns of impairment correlated to Aβ deposition in the hippocampus and cerebral 
cortex of the mice brains indicate a direct mechanism for working memory loss in this 
model of AD.   
APPsw (APP23) Model 
 The “Swedish mutation” transgene has also been used to create hAPP 
transgenic mice commonly used in Alzheimer’s research.  This transgene carries a 
double mutation at positions 670 (Lys?Asn) and 671 (Met?Leu) in the APP gene, a 
mutation originally discovered in a Swedish family predisposed to early onset AD 
(Mullan et al., 1995).  The most prevalent lines of mice carrying this mutation are the 
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APPsw/Tg2576 and the Psw/APP23 mice, which carry different promoters and have 
different transgene insert locations resulting in some distinct pathological features.   
 
 
Pathological Characterization of the Tg2576 Model 
 In Tg2576 mice, the APP transgene is expressed only by neurons, 
predominately in the hippocampus but with a constant, lower level of expression in 
other varied cortical regions (Irizarry et al. 1997).  By 6-7 months, insoluble Aβ is 
present in the brains of these mice, with levels of both Aβ1-42 and Aβ1-40 isoforms 
then increasing drastically through 10 months (Kawarabayashi et al. 2001).  Amyloid 
plaque deposition occurs by 11 months in cortical and limbic regions.  Past this time 
point and through 23 months of age, levels of both diffuse and neuritic plaques 
increase to levels similar to those found in AD.  As a result of plaque formation, 
decreases in plasma and CSF Aβ levels can be noted progressively through these age 
time points (Kawarabayashi et al. 2001).   
 Amyloid plaques in Tg2576 mice have been shown to be associated with 
gliosis and neuritic dystrophy, though importantly no loss of hippocampal CA1 
neurons have been reported (Irizarry et al. 1997).  Aβ formation and aggregation has 
also been associated with a number of other pathological and neurophysiological 
features, including activation of microglia and astrocytes, induction of oxidative 
stress and damage including lipid peroxidation, and impairment of LTP in CA1 and 
dentate gyrus neurons (Frautschy et al. 1998, Benzing et al. 1999, Mehlhorn et al. 
2000, Smith et al. 1998, Practico et al. 2001, Chapman et al. 1999).  Activated 
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microglia were shown to localize with Aβ depostits and increase expression of 
Interlukin-1β (IL-1β) and Tumor Necrosis Factor-α (TNF-α) (Benzing et al. 1999).  
Immunoreactive astrocytes directly adjacent to plaques were shown to increase 
expression of IL-6 and Glial Fibrillary Acidic Protein (GFAP) (Mehlhorn et al. 2000).  
These activated immunoreactive cells serve to enhance the inflammatory response 
elicited by Aβ.  Tg2576 mice have also been shown to have an increased risk for 
development of ischemic brain damage, either as a direct result of amyloid plaque 
formation or as a result of the inflammatory response process (Zhang et al. 1997). 
Pathological Characterization of the APP23 Model 
 The Psw or APP23 model differs in pathology from the Tg2576 model in one 
major respect.  These mice are known to develop Cerebral Amyloid Angiopathy 
(CAA), which results from amyloid plaque formation in the cerebral vasculature.  
This severe pathological feature is not present in Tg2576 mice but occurs at as early 
as 14 months in the Psw model.  CAA in these mice is associated with loss of neurons 
in areas adjacent to CAA pathology (Calhoun et al. 1999).  Synaptic abnormalities, 
microglial activation, and microhemorrhage are also prevalent in these regions.  
Damage to the vasculature can be extreme, beginning with loss of vascular smooth 
muscle cells, aneurismal vasodialation and microhemorrhages and eventually leading 
to large hemotomas and in some cases hemorrhagic stroke (Winkler et al. 2001).  
CAA has been noted in AD, leading some researchers to believe that the Psw mouse 
provides a more realistic AD model (Calhoun et al. 1999, Winkler et al. 2001). 
Behavioral Characterization of the Tg2576 Model 
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 Behavioral deficits have been found in both Swedish mutation transgenic 
mouse models.  Initial studies in Tg2576 mice showed behavioral impairment in Y-
maze and Morris water maze tasks by 10-11 months of age, at the same time plaques 
developed in these animals (Hsiao et al. 1996, Irizarry et al. 1997).  Impaired CA1 
and dentate gyrus neuronal LTP was also found to correlate to spatial working 
memory impairment based on T-maze alternation impairments at 16 months 
compared to non-transgenic controls (Chapman et al. 1999).  In two separate studies, 
Holcomb et al. showed that Y-maze impairment with regards to percent alternation 
was present at 3 and 6 but not 9 months, that no impairment was present at any of 
these time points for Morris water maze, and that Tg2576 mice were not impaired in a 
number of sensorimotor baseline tasks (Holcomb et al. 1998, Holcomb et al. 1999).  
In 1999, it was shown that impairment was present in 7 month old Tg2576 mice not 
for initial application but for reversal learning of the circular platform task (Pompl et 
al. 1999).   
In 2002, King and Arendash behaviorally characterized the Tg2576 model at 
3, 9, 14, and 19 months, providing a comprehensive overview of impairment in this 
model.  This was done via application of a 6-week battery of sensorimotor and 
cognitive based tasks.  Over all timepoints, it was shown that Tg2576 mice were 
impaired in Y-maze spontaneous alternations, by nine months in visible platform 
recognition, and over numerous timepoints in sensorimotor tasks such as balance 
beam and string agility tasks. Continued levels of performance on par with non-
transgenic mice in cognitive based tasks such as Morris water maze, circular 
platform, and both passive and active avoidance through 19-months indicated that 
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profound cognitive impairment is not present in this model even into old age (King et 
al. 2002 (1)).  Westerman et al. (2002) found that memory loss in Tg2576 mice at as 
early as 6 months could actually be attributed to formation of small insoluble Aβ 
aggregates, though at later time points a correlation between these aggregates and 
impairment could no longer be drawn based on Morris water maze task results alone 
(Westerman et al. 2002).  Also in 2002, however, King et al. showed that age 
dependent impairment in Morris water maze and platform recognition could be 
correlated with synaptophysin staining levels present in APPsw mice through 19 
months of age, indicating a connection between impairment and compensatory 
measures taken by the mouse brain to combat loss of function (King et al. 2002 (2)).   
In 2004, Arendash et al. reported early impairment at 5 months in APPsw 
mice in balance beam but no other sensorimotor or anxiety based tasks.  Between 5 
and 8.5 months, these mice were significantly impaired in Y-maze percent 
alternations.  Impairment was also noted between 5 and 7 months in Morris maze 
acquisition and retention, platform recognition, and RAWM, indicating that for these 
mice cognitive impairment is present at an earlier time point than was previously 
noted.  This was thought to be due to actions of soluble Aβ oligomers present in the 
mouse brains at these timepoints, with increased affects due to continual cross-
breeding of transgenics and a resulting increased influence of the APP transgene. 
(Arendash et al. 2004). 
Behavioral Characterization of the APP23 Model 
 In the APP23 model, three recent studies have shown that cognitive 
impairment is present at various timepoints in these animals.  In 2003, Kelly et al. 
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tested APP23 mice at 3, 18, and 25 months in passive avoidance as well as small and 
large Morris water maze and platform recognition.  Passive avoidance and small pool 
performance impairments were shown to be age-related when comparing APP23 mice 
to non-transgenic controls, while large pool performance was highly impaired across 
timepoints.  No impairment was noted for platform recognition performance, which 
occurred during large Morris maze testing (Kelly et al. 2003).  Also in 2003, Van 
Dam et al. also tested APP23 mice in Morris water maze and passive avoidance at 6-8 
weeks, 3, and 6 months.  Impairment in Morris water maze was found to be age 
related in this study as well, however passive avoidance was not found to be impaired 
at these early timepoints.  No significant differences between APP23 mice and non-
transgenics were noted in a variety of behavioral and neuromotor measures at any 
timepoint except for increased total path length for APP23 mice in open field at 6 
months.  It was also noted that overnight cage activity appeared to be higher for 
APP23 mice than non-transgenics at various time points (Van Dam et al. 2003).  In 
2004, Dumont et al. tested aged (24 months) female APP23 mice in open field, 
elevated plus-maze, and Morris water maze.  These mice showed hyperactivity 
compared to controls, decreased anxiety based on elevated plus-maze performance, 
and impairment in Morris water maze acquisition, but not retention.  This impairment 
did not extend to probe or platform recognition trials (Dumont et al. 2004).  The three 
studies described above give a very general picture of spatial learning impairment in 
APP23 mice and hint at some of the behavioral disturbances present in these animals, 
however comprehensive assessment of impairment including application of working 
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memory tasks has not been performed.  Future testing may provide insight into the 
exact progression of impairment in this model. 
 
 
APPsw+PS1 Model 
 Formation of a mouse line transgenic for a FAD PS1 mutation was thought to 
be the next logic step in creation of an AD mouse model based on the relatively high 
frequency of PS1 mutations among FAD cases.  Single transgenic mice carrying 
human PS1 alleles, however, were found to be lacking significant Aβ pathology at 
any time point, despite a drastic (approximately 51%) increase in Aβ1-42 to Aβ1-40 
ratios in the brains of these mice as well as in overall Aβ levels (Duff et al. 1996).  It 
was found however, that by crossing these mice with APPsw transgenics, a double 
mutant model could be created which exhibited dramatically accelerated AD-type Aβ 
pathogenesis (Borchelt et al. 1997, Holcomb et al. 1998).  These APPsw+PS1 mice 
have been characterized by a number of groups with respect to both pathology and 
behavior and have proven useful for numerous treatment and preventative studies in 
AD research because of their early age of onset for Aβ pathology and correlated 
cognitive impairment. 
Pathological Characterization of the APPsw+PS1 Model 
 Early work in the APPsw+PS1 model by Borchelt et al. showed that, similar 
to PS1 single transgenic mice, these mice show an approximate 50% increase in 
soluble Aβ1-42 to Aβ1-40 ratios at an early timepoint (Borchelt et al. 1996).  Double 
transgenics were found to develop amyloid plaques prior to APPsw single 
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transgenics, measured by Borchelt et al. at 12 months, and reactive astrocytes were 
shown to be associated with these plaques.  Many of these plaques were found to 
stain mostly for Aβ1-40 at this timepoint, despite increased Aβ1-42 levels.  It was also 
found that double transgenics carrying a wild-type human PS1 gene did not display 
accelerated Aβ deposition, indicating that the mutant allele PS1-A246E used in the 
study was necessary to bring this acceleration about (Borchelt et al. 1997).   
 In 1998, Holcomb et al. confirmed that a dramatic increase in Aβ1-42 to Aβ1-40 
ratios is present in double transgenics, this time in a APPsw+PS1-M146L line at 6 
weeks of age.  At 13-16 weeks, it was shown that these mice also exhibit small 
numbers of deposits after thioflavin S staining, which stains for plaques containing 
fibrillar and β-pleated amyloid, with dramatically increased staining appearing at 24-
32 weeks.  Many of these deposits were also shown to be congophilic (Holcomb et al. 
1998).  A year later, the same group showed that by 6 months of age, all double 
transgenic exhibited amyloid deposits, though none were present at a 3 month 
timepoint (Holcomb et al. 1999).  In contrast, Takeuchi et al. found that deposition 
occurs in APPsw+PS1 mice at as early as 3M in the frontal cortex and CA1 region of 
the hippocampus.  At 12 months, they showed that 28.3% of the superior frontal 
cortex and 18.4% of the CA1 was covered by amyloid plaques, which is 
approximately 20-40 times greater than coverage levels in APPsw single transgenic 
mice.  It was also noted that neuronal counts did not differ significantly among 
double or single transgenic from 3 to 12 months, despite apparent disruption of 
neuronal architecture in doubles by compact plaques (Takeuchi et al. 2000).   
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 Plaque formation at 3 months was corroborated by Gordon et al. in 2002.  
This group also found that compact plaques continue to form through 12 months in 
both the hippocampus and frontal cortex, followed by formation of diffuse plaques in 
these as well as other regions.  These diffuse plaques were shown to be composed 
almost entirely of Aβ1-42, while compact plaques were indicated as being composed 
of both Aβ1-42 and Aβ1-40, thus providing an explanation for findings by Borchlet et 
al. that plaques formed prior to 12 months showed higher ratios of Aβ1-40 relative to 
Aβ1-42.  Vascular Aβ was also detected by this group and was typically noted to be 
Aβ1-40.  Importantly, it was shown that compact plaques are associated with 
dystrophic neurites, GFAP expressing astrocytes, and MHC-II immunoreactive 
microglia even at early timepoints, indicating that these plaques elicit a similar 
neuroinflammatory response to those in Alzheimer’s via both neuronal degradation 
and direct interaction with immune cells (Gordon et al., 2002). 
 The effects of both soluble and insoluble Aβ in the brains of these double 
transgenics appear to center on loss of neuronal function, loss of LTP in memory 
centers and increases in inflammatory responses in areas surrounding deposits of Aβ.  
In 1999, Wong et al. found that cholinergic synapses in the frontal cortex of the 
brains of double transgenics showed a lower density than those of single transgenic 
and non-transgenic groups.  A lowered average cholinergic synapse size in both the 
frontal cortex and hippocampus was also noted, though no changes were noted in 
basal forebrain cholinergic cell body numbers (Wong et al. 1999).  In 2003, Dickey et 
al. reported that aged, 17-18 month-old APPsw+PS1 mice show reduced mRNA 
expression of genes involved in LTP and memory formation, specifically in regions 
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where Aβ accumulation had already occurred (cortex and hippocampus).  Changes in 
synaptic structure, such as those noted by Takeuchi et al. (2000), were not shown to 
be associated with any altered mRNA levels, however inflammatory genes were 
upregulated.  These findings were thought to provide an example of how memory 
capacities can be affected prior to any loss of neurons via modulation of LTP and 
other neuronal functions (Dickey et al. 2003).  In a recent study, Trinchese et al. 
(2004) delved further into the study of LTP loss in APPsw+PS1 transgenics, finding 
that abnormal LTP is present at as early as 3 months, the same time point at which 
plaque formation begins and abnormal short-term working memory was first 
apparent, as indexed by the RAWM task.  It was also shown that by 6 months, after 
increases in overall Aβ loads, basal synaptic transmission is impaired, coupled with a 
loss of long-term spatial learning/memory beginning at this time point in a plaque 
independent manner (Trinchese et al. 2004).  These connections to cognitive 
impairment show correlations to many, but not all, studies focused on behavioral 
characterization of this mouse line.  
Behavioral Characterization of the APPsw+PS1 Model 
 Early testing by Holcomb et al., 1998 found a similar level of performance 
among APPsw+PS1 double transgenics, single transgenic APPsws and PS1s, and 
non-transgenics in sensorimotor tasks at 3-4 months, indicating no baseline 
impairment in motor or sensory functions is present in these transgenics.  Both the 
APPsw and APPsw+PS1 groups were found to exhibit decreased Y-maze 
spontaneous alternations compared to PS1 and non-transgenic mice at this same 
timepoint, indicating a decrease in cognitive performance in these groups.  Only 
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double transgenic mice also showed an increase in overall activity in this task, which, 
when coupled with decreased percent alternation performance, was thought to 
correlate to hippocampal dysfunction (Holcomb et al. 1998).  In 1999, Holcomb et al. 
continued testing of double transgenics in the Y-maze task, as well as in Morris 
Water Maze, over two additional time points.  The same deficits were found in Y-
maze at 6 and 9 months for these animals, though no significant differences were 
noted among groups for any measure in Morris Water Maze at any time point.  
Furthermore, it was noted that findings of decreased Y-maze performance at 3 
months occurred prior to Aβ deposition in these mice, indicating loss of cognition did 
not necessarily require plaque formation directly (Holcomb et al. 1999).  As was 
already shown, however, several other studies did find that some level of Aβ 
deposition does occur at this early time point, including the 1998 study by Holcomb 
et al., perhaps confounding interpretation of these results (Holcomb et al. 1998, 
Takeuchi et al. 2000, Gordon et al. 2002; Trinchese et al. 2004. 
 In 2001, Arendash et al. found impairment in aged APPsw+PS1 mice in the 
Radial Arm Water Maze task, and found a correlation between the level of 
impairment in individual mice and the level of plaque formation.  Arendash et al. 
(2001) comprehensively tested the double transgenic mouse model in a full 
behavioral test battery, cross-sectionally at two time points.  It was noted that 
transgenicity did not appear to affect cognitive performance in Y-maze, circular 
platform, standard water maze, or platform recognition at 5-7 or 15-17 months, and 
anxiety levels measured via the elevated plus maze task did not appear to differ 
among groups.  However, double transgenics did exhibit progressive increases in 
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open field activity and in string agility impairment, coupled with continual 
impairment in the balance beam task.  Most significant, though, were findings of 
cognitive impairment in both water maze and RAWM.  Water maze acquisition was 
found to be impaired at the later timepoint, though importantly no significant 
impairment was noted during probe trials for this task.  RAWM impairment was 
limited to the later time point for this study as well.  These findings indicate that 
progressive impairment in spatial reference and working memory is present in these 
mice.  (Arendash et al. 2001).  In a more recent report involving the same 
investigators, Jensen et al. (2005) reported much earlier impairment at 4.5-6 months 
in APPsw+PS1 transgenic mice in Morris water maze and RAWM (Jensen et al. 
2005).  This early impairment is consistent with findings of early impairment in other 
studies such as Trinchese et al. (2004), in which it was reported that APPsw+PS1 
mice are impaired in RAWM at as early as 3-4 months and in Morris water maze at as 
early as 6-8 months (Trinchese et al. 2004).  This difference from previous studies 
such as Arendash et al. 2001, in which early impairment was not reported, are most 
likely due to the effects of crossbreeding of APP transgene bearing mice resulting in 
an increase of its effects.  These effects were attributed to soluble Aβ constructs in the 
brains of these mice which resulted in their earlier impairment.   
Sadowski et al. (2004) reported impairment at 8 and 22 months for 
APPsw+PS1 transgenics in Morris water maze as well as in Hebb-Williams maze.  
Impairment in spatial memory at the 22 month time point was correlated to both a 
loss of neurons (35.8%) in the hippocampal CA1 region and to reduced glucose 
utilization in the hippocampus (Sadowski et al. 2004).   
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Based on results from studies performed with APP transgenics, it is clear that 
the resulting presence of Aβ in both soluble and insoluble form is sufficient to elicit 
cognitive impairment in these mice which in many way parallels that of Alzheimer’s 
Disease (Chen et al. 2000, Arendash et al. 2001).  Progressive loss of short-term and 
spatial memory as well as loss of long-term memory has been reported in animal 
models of AD.  These losses may be associated with loss of LTP and decreased basal 
synaptic transmission as discussed above.  This loss has been attributed to Aβ levels 
(soluble and/or insoluble) as well as plaque deposition.  Early decreases in LTP and 
early memory impairment may result from actions of soluble Aβ oligomers including 
neurotoxic protofibrils, while later deficits may be due to progressive Aβ plaque 
burdens (Dickey et al. 2003, Trinchese et al. 2004).  Several studies have been 
conducted which have indicated that cognitive performance can be altered via 
modulation of Aβ levels and/or clearance of Aβ plaques, as will be elicited in 
discussion of current immunotherapeutic research in AD.  These findings generate 
excitement over the prospect of developing a preventative or treatment based on these 
results.  At the same time, however, it must be kept in mind that these models lack 
complete development of all the pathological hallmarks of Alzheimer’s Disease, and 
complete characterization of behavior in such models is simply not possible, making 
them in many ways incomplete representations of the disease. 
Mutant APP Mice as Incomplete Models of AD 
 Behaviorally, it is impossible to gauge all measures of disturbance in mouse 
models to the extent that this can be accomplished in humans for obvious reasons.  
Typical tasks for behavioral assessment in mice measure exploration, object 
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recognition, anxiety and fear, and cognitive impairment with regards to spatial short-
term or long-term memory.  Disparities noted during these tasks are thought to 
correlate to disruptions common to Alzheimer’s, from decreased mobility and 
motivation to visuospatial learning deficits to heightened anxiety (Janus and 
Westaway 2001).  However, it is clear that these tasks, while useful for gaining a 
general picture of mouse behavior, are not specific enough to elicit findings 
comparable to those obtained in humans using a wide variety of interactive tests such 
as the MMSE, and even in humans diagnosis of AD is convoluted as a result of often 
insufficient and sometimes contradictory data noted in such studies.   
 The question also arises:  are the behavioral deficits noted in animal models of 
AD associated with the transgene product via the same mechanism noted in humans?  
Mice have different cellular machinery involved in post-translational modification of 
proteins such as APP, and the exact process for neuronal production of hAPP in these 
models, as well as any subsequent modifications which occur during processing to 
form Aβ, has not fully been explored.  Thus, the results of microinjection of such 
transgenes must be elicited via pathological analysis and comparison with AD 
pathology.  Only the results of transgenicity can be compared, not the cause (Schwab 
et al. 2004).   
 In APP transgenics, a number of distinct differences can be noted immediately 
in comparison with human pathology.  Spontaneous NFT formation has not been 
noted for any APP model (tau transgenicity has been necessary to induce such 
formation) despite the fact that FAD genes are known to directly result in AD 
development with full pathology in humans, including NFT formation.  The cause of 
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this NFT formation in humans has not been entirely elucidated, but as described 
above it may be associated with Aβ formation.  Aβ itself is thought to act differently 
within animal models as well.  Although this peptide is known to be neurotoxic in 
humans, perhaps resulting in the widespread neuronal loss in hippocampal and 
cortical regions noted in AD, such loss of neurons simply does not occur in many 
APP transgenic models, and in no model does it occur at levels similar to those 
present in AD (Janus and Westaway 2001, Schwab 2004).  Inflammatory responses to 
Aβ once it has deposited into plaques is significantly lessened as well in mice, with 
little or no complement system activation and lessened microglia activation.  This can 
lead to misinterpretation of results in studies such as those designed to clear plaques 
from the nervous system without overactivation of the inflammatory system.  These 
differences may result from variations in Aβ pathology in transgenic mice as 
compared to humans, such as morphological plaque density in APP models, which 
tend to have less compact cores.  This is most apparent in the APP23 model where 
dense, congophilic plaques have also been noted to be still SDS soluble (Ashe 2001, 
Schwab 2004).   
 It is apparent that despite similarities in Aβ pathology between transgenic 
models and humans with AD, distinctions must be drawn when considering not only 
the biochemical nature of plaques but their effects on cognitive performance as well.  
Evaluation of these effects cognitively is made difficult for reasons outlined above.  
Thus, behavioral and pathological studies in transgenic models must be limited in 
application to specific and well designed treatment or prevention studies to elicit 
effects, and the results of such studies must be weighed against the faults intrinsic to 
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them.  Nonetheless, the paradigm of repeated testing in various models followed by 
subsequent staged clinical trials is still the most efficient protocol for gaining insights 
in to AD therapies in a safe fashion, and thus continued behavioral testing in such 
models, though found to be lacking, is still essential to AD research. 
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Inflammatory Responses in AD 
 
 Neuroinflammation is a term which has evolved to specifically describe 
chronic inflammation within the central nervous system involving glial cell activation 
and subsequent neurodegeneration, a process for which Alzheimer’s Disease provides 
a unique but complete representation (Streit et al. 2004).  In AD, this inflammatory 
process appears to be induced directly by Aβ, as described above, and involves 
activation of glial cells, both asctocytes and microglia.  Also reactive to Aβ, activated 
T-cells can play a formative role in the progression and severity of 
neuroinflammation in AD via direct action or through co-stimulation with microglia 
and production of cytokines.  This is one main distinction between 
neuroinflammation in AD and other chronic forms of neuroinflammation, which do 
not typically involve T lymphocytes.  It may be that disruption of the BBB allows 
these lymphocytes access to the AD brain, further influencing the inflammatory 
cascade which occurs progressively throughout the disease.  Along with the direct 
affects of immunoreactive cells, cytokines and inflammatory proteins (and in some 
cases complement proteins expressed by these glial cells and lymphocytes) have 
widespread impact within regions of the CNS affected by AD.     
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Microglia Activation 
 Microglia, resident phagocytes of the CNS, are thought to be derived from the 
same cell lineage as macrophages and monocytes and to provide similar functions 
within the brain to those provided by these cells in the periphery.  In 
neuroinflammation associated with Alzheimer’s, it appears that it is the non-
phagocytic capabilities of these cells which play a major role in inflammation 
associated with the disease, though these may only be induced after frustration of 
phagocytic attempts (Streit 2004).  Specifically, microglia are known to associate 
with neuritic plaques in AD brains as well as in hAPP transgenic mouse brains, and it 
has been shown that these cells can be activated by Aβ, especially the fibrillar, 
neurotoxic form of this peptide commonly found in neuritic plaques.  Other materials 
associated specifically with compact neuritic plaques are also proposed to be involved 
in activation of these cells, as Aβ itself does not generally elicit the exaggerated 
response seen therein (D’Andrea et al. 2004).  It is thought that these microglia are 
induced by aggregated Aβ and these other factors to attempt phagocytosis of Aβ 
aggregations; however, it is also apparent that they are largely unsuccessful at 
degrading the dense plaques they are typically associated with (Streit et al. 2004).   
 In contrast to these findings, in human brains after postmortem analysis as 
well as in transgenic mice brains taken after development of neuritic plaques, it has 
been shown that microglia are indeed capable of clearing Aβ in rodent brains and that 
human microglia can be induced to ingest Aβ in vitro (Frautchy et al. 1992).  In 
rodent models, such clearance is significantly increased by brain lesioning and by 
injection of either Lipopolysaccharide (LPS) or Aβ antibody (Smith et al. 1998, 
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DiCarlo et al. 2001, Bard et al. 2000).  All of these factors tend to either activate the 
overall immune and inflammatory systems or to interact with Aβ and microglia 
directly to facilitate phagocytosis.  In vitro studies have also shown that complement 
system proteins such as the C1q protein may facilitate microglial phagocytosis of Aβ 
(Webster et al. 2000).  Furthermore, postmortem analysis from an Aβ vaccination 
clinical trial indicated an association between microglia activation and amyloid 
clearance in humans (Nicoll et al. 2003).  These and other studies have shown that 
microglia are quite capable of clearing Aβ in all configurations under the right 
circumstances, however such clearance is obviously deficient for some reason in AD.  
Thus it is either:  1) an overall failure of these cells to maintain clearance of plaques, 
due perhaps to an inherent dysfunction of these cells 2) an overwhelming effect 
following increased Aβ production later in life, or 3) the nature of the plaques 
themselves, which prevents their breakdown.  If the first is true, it is possible that 
Alzheimer’s is due simply to a failure of microglia to maintain proper balances of Aβ 
within the brain, while the last hypothesis would seem to indicate that the progressive 
nature of plaque formation may allow this process to be too far along prior to 
microglia activation for these cells to be effective as phagocytes after such activation 
(Streit 2004).  Future studies may elicit which of these is the true initial failure of 
microglia, thereby allowing researchers to gain insights into how to alter this process 
early on.  In the present, however, it is the role of activated microglia in the 
Alzheimer’s neuroinflammatory cascade which has received the most study in AD 
research due to the neurotoxic potential of the cells therein. 
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 As stated, the major role of microglia in exacerbating the inflammatory 
damage noted in AD does not appear to be related to the phagocytic role of these 
cells.  Once activated, microglia often become “frustrated” due to the persistence of 
the compact neuritic plaques with which they are associated, in much the same way 
that immune cells of the periphery can, during certain autoimmune diseases or in 
response to mitogens, be activated excessively (D’Andrea et al. 2004).    Once over-
stimulated and after failed attempts at Aβ clearance, these microglia then proceed to 
produce a wide array of inflammatory factors including reactive oxygen species, 
complement proteins, cytokines (such as IL-1, IL-6, and TNFα), and a number of 
other factors which may be considered neurotoxic or which may stimulate further Aβ 
aggregation (Akiyama et al. 2000).  Local neuronal degradation causes release of 
cytoplasmic inflammatory factors leading to further activation of glial cells.  
Astrocytes activated by these factors, as well as by cytokines released from microglia, 
are attracted to the plaque periphery where they begin to produce their own set of 
inflammatory proteins and cytokines, resulting in a co-stimulatory effect with 
neighboring microglia (D’Andrea et al. 2004).  Inflammatory proteins such as ApoE 
(produced by subsets of both glial cell types), α-ACT (produced by astrocytes), 
complement proteins, and perhaps other factors all associate with neuritic plaques and 
may be involved not only in promoting further Aβ aggregation, but in further 
stimulating microglial response via receptor mediated activation of these cells 
(Nilsson et al. 2004, Uchihara et al. 1995, D’Andrea et al. 2004).  The end result is a 
localized inflammatory cascade with potentially widespread repercussions due to 
cytokine diffusion. 
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T Cell Activation  
 In a general sense, T cells can be divided based on expression of either the 
CD4 or CD8 co-receptor, which primarily segregates the cells into helper and 
cytotoxic lines respectively.  T helper (Th) cells produce a variety of cytokines when 
activated which are involved in mediating inflammatory and immune responses, 
while cytotoxic cells are largely involved in recognition and destruction of abnormal 
or aged self cells.  Helper cells can be further divided into Th1 and Th2 subsets, each 
with distinct and often antagonistic roles in the immune system.  The former tends to 
promote inflammation and cellular based immunity via activation of macrophages 
and cytotoxic T cells (TC) as well as other immune cells such as neutrophils, while the 
latter tends to initiate a humoral based response via activation of B cells (Vallejo et al. 
2004).   
 Each subtype of T cells requires a different combination of receptor mediated 
activation to initiate the effects they are known to elicit.  Receptor activation also 
dictates if and when T cells will begin to differentiate and mature.  All T cells begin 
as naïve cells and remain so unless they encounter a recognizable antigen properly 
presented by an antigen presenting cell (APC) for Th cells or by the majority of self 
cells for TC cells.  T cell recognition is dictated by variations in T cell receptor (TCR) 
subcompontents, which alters initial ability of a cell to recognize antigens presented 
by major histocompatibility (MHC) II complexes of APCs or to recognize peptides 
presented by MHC I complexes of self cells.  Antigens presented by APCs are 
typically produced after breakdown of foreign peptides extracellularly via enzymatic 
degradation or intracellularly after phagocytosis.  The peptides presented by self cells 
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are typically derived from viral or intracellular microorganisms which have infected 
these cells; however aged, cancerous, or otherwise altered cells may also present 
peptides which promote their own death (Vallejo et al. 2004, Crow 2004).   
 Coupling of the TCR with the antigen/MHC II complex or peptide/MHC I 
complex initiates T cell activation and can result in differentiation into effector T 
cells capable of varying functions, however further interaction of secondary cell 
surface proteins is also required for induction of such activities.  In many cases, such 
proteins are not expressed unless secondary activation via cytokine receptors has 
occurred.  Thus, activation of individual T cell subtypes depends not only on 
recognition of the appropriate antigen / MHC complex, but also on stimulation of 
regulatory cells to produce appropriate cytokines which then mediate which specific 
subtype of T cells will be activated.  Once fully activated, memory T cells may 
develop which proliferate and remain present in the body, awaiting reactivation or 
continuing to act in the presence of persistent stimuli (Vallejo et al. 2004, Chandock 
et al. 2004). 
 The role of TC cells in Alzheimer’s neuroinflammation is thought to be 
primarily detrimental due to the ability of these cells to induce neuronal or glial 
apoptosis, and thus Th1 cells activation may also be considered disadvantageous due 
to subsequent activation of TC cells.  At the same time, microglia can be activated by 
Th1 cells resulting in a positive effect if phagocytosis of Aβ can be induced and a 
negative effect if phagocytic frustration results, as discussed above.  Th2 cell 
activation may prove to be beneficial in Alzheimer’s if Aβ antibody formation by B 
cells is then induced, enhancing clearance of Aβ, as will be discussed later, and other 
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distinct capabilities of unique T cell subtypes may also be either detrimental or 
therapeutic based on extent of activation and timing of such activation. 
Microglia and T Cell Co-activation 
 As discussed above, both microglia and T cells are heavily reliant on 
activation by other cell types via cytokine receptor activation or direct receptor 
protein interactions with surface proteins of these other cell lines.  As phagocytes, 
microglia are among the few cell types capable of internalizing, digesting, and 
presenting proteins in association with MHC II receptors in the CNS, thus acting as 
APCs (Hickey et al. 1988).  Specific lines of T cells, largely among the Th1 subtype 
but also among the Th2 subtype, are capable of inducing microglia to carry out this 
activity, and in certain cases microglia will remain inactive without such input.  Thus, 
though many other cell lines may be involved in the process, activation of microglia 
and T cells can occur concurrently and can have a tendency towards exponential 
propogation under certain conditions.  As will be shown, however, the true 
interactions which have been shown to occur between microglia and T cells in the 
presence of Aβ are convoluted and often difficult to interpret. 
 In 2003, Monsonego et al. showed that mouse microglia primed with INF-γ 
are capable of serving as Aβ APCs for both Aβ1-40 and Aβ1-42, presenting these 
peptides to Aβ-specific T cells.  Both Th1 and Th2 subtypes were shown to be 
activated by these peptides when presented by microglia.  Th1 cells were shown to be 
activated in the short term, with increased expression of IFN-γ (a microglial activator 
and inhibitor of Th2 proliferation) noted.  Coactivation of microglia resulted in their 
expression of TNF-α (an inflammatory cytokine) and IL-10.  As an anti-
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inflammatory cytokine, IL-10 is known to inhibit TH1 subset activation, and to inhibit 
monocyte/macrophage lineage production of NO and a variety of cytokines involved 
in inflammation.  In contrast to this, it was shown that microglia were actually 
stimulated by Th1 cells to increase their production of NO, which is a known general 
T cell inhibitor.  Inhibition of iNOS to reduce this production of NO resulted in 
restoration of Th1 cell proliferation.  Anti-IL-10 and IFN-γ antibody treatments also 
elucidated that this inhibition could not be reversed simply by blocking these 
cytokines without inhibition of iNOS, indicating that the normal control of IL-10 over 
Th1 cell lines was not the pathway of T cell regulation in this case.  Thus it appears 
that the interactions between microglia and Th1 subsets in mice are in many ways 
distinct from normal interactions between Th1 cells and cells of the monocyte 
lineage, and that microglia are capable of inhibiting Th1 cells as a result of Th1 cells 
stimulating microglia to produce NO.  This high level of NO and perhaps other 
mediating factors is thought to then bring about apoptosis of Th1 cells (Monsonego et 
al. 2003). 
 It was also noted that in cultures of microglia with Th2 subset cells, there was 
an increase in production of IL-4 (promotes TH2 proliferation), IL-10, TNF-α, and 
granulocyte-macrophage colony-stimulating factor (GM-CSF).  These T cells did not 
undergo apoptosis, but were instead activated and induced to proliferate.  Thus it was 
assumed that the Th2 repetoire of cytokines is sufficient to block NO mediated 
apoptosis of T cells, as has been shown in previous studies, despite an up-regulation 
of NO which was noted in these cultures (Monsonego et al 2003).   
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 Based on these in vitro results coupled with those of previous studies, some of 
the potential interaction which occur between T cells and microglia in Alzheimer’s 
may be speculated upon and are summarized in Figure 1.  The two major effectors of 
microglia activation noted in the study conducted by Monsonego et al. (2003) were 
IFN-γ and GM-CSF, produced by the Th1 and Th2 subsets respectively, which 
promoted presentation of Aβ by microglia to these cells.  Other cytokines such as IL-
10 were shown to decrease production of NO by microglia in vitro.  Depending on the 
type of interactions which occur during and following activation, however, microglia 
can then act to regulate T cell activity via production of a variety of mediating factors 
such as NO, as discussed above.  Therefore, with development of an understanding of 
the interaction which occur between these cell types, it may be possible to alter 
activation of specific T cell types to promote clearance of Αβ by microglia while 
preventing inflammatory damage due to secondary activities of both T cells and 
microglia. 
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Figure 1.  IFN-γ primed Microglia cultured in the presence of Aβ are capable of 
MHC II associated presentation of Aβ to both Th1 and Th2 cell types.  This leads 
to short term activation of Th1 cells with potential for subsequent inhibition following 
release of Nitrous Oxide (NO) and IL-10 by microglia (red).  Activated Th2 cells are 
protected from inhibition however, perhaps via autocrine action of GM-CSF and/or 
IL-4 cytokines (blue).  In both instances, microglia remain active and produce 
inflammatory cytokines such as TNF-α, as well as NO (green).
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Vaccination in AD Research 
 
 In the late 1990’s, in vitro studies reported that antibodies specific to various 
Aβ epitopes can disaggregate amyloid plaques and prevent Aβ fibrilogenesis.  It was 
not long thereafter that researchers began focusing on the idea of an amyoid 
vaccination as a treatment or even preventative for AD.  Promising results in early 
work in vitro and in vivo with animal models of AD culminated in early phase clinical 
trials in humans using Αβ immunizations.  These trials were halted after death of a 
small number of individuals was reported due to CNS inflammation.  Since that time, 
intense focus has been placed on finding an immunotherapeutic strategy for fighting 
AD which does not instigate the type of inflammatory response initiated by active Aβ 
immunization. 
In Vitro Aβ Vaccination Studies 
 Two of the earliest studies in vitro which contributed to initiating the current 
immunotherapeutic era of Alzheimer’s research were conducted by Solomon et al. in 
1996 and 1997.  In the former study, it was noted that monoclonal antibodies 
recognizing either aa1-28 or aa8-17 residues of the Aβ peptide are capable of 
inhibiting normal in vitro aggregation of Aβ (Solomon et al. 1996).  In the latter study 
it was shown that the antibodies recognizing the aa1-28 residue of Aβ were actually 
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capable of disaggregating insoluble Aβ fibrils into soluble Aβ (Solomon et al. 1997).  
In 1998, Frenkel et al. found that these same antibodies specifically bind to aa3-6 
(sequence EFRH), and it was inferred from these results that this sequence must be 
involved in the Aβ aggregation process (Frenkel et al. 1998).  A year later, this group 
published findings which indicated that not all Aβ antibodies recognizing the region 
of the peptide containing this residue were as effective at binding to it, and that low 
binding affinitity antibodies were not capable of preventing Aβ aggregation (Frenkel 
et al. 1999).  From the results of these four in vitro studies, it was deduced that 
carefully selected antibodies to Αβ had the potential to block or even reverse amyloid 
aggregation, paving the way for future in vivo studies in Aβ vaccination. 
Innate Immune Responses to Aβ 
 On a cellular level, the response of the immune system to Aβ is three-fold.  B 
cells can be stimulated to produce Aβ antibodies, glial cells can be stimulated to 
produce a variety of inflammatory molecules and in the case of microglia to attempt 
phagocytosis of Aβ plaques, and T cells can be stimulated to produce an array of 
modulatory cytokines as discussed above.  Prior to Aβ vaccination, these responses 
are present in varying levels.  Localized, high levels of glial cell activation are 
common near Aβ plaques (D'Andrea 2004), and aged AD patients are significantly 
more likely to exhibit strong T cell reactivity to Aβ (Monsonego et al. 2003).  Finally, 
Aβ antibodies are known to be produced in AD and may be involved in triggering 
microglia response to plaques, thus facilitating phagocytosis (Nath et al. 2003, 
Wilcock et al. 2004).  These reactions to Aβ are also evoked in varying degrees 
   
60 
following Aβ vaccination (Nicoll et al. 2003).  The current goal of 
immunotherapeutic research in AD is to establish a means of creating a balanced 
response incorporating each of these responses only to the extent necessary to be 
beneficial. 
Active Aβ Immunization in Animal Models  
 A wide variety of active Aβ-based immunization studies have been reported 
on since the first reports in 1999.  Retrospectively, with the knowledge we now have 
of consequences of standard Aβ immunization in humans, it is perhaps most simple to 
divide these studies into three main categories.  The first consists of those studies 
which provide a general understanding of the positive pathological consequences of 
Aβ immunization, which are based largely on amyloid plaque clearance and reduction 
in plaque associated pathology.  The second consists of those studies which provide 
insight into how side-effects from such administrations in humans could be 
anticipated by both characterizing the neuroinflammatory response elicited by these 
or which provide alternative, less dangerous modes of eliciting an anti-Aβ immune 
response.  Finally, studies providing behavioral characterization of treated animals as 
potentially indicative of the cognitive protection that may or may not result after 
administration of an Aβ vaccine.   
Pathological Benefits of Active Aβ Immunization 
 A number of studies focused on eliciting the pathological benefits of Aβ 
vaccination while not reporting results showing the potential for negative impacts or 
the behavioral consequences that result from such vaccination.  In 1999, Schenk et al. 
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reported results from the first attempted active Aβ immunization study in a mouse 
model of AD.  Injections of Aβ1-42 were performed monthly for 11 months starting at 
2 months in PDAPP mice.  A separate group of mice was injected with SAP peptide, 
a separate component common to amyloid plaques.  Initial injections contained 
complete Freund’s adjuvant, while each additional injection contained incomplete 
Freund’s adjuvant, a protocol used in the majority of future active Aβ vaccination 
studies.  Titres of antibodies to the injected antigen were measured at higher than 
1:10,000 for most Aβ injected mice and between 1:1,000 and 1:10,000 for SAP 
injected mice.  The mice were sacrificed at 13 months, and it was found that Aβ 
immunized mice were almost completely protected against development of Aβ 
plaques in the CNS, while SAP immunized mice showed statistically similar levels of 
plaques compared to non-treated controls.  This latter data would seem to indicate 
that an immune response elicited towards any Aβ plaque component is not 
necessarily capable of clearing these plaques.  Almost complete protection against 
development of dystrophic neuritis and reduction of astrocytosis and microglia 
activation was also noted in Aβ immunized mice (Schenk et al. 1999).   
 This group also performed additional experiments to determine if reduction of 
plaque loads could be accomplished in aged mice.  11-month-old female PDAPP 
mice were again immunized with Aβ1-42.  Sacrifice of the mice occurred at either 15 
or 18 months.  At both time points, Aβ burdens were significantly reduced compared 
to PBS treated transgenic controls.  Reduction in both diffuse and compact plaque 
counts were attributed to clearance of already formed deposits.  Existing plaques were 
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noted to be coated in IgG antibodies to Aβ1-42, indicating a direct mechanism of 
action for these antibodies within the CNS.  Lack of plaques in regions such as the 
entorhinal cortex were attributed to blocked formation of plaques typically not 
deposited until later time points in PDAPP mice.  Aβ containing cells thought to be 
microglia or monocytes were present in areas normally containing high plaque counts 
at aged timepoints, indicating an activation of these cells to phagocytize existing Aβ 
deposits, perhaps via antibody receptor mediated activation.  Astrocytosis was noted 
to be reduced in these Aβ treated mice, as were other neuritic plaque pathologies.  
This second round of results would seem to indicate that while Aβ vaccination does 
show potential efficacy as a treatment due to partial clearance of plaques at an aged 
time point in transgenic mice and prevented formation of additional plaques, clearly 
the most benefit stands to be gained from earlier, prophylactic administration of Aβ 
(Schenk et al. 1999). 
 In 2000, Weiner et al. found that intranasal administration of synthetic Aβ1-40 
peptide, as opposed to injections of Aβ1-42, between 5 and 12 months in PDAPP mice 
resulted in significantly decreased neuritic plaque burden and overall Aβ1-42 levels 
compared to controls treated with myelin based protein or standard controls.  
Decreased microglia and astrocyte activation, decreased neuritic dystrophy as seen in 
Schenk et al. (1999), and decreased reactive mononuclear cell activation was also 
reported.  Importantly, this study demonstrated the efficacy of intranasal Aβ 
vaccination for the first time. (Weiner et al. 2000). 
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 In 2001, Das et al. showed that effectiveness of Aβ1-42 immunization 
correlates inversely to amyloid deposition levels in Tg2576 mice.  Mice with 
minimal, modest, and significant Aβ deposition (7-8, 10-11, and 18 months) were 
immunized with the peptide, and reductions in cerebral Aβ were noted to be highest 
in mice immunized at younger timepoints.  It was also noted that Aβ1-42 was reduced 
at higher levels than Aβ1-40.  This study clearly indicated the importance of early 
vaccination as a preventative/treatment for AD (Das et al. 2001). 
 Further expanding on the potential benefits of Aβ vaccination, Oddo et al. 
(2004) reported for the first time that Aβ immunization results in clearance of non-
hyperphosphorylated (early) but not hyperphosphorylated tau aggregates in a 
APPsw+PS1+Tau transgenic model, along with the normal reduction in Aβ pathology 
expected after such immunization.  It was also noted that Aβ pathology was necessary 
for formation of tau pathology, and clearance of the former via non-immunological 
methods resulted directly in clearance of the latter (Oddo et al. 2004).  
 Lemere et al. (2003) reported that the typical reduction in Aβ pathology 
associated with Aβ immunization such as that noted in the above three studies was 
coupled with a dramatic increase in Aβ levels in the serum of APP transgenic mice.  
It was suggested that the main mechanism of action of Aβ immunization is thus 
stimulation of Aβ antibodies largely restricted to the blood, association of these 
plasma antibodies with Aβ, and clearance of CNS antibody/antigen complexes into 
the vasculature, resulting in reduced Aβ levels in the CNS (Lemere et al. 2003).   
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 To better understand the time course for immune system reactivity to Aβ, 
Wilcock et al. (2001) delved further into the specific immune responses elicited by 
various numbers of Aβ1-42 vaccinations, reporting that anti-Aβ antibody titers 
remained low after only 3 innoculations in APPsw+PS1 mice but were significantly 
higher after nine inoculations.  After 5 innoculations there was a high level of 
microglia activation which tapered off by nine injections.  A correlation was found 
between microglia activation and reductions in congo red staining, suggesting that 
microglia may be involved in clearing compact Αβ plaques in these mice.  Thus this 
study and that by Lemere et al. (2003) provided two distinct and probable modes of 
action for anti-Aβ antibodies in clearing amyloid from the CNS (Wilcock et al. 2001). 
 In further examining the potential for microglial phagocytocis of Aβ plaques, 
it was shown that Aβ1-42 immunization of Tg2576 mice crossed with FcRγ-/- (Fc 
receptor knock-out) mice resulted in unimpaired reduction in Aβ levels according to 
Das et al. (2003) compared to immunization of Tg2576, Fc receptor-sufficient mice.  
This would seem to indicate that microglial, FcR-mediated phagocytosis is not 
required for effectiveness of the Aβ vaccination and is not the main mechanism for 
Aβ clearance (Das et al. 2003a).  Das et al. (2003) also showed that B and T cell 
responses to Aβ1-42 immunization vary greatly based on specific MHC class II 
expression patterns, indicating that some combinations of expression among these 
molecules result in better presentation of the Aβ peptide to these cells and once again 
emphasized the importance of these immune cells in determining immune response to 
Aβ (Das et al. 2003b).   
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 Along with an understanding of the reactions of the immune system of APP 
transgenic mice to Aβ inoculation and the mechanisms of Aβ clearance, it is also 
necessary that the impact of expression of this human transgene on the response of 
these animals be understood.  In comparing the immune response of APP transgenics 
and non-transgenics to Aβ inoculations, Monsonego et al. (2001) reported that APP 
transgenic mice immunized with either Aβ1-40 or Aβ1-42 displayed 
hyporesponsiveness to these peptides immunologically.  This was thought to be 
associated with a lack of T cell response in these animals, perhaps due to long-term 
presence of Aβ peptides in transgenic mouse brains from an early time point.  It was 
suggested that if the T cell response could be raised during the vaccination period, 
such immunotherapy would prove more successful (Monsonego et al. 2001).   
 Further emphasizing the hyporesponsiveness of the the APP transgenic mouse 
immune system to Aβ, Dickey et al. (2001) reported that three vaccinations with Aβ1-
42 was necessary to elicit a significant immune response in APPsw+PS1 transgenic 
mice based on IgG levels.  Subsequent administrations of the vaccine resulted in 
moderate immune responses through 5 months.  It was also noted that the highest 
immune response was to the Aβ N terminus, and it was suggested that because the 
main humoral response was IgG1- and IgG2-based, a TH2 T cell subset activation was 
likely to be involved in generating this response.  Importantly, it was also noted that 
the immunized mice displayed T-cells stimulated specifically by the Aβ peptide, 
again emphasizing the potential for T-cell activation to regulate the immune response 
to Aβ vaccination (Dickey et al. 2001).  Both of these previous two studies provided 
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insight into the importance of proper regulation of T cell activation following 
immunotherapy. 
 Additional support for the important regulatory role of TH2 cells following Aβ 
immunization in transgenic mice was provided by Town et al. (2002).   It was 
reported that a bias towards this T cell subset in both C57BL/6 non-transgenics and 
APP mice inoculated with Aβ1-42 was found.  Importantly, this bias was not noted 
following Aβ1-40 immunization, indicating an altered immune response based on 
antigen selection (Town et al. 2002). 
 In 2004, Li et al. reported that while anti-Aβ levels from Aβ immunized APP 
transgenic mice are masked in ELISA measurements if not first treated with a low-pH 
solution to dissociate anti-Aβ/Aβ complexes, these levels are still significantly lower 
than those of non-transgenic mice of the same background following immunization 
even after such treatment.  Only when Aβ was administered associated with 
papillomavirus virus-like particles (VLPs) were levels of anti-Aβ comparable in APP 
and non-transgenic mice, indicating that self-tolerance to Aβ in APP mice results in 
hypoimmune responsiveness in these mice after normal active Aβ immunization (Li 
et al. 2004). 
 Based on findings that aged Caribbean Vervets, which are primates, often 
develop cerebral Aβ plaques, Lemere et al. (2004) vaccinated a number of these 
animals for 10 months with a cocktail of Aβ1-40 and Aβ1-42 in a 3:1 ratio.  No plaques 
were found in the four surviving immunized animals, while 11 of 13 controls showed 
plaque development.  It was also noted that rises in plasma Aβ were associated with 
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decreases in brain Aβ levels in immunized animals, and antibodies to Aβ were noted 
in both the plasma and CNS.  This study was the first to report Aβ clearance 
following Aβ vaccination in a non-human, non-transgenic mammal which normally 
develops Aβ plaques with aging (Lemere et al. 2004). 
 The above studies elucidated the potential for active Aβ immunization in AD 
animal models to elicit an immune response at numerous timepoints in the 
development of amyloid pathology, including production of various anti-Aβ antibody 
isoforms and stimulation of cellular-based immunity mediated by T lymphocytes.  It 
was demonstrated that such immune system activation leads to varying levels of 
clearance of Aβ pathology from the CNS based on background strain interactions, 
antigen selection, antigen delivery, adjuvant selection, and age.  This generated 
excitement at the possibility of developing a vaccination-based therapeutic for 
Alzheimer’s disease.  Still left to be discovered by additional studies, however, was 
the potential for such immunization to also lead to devastating consequences in the 
AD brain, as well as the actual cognitive benefit to be gained by Aβ vaccination. 
Deleterious Effects of Active Aβ Immunization and Alternative Active 
Immunization Approaches. 
 Two major studies in Aβ vaccination focused largely on its negative 
consequences.  Su et al. (1999) reported that low-level infusions of soluble Aβ1-40 
intravascularly in 3 month old male rats over the course of 2 weeks resulted in blood 
vessel damage including gross pulmonary hemorrhage, disruption of the BBB, and 
activation of microglia and astrocytes in the CNS.  While these physiological 
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consequences were not coupled with impairment in water maze, they did provide 
evidence that even short, low-level administrations of Aβ can result in damage to 
both the vasculature and perhaps the CNS via initiation of widespread inflammation.  
This again emphasized the importance of determining a method for vaccination which 
does not instigate such damage (Su et al. 1999).     
 Furlan et al. (2003) further elucidated our understanding of the potential for 
neuroinflammatory damage resulting from Aβ vaccination.  Young C57BL/6 mice 
immunized with Aβ1-42 were shown to display inflammatory foci in the brain and 
spinal cord associated with the vasculature of these areas.  These foci were noted to 
contain microphages, T and B cells, and immunoglobulins.  This response was 
attributed to Th1 subset mediation of inflammatory events coupled with high anti-Aβ 
levels.  Importantly, these results were noted only when a co-administration of Aβ 
and pertussis toxin (which elicits autoimmune processes) was performed; thus the 
extent to which the toxin contributed to development of these foci is important in 
interpretation of these results (Furlan et al. 2003).   
 It was apparent following the Su et al. 1999 study and based on results of 
phase II clinical trials in humans that there are dangers associated with simple Aβ 
vaccinations mainly associated with increased neuroinflammation, and numerous 
studies which followed focused largely on searching for more unique modes of 
immune system activation which do not invoke such reactions.  In 2000, Frenkel et al. 
attempted active Aβ immunization in both BALB/c mice and guinea pigs via either 
intranasal administration and s.c. or i.p. injection of a phage displaying the Aβ 3-6 
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peptide residue EFRH.  Seven days following injection, serum levels of IgG reactive 
against both wt-phage and Aβ were measured for three injections spaced 14 days 
apart.  Mice injected i.p. with Freund’s adjuvant developed large titres of antibodies 
which increased after each injection.  Specific IgG and IgA antibodies were noted 7 
days after only one booster injection of phages.  Guinea pigs injected s.c. were noted 
to develop very high titres of anti-Aβ antibodies following the same injection 
protocol.  The guinea pig EFRH sequence is homologous to that of humans, whereas 
in mice the sequence is EFGH, so the effectiveness of the phage administration in 
both species emphasized the potential of this vaccination for effectiveness in humans.  
It was shown that in both animal groups, sera containing antibodies produced was 
able to bind specifically to the Aβ peptide, and that this sera protected against Aβ 
neurotoxicity in vitro.  Also noted was the ability of this sera to disrupt Aβ fibril 
formation in vitro (Frenkel et al. 2000).  In 2003, Frenkel et al. again immunized mice 
with EFRH presenting phages, this time in the APP transgenic model.  This 
immunotherapeutic approach was shown to again dramatically reduce Aβ pathology 
in these mice.  Importantly, it was noted that two mice receiving the phage did not 
develop high titers of anti-Aβ antibodies, indicating less than perfect penetrance 
(Frenkel 2003). 
 In 2001, Sigurdsson et al. were able to show that immunization with a 
nontoxic, soluble Aβ homologue results in a similar reduction in amyloid pathology 
to those noted after standard Aβ administration in APP transgenic mice.  Along with 
reductions in soluble and insoluble Aβ, these mice also exhibited decreased microglia 
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activation, thought to be associated with an overall reduction in inflammation levels 
(Sigurdsson et al. 2001).  In 2004, Sigurdsson et al. carried out active immunization 
in APP mice with this same nonfibrillogenic, nontoxic derivative of Aβ, K6Aβ1-30, 
which was known to induce Aβ clearance in similar levels to Aβ1-42 treatments.  A 
primarily IgM response resulted in these mice, and Aβ pathology was significantly 
reduced in inverse correlation to levels of these antibodies.  IgM is not able to cross 
the BBB, so it was inferred that Aβ clearance resulted from these antibodies acting as 
a peripheral “sink” for these peptides.   
 In 2002, a study conducted by McLaurin et al. showed that antibodies 
recognizing the 4-10 residues of Aβ1-42 are capable of inhibiting fibrillogenesis of 
Aβ in TgCRND8 transgenic mice without invoking activation of the inflammatory 
system.  This antibody was shown to target protofibrillar Aβ, which is thought to be 
important in formation of Aβ plaques, and provided an important mechanism for 
blockage of said formation.  It was further reported that the immunization which led 
to this antibody formation caused a biased T cell response, downregulating 
inflammatory events associated with Th1 cell activation while upregulating some 
aspects of the humoral responses elicited by Th2 cells (McLaurin et al. 2002).  
 Koller et al. (2004) found that immunization of APP transgenic mice with 
Aβ1-42 coupled with DnaK, a heat shock protein 70 analogue and strong adjuvant, 
resulted in measurable levels of anti-Aβ antibodies after only one innoculation with 
maximal titers of these antibodies present after the first booster inoculation.  These 
levels were still significantly lower than those achieved in non-transgenic controls 
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receiving the same vaccination.  This emphasized the importance of adjuvant in 
determining the immune response elicited by active immunization, and provided a 
method for reducing the total number/amount of Aβ administration necessary to elicit 
an appropriate immune response.  Importantly, however, these immunizations were 
all administered by 3 months of age, and as a result no affect was seen on Aβ levels 
and plaque burdens after sacrifice at an aged time point, suggesting that prophylactic 
immunization occurring too early in life, without continuation, may prove ineffectual. 
(Koller et al. 2004).   
 Hara et al. (2004) found that oral administration of a recombinant adeno-
associated virus vector containing cDNA for Aβ resulted in expression and secretion 
of both Aβ1-43 and Aβ1-21 within the intestine of hAPP transgenic mice.  This resulted 
in anti-Aβ antibody production through 6 months and significant decreases in CNS 
Aβ levels.  These decreases were not associated with any notable inflammation or T 
cell response (Hara et al. 2004). 
   The work of Su et al. (1999), Furlan et al. (2003), and results from Aβ 
vaccination clinical trials served as a warning for researchers, demanding that new 
understanding of the true consequences of Aβ immunization should be gained before 
any further clinical trials are conducted.  Many of the studies which followed thus 
searched to explore alternative Aβ vaccination methodologies to reduce 
neuroinflammation and a cellular-based immune response.  Even these studies, 
however, are not fully sufficient to gain true understanding of the potential effects of 
Aβ vaccination is AD models.  Yet to be determined is the effects of Aβ vaccination 
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on cognitive behavior, as most of the studies mentioned above did not seek to 
correlate any pathological findings with cognitive impacts. 
Behavioral Characterization in Active Aβ Immunotherapy 
 Due to the potential for neuroinflammatory damage associated with Aβ 
immunization, it was necessary to establish that cognitive protection could be elicited 
by such treatment despite these potential negative consequences.  Janus et al. (2000) 
reported that vaccination of young TgCRND8 mice with Aβ1-42 peptide in complete 
Freund’s adjuvant resulted not only in plaque load reductions, but also in decreased 
impairment in Morris water maze acquisition, though these mice still did not perform 
at the same level as non-transgenic controls.  3 cohorts of mice were immunized at 6, 
8, 12, 16, and 20 weeks of age with either Aβ1-42 peptide or islet-associated 
polypeptide (IAPP), both in β-pleated sheet formation.  This control antigen was 
selected based on its similarity to Aβ, but also on the fact that it only causes 
amyloidosis outside of the CNS.  Both peptides were shown to induce antibody 
production by 13 weeks when the first group of injected animals underwent sacrifice.  
A second group of animals were sacrificed at 23 weeks and showed 2-3 fold increases 
in antibody productions by this time point.  These antibodies were shown to strongly 
bind to dense Aβ plaques but to only weakly interact with diffuse, non-fibrillar 
deposits of Aβ.  Also, these antibodies did not appear to be reactive to APP, as 
normal neurons were not detected by the antibody.  Impacts of immunization on Aβ 
pathology were noted to be similar to those from previous studies with regards to 
density and size changes of dense-cored plaques, however at both 13 and 25 weeks, 
   
73 
no changes in formic-acid-extractable (soluble) Aβ were noted, perhaps because of 
the specificity of anti-Aβ antibodies to the β-pleated sheet formation of deposited Aβ.  
Behavioral testing of mice by Janus et al. (2000) consisted of longitudinal 
testing (at 11, 15, 19, and 23 weeks of age) in a reference memory version of Morris 
water maze, with the submerged escape platform in a different location at each test 
age.  Aβ1-42 immunized transgenic mice were shown to perform significantly better 
than non-immunized transgenics, however performance was not improved to the level 
of non-transgenic mice.  Aβ immunized mice were also shown to significantly 
improve in task performance after repeated reversal testing, indicating a learning 
affect in these mice. In probe trial testing following Morris water maze testing, no 
significant differences were noted among groups.  However, this was attributed to the 
close temporal proximaty of task administration (30 minutes) to final day Morris 
water maze administration.  Controls studies indicated that no performance changes 
were noted for non-transgenic mice following any form of PBS, Aβ, or IAPP 
injection with or without adjuvant (Janus et al. 2000).   
Morgan et al. (2000) and Arendash et al. 2001 found that APPsw+PS1 mice 
immunized monthly with Aβ1-42 in Freund’s adjuvant (mineral oil after 3 months) 
showed significant protection against impairment in the RAWM task at an aged time 
point compared to controls receiving a control vaccine of keyhole limpet 
haemocyanin.  Behavioral assessment of double transgenic mice by Morgan et al. 
(2000) and Arendash et al. (2001) consisted of pre-immunization administration of a 
6-week battery of sensorimotor and cognitive based tasks between 5 and 7 months of 
age followed post-immunization by Radial Arm Water Maze testing at 11.5 and 15.5 
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months and balance beam, string suspension, open maze, and Y-maze tasks at 16 
months.  No differences were noted among groups in pre-immunization 
performances, except in balance beam performance in which transgenic animals were 
impaired overall.  In RAWM testing at 11.5 months, transgenic animals performed at 
the same level as non-transgenic controls.  Results from repeated testing at 15.5 
months demonstrated that Aβ immunized mice reached similar levels of performance 
to non-transgenics by final trials of testing, however it was demonstrated that these 
mice required more trials to reach this level of performance than these non-
transgenics.  Working memory was thus shown to be greatly improved in 
APPsw+PS1 mice following repeated Aβ1-42 immunizations over an 8 month period 
(Morgan et al. 2000). 
Mice immunized with Aβ, both transgenic and wild-type, showed high anti-
Aβ serum activity while non-Aβ immunized animals showed no such activity.  
Modest to no reduction in Aβ plaque burdens in the frontal cortex and hippocampus 
were noted post-immunization.  Though no measures of soluble Aβ levels were noted 
in these studies, it was suggested that reduced levels of soluble, toxic Aβ oligomers 
may have contributed to the lack of cognitive impairment present in these Aβ 
immunized animals, despite their high levels of Aβ pathology remaining in the CNS. 
Based on correlation analysis of behavioral task performances and Aβ burden 
measures, a number of correlations were evident in the same study’s animals 
(Arendash et al. 2001).  While there was no correlation between total Aβ 
immunostaining (compact and diffuse plaques) and RAWM performance, T4 error 
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measures did correlate with both Aβ1-40 immunostaining and congo red staining in 
frontal cortex as well as with immunostaining in both the hippocampal CA1 region 
and dentate gyrus.  However, as Aβ reduction was modest at best it is likely the 
impact of vaccination on soluble Aβ constructs in the CNS (neutralization and/or 
clearance by anti-Aβ antibodies) that played a larger role in providing cognitive 
benefit (Morgan et al. 2000, Arendash et al. 2001).   
 Jensen et al. (2005) vaccinated APP+PS1 mice with Aβ1-42 in Freund’s 
adjuvant (complete for initial injection, incomplete for monthly booster injections) 
from 2-16.5 months of age and determined the effect of these injections at 4.5-6 
months and 15-16.5 months longitudinally via administration of a 6 week behavioral 
test battery at each time point.  The study cohort was divided into control transgenic, 
vaccinated transgenic, and non-transgenic mice.  At the 4.5-6 month time point, both 
transgenic groups displayed increased open field activity, while no group differences 
were noted at the 15-16.5 month time point.  Only young (early time point) treatment 
mice were impaired at the balance beam task, however this impairment was not 
present at the later time point and no impairment was present for string agility 
performance at any time point.  Comparing early and late time point performances, a 
significant increase in percent time spent in open arms during the elevated plus maze 
task in control mice was coupled with a significant decrease in the same measure for 
vaccinated mice, perhaps indicating an anxiolytic effect in the former and an anxiety 
increase in the former.  Consistent with open field results, vaccinated mice also 
showed significantly higher plus maze and Y-maze arm entries at the young time 
point.  Only Y-maze entries remained higher at the aged time point, however.  No 
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differences among groups were noted among percent alternations in Y-maze or 
circular platform acquisition, however significance was found for each additional 
cognitive based task administered.  In Morris water maze acquisition, vaccinated 
mice were protected against impairment noted in controls at both time points.  This 
same trend was noticed for young mice tested in Morris water maze retention, 
however both transgenic groups were impaired compared to non-transgenics at the 
later testing time point.  No impairment at the young time point was noticed in 
platform recognition, whereas vaccinated mice showed protection against impairment 
exhibited by control mice at the later time point in this task.  RAWM overall and last 
block performances were reported for these mice as well, and for both measures at 
both time points control mice showed performance impairment.  In contrast, only in 
overall RAWM performance at the young time point were vaccinated mice impaired; 
in last block, young time point performance and in both last block and overall aged 
time point performance vaccinated mice showed were protected against this 
impairment.  Discriminant function analysis using direct entry method revealed 
cognitive protection in vaccinated animals at the young time point.  Stepwise-forward 
analysis showed similar results for all measures, as well as cognitive measures, at 
both time points. 
 At 17 months of age, mice in the study conducted by Jensen et al. (2005) were 
sacrificed, and Aβ histopathology was performed on mouse brain sections.  No 
significant reduction in Aβ immunostaining (total Aβ) or Congo Red staining 
(compact Aβ) burdens were noticed in vaccinated mice overall, though one 
vaccinated mouse was noted to have significant reductions of up to 86% in Aβ levels.  
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Correlation analysis between the 8 Aβ deposition measures noted and nine cognitive 
measures taken at the aged time point in these mice revealed no correlations between 
Aβ histopathology and cognitive performance, in contrast to previous findings by 
Arendash et al. (2001) in which such correlation was made for certain measures 
despite a lesser duration of Aβ administration.  Still, factor analysis results from 
Jensen et al. (2005) did suggest an existing relationship between Aβ deposition and 
numerous cognitive measures, despite a lack of significant correlation therein.  More 
importantly, perhaps, is that this study demonstrated once again the potential for long-
term, active Aβ vaccination to result in cognitive protection in an AD transgenic 
mouse model without significant overall reductions in deposited Aβ levels (Jensen et 
al. 2005). 
 Austin et al. (2003) showed that 4 biweekly administrations of Aβ1-42 to 
APPsw+PS1 transgenic mice at 16-18 months of age did not result in improved 
cognitive performance in RAWM or other tasks between 18 and 20 months compared 
to cognitively intact non-transgenic mice.  Serologic anti-Aβ titers in these aged mice 
were measured at an approximately 10-fold lower level compared to the previous 
study by Morgan et al. (2000), indicating a possible mechanism for no improvement 
in cognition.  Prior to immunization, RAWM and platform recognition tasks were 
administered, and it was noted that impairment of APPsw+PS1 mice was only present 
in trial 5 performance of RAWM as well as overall in platform recognition 
performance.  Following immunizations, both immunized and non-immunized 
animals showed significant impairment compared to non-transgenics over a number 
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of RAWM measures.  Furthermore, both groups showed no pre- versus post-
treatment differences in RAWM performances for any trial or block combination, and 
in some instances these groups showed significant decline in performance measures.  
In contrast, non-transgenic animals showed significantly better trial 4 performances 
compared to testing results at a younger time point as well as stabilization of trial 5 
errors at a significantly lower level compared to the high stabilization levels of 
transgenic groups.  Impairment also continued in platform recognition performance, 
with significantly poorer performances displayed by both transgenic groups compared 
to non-transgenics.  Based on these findings, it seems that short-term immunization 
was not effective in eliciting a strong immune response in these aged APPsw+PS1 
animals resulting in no positive impact on cognitive performance.  If these results can 
be translated to human application, it would seem that Aβ vaccination will most 
likely be most effective in AD if administration is begun at early time points in 
disease development, resulting in increased administration periods (Austin et al. 
2003).   
Behavioral evaluation of vaccinated mice was also performed by Sigurdsson 
et al. (2004) following K6Aβ1-30 immunization.  Immunized mice performed 
significantly better than transgenic controls in the radial arm maze task, in many 
measures performing at a similar level to wild-type controls.  It is clear based on these 
results that cognitive protection is possible using a non-toxic, non-T cell activating 
Aβ derivative such as K6Aβ1-30 as an antigen, indicating possibilities for future 
vaccinations with reduced negative side-effects (Sigurdsson et al. 2004). 
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The above behavioral based Aβ immunization studies directly tie the 
pathological impacts of such vaccinations with cognitive benefits in AD transgenic 
mice.  The potential for Aβ vaccination as a therapeutic based on beneficial cognitive 
impacts following reduced CNS Aβ burdens is established (Janus et al. 2000), 
however, the potential of long-term vaccination to result in such benefit without 
dramatic decreases in Aβ pathology is also reported (Morgan et al. 2000, Arendash et 
al. 2001).  Thus, the positive effects of Aβ vaccination on behavior in APP transgenic 
mice appear to be mediated not simply by clearance of Aβ deposits, but by some 
other mechanism such as clearance/neutralization of soluble Aβ constructs.  Findings 
by Austin et al. (2003) establish the necessity for long-term vaccine administrations 
to achieve cognitive benefit, and it is apparent based on the overall results of the 
above studies that application of Aβ vaccination as a preventative as opposed to a 
treatment may result in increased efficacy.  Finally, findings reported by Sigurdsson 
et al. (2004) provide support for the concept of alternative immunotherapeutic 
approaches to Aβ vaccination.  Such results further reinforce the importance of 
developing AD therapeutics targeting Aβ in the CNS, and promote Aβ 
immunotherapy as a field of continued importance in AD research. 
Active Aβ Immunization in Humans 
 The collective results of Phase I and Phase IIa Clinical Trials conducted by 
Elan Pharmaceuticals in the U.S. and U.K. represent a disappointment which could 
only follow the highest level of anticipation.  Protocols consisted of administration of 
Aβ1-42 (An1792) to humans in initial and booster shots for Phase I and, with repeated 
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shots planned over a 12 month period for Phase II trials.  In January 2002, reports of 
nerve inflammation in four out of 298 patients in Phase II that had begun receiving 
active vaccination led to further administrations being halted.  Phase II was halted, in 
fact, after only the initial and one booster injection (after 2 shots separated by one 
month).  11 additional patients were reported to have developed similar 
symptomologies a month later, and one death was attributed to affects of the vaccine.  
Specifically, post-mortem analysis indicated neuroinflammation associated with T 
cell activation as a possible cause of death.  In the end, 18 individuals, or 
approximately 6%, were found to develop symptoms suggesting subacute 
meningoencephalitis (Orgogozo et al. 2003).  A number of reports of findings from 
these studies were still published, however.  In October, 2002, Hock et al. reported on 
the presence of anti-Aβ antibodies in the sera of 100% of 24 patients having received 
one primary and one booster injection i.m. of Aβ vaccine containing QS-21 as an 
adjuvant.  These antibodies were not found to be cross-reactive with APP or any non-
Aβ derivatives.  Sera taken from these patients were also found to bind to Aβ deposits 
in post-mortem brain tissues of AD and CAA patients.  CSF samples taken from 6 
patients were also analyzed for Aβ reactivity, and it was reported that 4 out of 6 
samples displayed positive results.  Importantly, the presence of anti-Aβ in the CSF 
was noted in patients with and without BBB dysfunction.  It was suggested that a 
combination of low Aβ antibodies and intact BBB’s resulted in prevention of these 
antibodies from entering the CSF in the two negatively tested patients. Aβ titers in 
serum samples ranged from 1:50 to 1:10,000, while in the CSF the highest 
measurement was 1:1,000 (Hock et al. 2002). 
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 In March 2003, the first case report from post-mortem analysis of the lone 
mortality of the Aβ1-42 vaccination trial was published by Nicoll et al.  
Neuropathological analysis of this woman’s brain revealed uncharacteristically low 
levels of plaques in various areas of the neocortex compared to seven unimunized AD 
patient brains.  It was noted that these areas still maintained levels of NFTs and CAA 
common to non-treated AD patients, but that dystrophic neurite levels and astrocytic 
activations typically associated with amyloid plaques were significantly reduced.  
Involvement of microglia in Aβ clearance was suggested by co-associated with Aβ 
immunoreactivity.  Perhaps most important, however, were findings of T-lymphocyte 
meningoencephalitis, indicating the potential mechanism by which 
neuroinflammation occurred in patients receiving the Aβ vaccine (Nicoll et al. 2003).  
This provides insight into the major disparity between immune reactivity to Aβ1-42 in 
mice and humans.  In mice, evidence suggests that hyppoimmune responses to Aβ 
may be due to low levels of T cell activation; however it is clear based on the above 
findings that heightened T cell response is present in at least some humans receiving 
the vaccine. 
 In May of 2003, Hock et al. reported on some of the positive cognitive effects 
of Aβ vaccination in humans.  19 of the 28 patients administered the vaccine in Phase 
I trials showed decreased decline in cognitive functions compared to non-treated 
individuals.  These patients were also noted to be the individuals who developed 
antibodies against Aβ.  Cognitive stability was determined via administration of tests 
such as the MMSE and Visual Paired Associates Test of delay recall from the 
Wechsler Memory Scale.  Declines in activities of daily living were also diminished 
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in treated individuals as determined from Disability Assessment for Dimentia results.  
Importantly, overall results from the 300 patients tested in Phase II AN1792 clinical 
trials did not parallel these findings, with no significant differences in cognitive 
decline noted between groups.  More information on the time course for antibody 
development was also relayed in this publication.  It was reported that both IgG and 
IgM levels against aggregated Aβ1-42 increased significantly in the first month 
following initial Aβ inoculation, and that maximal titers were reached by a month 
after the booster injection (Hock et al. 2003). 
 The various findings resulting from vaccination studies in humans reinforce 
the potential for variations between mouse model systems and human systems to 
result in imperfect translation of results from one to the other.  Important to consider, 
however, is the evidence shown that cognitive benefit and Aβ clearance can result 
from Aβ administration in humans.  Thus, while the risks associated with standard 
Aβ immunization outweigh potential benefits, it is clear that Aβ immunotherapeutic 
approaches to AD warrant further investigation. 
Passive Anti-Aβ Immunization in Animal Models 
 Pathologic Effects of Passive Anti-Aβ Immunization 
 Due to its neurotoxic properties, it is clear that the concept of Aβ inoculations 
should elicit some level of concern.  Passive administration of Aβ antibodies allows 
for introduction of these molecules without any need for Aβ inoculation or for 
immune system activations associated with antibody production.  The major methods 
proposed for vaccine efficacy are direct solublization of Aβ, peripheral sequestration 
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of Aβ by circulating antibodies, and antibody facilitated phagocytosis of Aβ by 
microlgia.  Thus, the potential for Aβ clearance based solely on the administration of 
Aβ antibodies is viable.  Bard et al. (2000) performed the first study involving passive 
immunization in a mouse model of AD.  It was shown that peripherally administered 
antibodies to Aβ are capable of entering the CNS of PDAPP mice to induce clearance 
of amyloid plaques by as much as 93%.  Two of a set of four monoclonal antibodies 
along with polyclonal antibodies from Aβ1-42 immunized mice were shown to induce 
this effect in 8-10 month-old mice.   No T-cell reactivity was seen to be evoked as a 
result of these procedures.  Analysis of microglia showed numerous Aβ containing 
vesicles, indicating a major phagocytic mechanism of plaque clearance.  Internalized 
Aβ was shown to be degraded by these cells, and the internalization process was 
shown to be Fc receptor mediated.  Additional work with 13 month old mice showed 
that modest reduction in existing small plaque counts could be seen as early as 3 days 
after treatment, while 35 days after treatment up to 60% of small and diffuse plaques 
had been cleared.  Large, compact plaques appeared to resist clearance.  Importantly, 
no correlation existed between binding affinity of antibodies to soluble Aβ and plaque 
clearing capabilities of these antibodies, indicating that affinity to deposited Aβ may 
play the larger role (Bard et al. 2000). 
 DeMattos et al. (2001) also showed that anti-Aβ antibodies are able to prevent 
Aβ deposition in PDAPP mice, however it was shown that the antibodies used in this 
study were not capable of binding to existing Aβ deposits.  It was found that these 
antibodies sequestered large quantities of Aβ in the serum, indicating that in this case 
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the ability of these molecules to act as a peripheral Aβ sink was the driving force 
behind protection against development of Aβ pathology.  CSF levels of Aβ were also 
found to increase, which was attributed to increasing levels of solublized Aβ 
(DeMattos et al. 2001). 
 Lambert et al. (2001) showed that antibodies generated in vivo against 
inoculated Aβ1-42 oligomers were capable of binding preferentially to Aβ constructs 
in vitro.  These antibodies were also shown to block toxicity of Aβ oligomers in vitro.  
As mentioned earlier, a study conducted by McLaurin et al. in 2002 showed that 
antibodies recognizing the 4-10 residues of Aβ1-42 inhibit fibrillogenesis of Aβ in 
TgCRND8 mice.  Again, the antibody was shown to target protofibrillar Aβ, an 
important Aβ plaque precursor.  These studies provide a clear mechanism for 
prevention of plaque formation via anti-Aβ administration which may potentially 
occur without modulation of Aβ levels.  (McLaurin et al. 2002). 
 In 2002, Chauhan and Siegel reported that a single ICV injection of anti-Aβ 
antibodies led to reduced plaque loads in the cerebrum and decreased astrocytosis in 
10 month-old Tg2576 mice.  In 2003, this same group reported that this same 
treatment was associated with reduction in activated microglia levels in areas 
surrounding existing Congophilic plaques- the study, however, only involved 
qualitative assessments of these levels.  Nonetheless, it was further reported that no 
signs of microhemorrhage were found in these mice (Chauhan and Siegel 2003).  
Wilcock et al. (2004) also showed that significant reduction in amyloid was possible 
in Tg2576 mice, this time in 19 month-old animals.  It was shown in this study that 
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microglia activation between 3-7 days after injection correlated to this clearance, but 
that other mechanisms were involved as clearance began as early as 24 hours post-
infusion.  Finally, a study by Lombardo et al. (2003) in aged PDAPP mice indicated 
that, along with clearance of Aβ as early as 4 days following a single administration 
of anti-Aβ antibodies, neuritic alterations attributed to neurotoxic properties of Aβ 
were reversed as a result of this administration.  This again emphasized the 
importance of achieving Aβ clearance from the CNS in AD. 
 Pfeifer et al. (2002) produced the first results indicating the possibility for 
negative consequences to passive anti-Aβ administration.  21 month-old APP23 mice 
showed reduced amyloid pathology following such treatment, mainly due to 
clearance of diffuse Aβ plaques, but also displayed increased levels of 
microhemorrhages.  It was also shown that CAA levels were not affected, only 
hemorrhages associated with this pathology were shown to increase in occurrence.  
CAA development appeared to be a requisite for this pathology to occur, as 6 month-
old APP23 mice lacking CAA did not develop these hemorrhages.  One suggested 
mechanism for triggering of these hemorrhages was that anti-Aβ antibodies are 
capable of binding to amyloid deposits in blood vessel walls, potentially causing an 
inflammatory event that served to weaken such amyloid-bearing blood vessel walls.  
It was suggested that because approximately 80% of AD patients over 65 develop 
CAA, and because only APP23 mice develop CAA at levels comparable to those 
found in AD, that results from other passive anti-Aβ studies may not be a perfect 
indicator of the response such treatment would elicit in humans (Pfeifer et al. 2002). 
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Behavioral Effects of Passive Anti-Aβ Immunization 
 Along with those studies focused solely on pathological impacts of passive 
anti-Aβ immunotherapy, a few studies also investigated behavioral impacts.  Dodart 
et al. (2002) reported that 24 month-old PDAPP mice treated i.p. with m266 anti-Aβ 
antibodies for six weeks showed performance in object recognition tasks similar to 8 
month old wild-type mice and significantly better than non-treated PDAPP mice or 
IgG1 isotype treated controls.  No significant reduction in Aβ pathology was noted in 
these mice, in contrast with previous findings from this same group in younger 
PDAPP mice, and task improvement was therefore attributed to reduced levels of 
soluble Aβ in the CNS.  This was supported by correlation analysis showing no 
correlation between Aβ burdens and behavior in m266 treated mice and by findings 
that 8 month old non-treated PDAPP mice were significantly worse than aged, treated 
PDAPP mice at recognizing novel objects despite having lower levels of Aβ 
deposition.   
Further work by Dodart et al. (2002) studied the impact of acute, single 
administrations of m266 on 11 month old PDAPP mice.  Again it was shown that 
these mice were better at recognizing novel objects than age-matched transgenic 
controls after receiving only one m266 administrations.  To further explore the effect 
of acute, single-dose m266 therapy on behavior in 11 month old PDAPP mice, 4 days 
of the holeboard task were administered.  It was reported that treated mice made 
significantly fewer errors in this task during the final two days of testing (data not 
reported for initial two days of testing), again emphasizing the potential for learning 
and memory benefits based on m266 therapy.  Finally, statistical analysis showed a 
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dose dependent correlation between object recognition performance and m266 
therapy dosage, and only mice receiving maximal dosage (250 µg) showed 
performance above chance levels in this task.  The antibody used in this study was 
known to not decorate existing Aβ plaques and was thought to not cross the BBB, 
however a dose-dependent correlation was made between plasma concentrations of 
Aβ isoforms and m266 therapy.  Based on these findings, it was suggested that the 
major mechanism of action for m266 therapy was for these antibodies to act as a 
peripheral Aβ “sink”, binding and sequestering peripheral amyloid and causing an 
equilibrium shift of CNS to peripheral Aβ.  Thus, according to this theory, cognitive 
protection can be gained via modulation of CNS soluble Aβ levels without reductions 
in Aβ plaque burdens.  (Dodart et al. 2002).   
 Kotilinek et al. (2002) reported similar results to those seen by Dodart et al. 
(2002).  It was shown that administration of the monoclonal anti-Aβ antibody BAM-
10 (which recognizes the N terminus of Aβ) did not lead to plaque clearance in the 
CNS of 9-11 month old Tg2576 mice, but that reversal of memory loss did correlate 
to such administration.  Baseline performance was measured just prior to 
immunization and consisted of administration of the visible platform task followed by 
hidden platform coupled with three intermittent probe trials (a variation of Morris 
water maze application).  Mice were divided into treatment groups based on mean 
probe trial performances.  4-5 days after baseline evaluation, treatment mice 
underwent 3 separate injections of BAM-10 over a period of one week.  11-12 days 
following baseline testing, hidden platform testing was administered using the same 
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protocol; however a different set of visual cues were arranged around the testing pool 
and a unique platform location was used.  Major differences among groups based on 
treatment revolved around probe trial results.  It was shown that percent time spent in 
the target quadrant for this task was significantly increased in BAM-10 treated mice; 
in specific probe trials, however this trend was not noted in overall percent time 
measures (averaged from all probe trials) and no significant difference was measured 
between BAM-10 treated mice and IgG treated control mice overall.  No 
improvements were noted for hidden platform performances.  The interpretation of 
this data by the authors was that BAM-10 treated mice showed a reverse of memory 
loss following treatment.  As there were not significant alterations in Aβ levels in 
these mice, the authors contributed this reversal of impairment to neutralization of Aβ 
assemblies in the CNS resulting in decreased neurotoxicity of these constructs.  It was 
shown that BAM-10 treatment eliminated the negative correlation between soluble 
brain Aβ and probe trial scores, indicating that this treatment did in fact reduce the 
impact of existing Aβ in the brains of Tg2576 mice (Kotilinek et al. 2002).   
 Wilcock et al. (2004) administered weekly doses of anti-Aβ antibody to 
Tg2576 mice for either 1, 2, or 3 months, with treatment beginning so that all mice 
finished the treatment regimen at 22 months of age.  Behavioral assessment of these 
mice consisted of a single, 8 minute administration of the Y-maze task 1 day before 
sacrifice.  Mice were treated with IgG antibody to Aβ28-40 with controls receiving an 
anti-Drosophilia amnesiac protein IgG1 antibody.  Only mice treated with Anti-Aβ 
for 3 months were shown to have significantly higher spontaneous alternation in Y-
maze performance compared to transgenic control groups.  Performance for mice 
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treated for 3 months was at the same level as non-transgenics, with reduced 
performances following lesser treatment periods.  However, after 1 or 2 months of 
treatment, immunized mice were not significantly different in performance from 
either non-transgenics or controls transgenics.  Hyperactivity based on Y-maze arm 
entries was noted in non-treated APP controls but was not noted in 2 or 3 month 
treated animals.   
Antibodies administered for all treated mice were shown to decorate plaques 
within the CNS, with direct proportionality between immunostaining and plaque 
density.  Following 1 month of anti-Aβ treatment, transgenic animals were noted to 
have slight but not significant reductions in Aβ deposition.  Following both 2 and 3 
months of treatment, however, significant decreases in Aβ immunostaining were 
found in hippocampal and frontal cortex regions, with both compact and diffuse 
plaque burdens reduced.  It was further shown that microglia Fcγ receptor expression 
was upregulated after 1 month of anti-Aβ antibody treatment, CD45 molecules after 2 
months, and that expression levels of both marks then returned to normal after three 
months, indicating temporal activation of these cells.  Based on these findings, it was 
suggested that Aβ clearance was thus mediated via a number of mechanisms, 
including solublization of deposited Aβ by antibodies, sequestering of Aβ in the 
plasma, as well as by microglia activation and phagocytosis of Aβ.  Furthermore, it 
was said to be this reduction in Aβ burden in the CNS which resulted in improved Y-
maze performance for treated Tg2576 mice (Wilcock et al. 2004), although no 
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correlation between Aβ deposition and Y-maze alternation was done for Aβ antibody 
treated mice. 
 The speed with which acute administration of anti-Aβ antibodies result in 
cognitive benefit in AD transgenic mice (based on findings by both Kotilinek et al. 
2002 and Dodart et al. 2002) and the lack of Aβ pathology decreases in these animals 
would seem to support the theory that these antibodies are acting more through either 
alterations in CNS:sera Aβ levels or neutralization of toxic Aβ constructs.  The rapid 
behavioral benefits reported by Dodart et al. (2002) and Kotilinek et al. (2002) could, 
however, result from alleviation of secondary effects of Aβ (a known vasoconstrictor) 
in the blood resulting in increased cerebral blood flow.  In any event, findings by 
Wilcock et al. (2004) still support the concept of cognitive protection following 
reductions in Aβ pathology due to passive Aβ immunization. 
Passive Anti-Aβ Immunization in Humans 
 While no data has been reported on passive Aβ immunization in humans, the 
potential exists for such studies to occur based on results noted above in assessment 
of such immunization in transgenic models of AD.  In the wake of findings from 
active immunization trials in humans, however, the climate for research along 
immunotherapeutic lines in humans with AD has changed dramatically in the last few 
years.  Findings such as those noted by Pfeifer et al (2002) suggest that inflammation 
following anti-Aβ administration can occur in transgenic animals which develop 
CAA, and it is not unreasonable to assume that similar side-effects would occur in 
humans following such treatment.  As Anti-Aβ antibodies have been shown to 
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sequester amyloid in the blood, it is also possible that increased development of CAA 
or other vasculature dysfunctions may occur.  Other side-effects from 
continual/repeated administration of antibodies in humans may result from eventual 
immune response to injected antibodies, resulting in accumulation of immune 
complexes and potentially further disruption of the vasculature (serum sickness) 
(Sigurdsson et al. 2002).  Such activation of the peripheral immune system may also 
lead to development of inflammation within the circulatory system.  Although many 
results from passive Aβ immunization in animal models of AD have been positive, it 
is clear that the immune environment of transgenic models is extremely variable even 
based solely on background differences among mice, and the major lesson to be taken 
from the human vaccination trials is the potential for differences between immune 
responses in these mice and in humans to result in devastating side-effects.  Until a 
valid and long-lasting therapeutic for Alzheimer’s Disease is discovered, however, it 
is likely that the need for such treatments will eventually outweigh other concerns, 
and immunotherapeutic approaches such as passive Aβ immunization will 
undoubtedly be assessed in human subjects at some point. 
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Other Immunotherapeutic Strategies for Alzheimer’s Disease 
 
 Based on our current understanding of immunotherapeutic approaches to 
Alzheimer’s Disease, it is clear that the most probable means of reducing Aβ 
pathology in the CNS is limited to two mechanisms.  The first is humoral based and 
involves clearance of Aβ from the CNS via two separate routes.  Solublization of Aβ 
in the CNS by direct actions of anti-Aβ antibodies can result in clearance of both 
soluble and insoluble forms of the peptide, while sequestration of the Aβ by anti-Aβ 
antibodies in circulation can lead to an equilibration shift of Aβ into the serum and 
out of the CNS.  The second is cellular based and relies on activation of key immune 
system cells within the CNS to clear Aβ by phagocytosis and internal degradation of 
the molecule or by production of extracellular peptidases capable of breaking down 
aggregated Aβ.  Aβ immunization, both active and passive, is known to initiate 
reduction of Aβ levels within the CNS, both soluble and insoluble, via both pathways 
as described above.   
Alternative immunotherapies attempt to achieve similar results without 
instigating inflammatory damages associated with Aβ vaccination.  Currently, two 
potential immunotherapies in particular show promise.  The first involves 
development of non-antibody Aβ binding agents which can be administered 
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peripherally and serve to sequester Aβ in a similar  fashion to anti-Aβ antibodies, 
again resulting in increased traffic of Aβ out of the CNS.  As discussed previously, 
these agents thus serve as peripheral Aβ “sinks” by increasing serum levels of Aβ via 
this mechanism. The second involves either stimulation of an appropriate T cell 
response via various mechanisms or direct infusion of specifically activated T cells to 
elicit a desired immune response. 
Alternative Peripheral Aβ Sinks 
 In 2002, Matsuoka et al. reported that peripheral administration of two 
separate Aβ binding molecules, gelsolin and GM1, in young APPsw+PS1 mice 
resulted in significant Aβ clearance from the brains of these mice.  These blood-
limited molecules were thought to sequester Aβ in the periphery, causing a shift in 
Aβ equilibrium away from the CNS, as described for anti-Aβ treatments.  Gelsolin in 
particular is unable to cross the BBB, and so its affects are attributed solely to 
peripheral binding of Aβ.  Importantly, it was noted after treatment that plasma levels 
of Aβ did not increase at anywhere near the levels seen after passive Aβ 
immunization, making the exact mechanism of action for Aβ sequestration in the 
periphery difficult to interpret.  Administration of these compounds in aged PDAPP 
mice did not result in significant reduction of amyloid plaques, apparently indicating 
once again that amyloid plaque burdens are more difficult to reduce in older animals 
(Matsuoka et al. 2002).  This resiliency of established plaques in aged mice against 
reduction following immunotherapy has been established in numerous studies 
(Morgan et al. 2000, Arendash et al. 2001, Dodart et al. 2002, Kotilinek et al. 2002).  
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In 2003, Deane et al. showed that sRAGE, derived from the RAGE Aβ binding 
protein, can also act to sequester Aβ in the periphery, providing another potential for 
Aβ-binding protein therapy. 
 The exact mechanism by which Aβ is transported across the BBB to the 
periphery is thought to be mediated by the LRP clearance receptor for Aβ, while re-
entry of the peptide into the CNS appears to be mediated by RAGE receptors.  Other 
carrier proteins such as albumin and transhyretin are also thought to be involved in 
this process.  Modification or inhibition of certain aspects of these pathways or 
treatments may provide a mechanism for altering sera:CNS Aβ ratios, providing 
another mode of Aβ clearance from the CNS (Zlokovic et al. 2004).  
T-cell Based Therapy 
 As indicated above, immunotherapeutic treatments for neurodegenerative 
diseases such as AD result in varied levels of activation among separate T helper cell 
subtypes.  The actions of these reactive T cells then bias the overall immune response.  
In the most general terms, Th1 T cells cause a cellular based response and Th2 cells a 
humoral response (Vallejo et al. 2004).  Either response, if elicited in an appropriate 
fashion, may have a beneficial effect in the AD brain; the former via activation of 
phagocytes, the latter via activation of antibody-producing B cells and/or 
downregulation of neuroinflammation.  The potential for such bias to result in 
negative consequences has also been well established, for instance it has been 
indicated in vaccination studies that a Th1 biased immune response results in 
increased inflammation, potentially leading to an aberrant auto-immunee reaction 
(Furlan et al. 2003).  These responses are the most general aspects of T cell activities, 
   
95 
however, and, especially with regards to active immunization, it is unclear to what 
extent undesirable T cell activation and the neuroinflammatory events which result 
are due simply to the unique reactions elicited by the antigen and/or adjuvant used.   
Modulation of the T cell response via alterations in antigen/adjuvant vaccine 
components, as well as delivery routes/vehicles, could potentially result in benefit 
without neuroinflammation (Cribbs et al. 2003), and certain immunological 
treatments have been shown to elicit such benefit without any T cell activation 
(Schenk et al. 2004).  However, it is important to consider that T cell subsets as a 
whole are not anathema.  The potential activities of these cells in response to antigen 
based activation are wide ranging, and it remains to be seen whether such activation 
in the context of a non-immunized system is beneficial or detrimental.  Infusion of 
Aβ reactive T-cells has never been attempted in any animal model of AD, however 
the concept of such adoptive immunotherapy has been established for some time in 
other fields of study.  In individuals with lowered immune system efficacies or hypo-
responsiveness to specific antigens, T cell infusions act to prime these systems to 
counterbalance such deficits.  
Donor Lymphocyte Infusion For Non-CNS Diseases 
 Infusion of activated T cells has been used in the treatment of a number of 
disorders and diseases, with benefit gained due to actions of both CD4+ and CD8+ T 
cells individually and in concert.  There is great potential for such adoptive transfers 
to serve as anti-tumor treatments due to the activity of both cytotoxic cells 
recognizing tumor specific antigens and memory T helper cells capable of sustaining 
an immune response to malignant cells (Vonderheide and June et al. 2003).  Findings 
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that graph-versus-leukemia anti-leukemia affects were more likely to occur following 
transplant of non-T-cell-depleted bone marrow transplants resulted in a number of 
studies being conducted to test the efficacy of T cell Donor Lymphocyte Infusions 
(DLI), or selective infusion of non-patient lymphocytes, in treating various leukemias 
(Kolb et al. 1995, Collins et al. 1997, Slavin et al. 1996) as well as myelodysplastic 
syndrome (Bressoud et al. 1996), multiple myeloma (Lokhorst et al 1997), and non-
Hodgkin’s lymphoma (Bernard et al. 1999).  Complications were most prevalent 
following bone marrow transplant-based treatments and consisted mainly of marrow 
aplasia, or failure of the bone marrow to thrive, though this was resolved in as many 
as 80% of patients (Collins et al. 1997).  The potential for T cell infusions to serve as 
a treatment for numerous cancers, especially for recurrent hematalogic cancers post-
bone marrow transplant, has thus been established (Szer et al. 1993).   
Continuing research in immune system diseases have shown that T cell 
infusions serve to re-establish immune functions in patients with Epstein Barr Virus 
(EBV), cytomegalovirus, and Human Immunodeficiency Virus (HIV) infections, 
though not always without some adverse affects (Heslop and Rooney 1997, Walter et 
al. 1995, Levine et al. 2002).  This research elicits the potential for recharging of the 
immune system following DLI in immune compromised individuals or in 
counteracting hypo-immuneresponsiveness to a toxic self peptide such as has been 
implicated in AD. 
Priming of the CNS Immune System With T Lymphocytes 
 APP transgenic mice display a tolerance-based effect after immunization with 
Aβ which results in a decreased immune system response (Monsonego et al. 2001).  
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To elicit an immune response to Aβ in humans, it was deemed necessary to 
administer an adjuvant in concert with the peptide (Hock et al. 2002).  Otherwise the 
Aβ peptide, which is formed via proteolytic processing of the endogenously 
expressed APP molecule found in all humans, would not likely elicit a significant 
immune response until late in AD development when it is associated with 
neuroinflammation.  This self tolerance may affect the ability of Aβ vaccination to be 
effective as a treatment, especially as immune system activation in AD is largely 
restricted to local, glial based, non-systemic types (Streit 2004, D’Andrea 2004).  An 
exploration of the ability of T cells to prime the immune systems of AD models is 
thus warranted to determine the potential for such cells to overcome or reverse self 
tolerance to Aβ,  inducing either microglial phagocytosis of Aβ or B cell anti-Aβ 
antibody production.   
 As described above, APP mice display a lessened immune response following 
Aβ immunization compared to wild-type controls, most likely due to self tolerance.  
As both APP and Aβ are present under normal conditions in humans throughout 
aging, it is likely that a certain level of tolerance is present in humans as well 
following similar vaccination.  DLIs have been used to combat deficient immune 
systems in murine models as well as humans, whether these deficiencies be 
congenital or due to an infectious disease of the immune system.  It has been 
suggested a deficiency in the immune system may be present in AD which prevents 
the immune cells of the CNS from taking appropriate action against the insults 
inflicted therein during the course of disease.  Both microglia and T lymphocytes are 
likely to be drawn to areas of inflammation associated with Aβ pathology in AD 
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brains (D’Andrea 2004, Farkas et al. 2003).  However, these cells may not be 
appropriately activated early enough along the course of the disease to be affective, or 
may be deficient in their activity (Streit 2004, Monsonego et al. 2001).  Prior to 
compact neuritic plaque formation, microglia could potentially be stimulated to clear 
deposited Aβ.  At the same time, activated T cells can both regulate the immune 
response to Aβ associated damage and, as will be elicited later, potentially play a 
neuroprotective role against further damage.  If activated too late, however, 
frustration and continual stimulation of microglia and T cells (via co-stimulation) 
may occur, resulting in exacerbation of the inflammatory cascade rather than 
protection.   
 Aβ-sensitive T cells are unlikely to be found in large numbers in APP 
transgenic mice or in humans due to selection against thymocytes reactive to self 
proteins which occurs during T cell development.  As AD progresses and Aβ 
becomes more prevalent and is associated with inflammation and cellular damage, 
however, is likely that Aβ-senstive T cells would be activated and proliferate.  This is 
supported by findings by Monsonego et al. (2003) that Aβ-sensitive T cells are 
common in both elderly, healthy individuals and AD patients, with AD patients more 
likely to possess these cells.  What is not clear, however, is if this immune response to 
an endogenous peptide is beneficial but is simply deficient in AD patients, or is a 
detrimental autoimmune dysfunction.   
If T cells do possess the potential to combat the damage associated with 
amyloid pathology, it is possible that Aβ-sensitive T cells themselves could serve as a 
potential therapeutic in AD.  These cells may then play a role in activating other 
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immune system cells as described above, causing an upregulation in immune system 
activity, or a “charging” of the AD immune system.  The potential drawback of such 
activation, of course, is that an incorrectly balanced immune reaction can lead to a 
strong bias towards a cellular or humoral based response, and under certain 
conditions this can lead to increased neuroinflammation, as seen in human clinical 
trials for Aβ vaccination (Nicoll et al. 2003).  Careful study of the effects of 
Aβ−sensitive T cell infusions in AD models will be necessary to determine the true 
potential of such cells. 
Neuroprotective Actions of T Lymphocytes 
It is thought that in AD, immune hyporesponsiveness to Aβ prevents 
effectiveness of some Aβ immunotherapies, as would be true for any endogenously 
expressed peptide due to self-tolerance.  To overcome this deficit, adjuvant coupled 
administration of Aβ peptide was used in human clinical trials, and it was found that 
this led to potentially lethal inflammation in the CNS of immunized individuals.  This 
may have occurred in part due to activation of cells sensitive to a “self” peptide.  
Autoimmunity of this type is typically associated with a negative connotation due to 
such devastating effects, which are not un-similar to those noted in autoimmune 
disorders.  However, new research in this field has begun to reveal that autoreactive 
cells, specifically T cells, are actually capable of providing neuroprotective benefits 
in areas of CNS inflammation and neuronal damage.  Understanding and harnessing 
of this potential may lead to potential new therapeutics for neurodegenerative 
diseases such as AD, in which neuroinflammation plays a key role. 
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Extensive research in neural injury repair has shown that T cells can play an 
essential role in modulating repair in neuroinflammatory-based damage.  Specifically, 
myelin-specific Th1 cells (the same proinflammatory, encephalitogenic cells capable 
of instigating onset of autoimmune diseases) seem to be capable of providing 
protection following neuronal injury.  It appears that these autoreactive T cells, 
capable of causing neuronal damage and inflammation when inappropriately 
activated, are also capable of being drawn to an area of injury and in some way acting 
as neuroprotectants under the correct neurophysiological paradigm (Kipnis et al 2002, 
Schwartz et al. 2003).   
One pathway of this protection appears to be regulation of microglia activity.  
Microglia, known to both be activated by and activators of T cells as discussed above, 
can contribute to continued neuronal damage following initial insult if left unchecked.  
T cells do possess the ability to prevent frustrated microglia from continuing to cause 
neuronal damage (Avidan et al. 2004).  A second route of action for T cell mediation 
of CNS damage may be production of neurotrophins.  Infused autoimmune T cells are 
capable of producing such factors after reactivation due to antigen presentation.  Both 
Th1 and Th2 subsets of autoimmune cells have been shown to produce these factors 
following injury to the CNS, resulting in neuroprotective effects.  These effects can 
be blocked via inhibition of NT-receptor activity, indicating that it is the direct 
interactions of these factors with neurons which is providing protection, and these 
receptors are known to be upregulated on injured neurons (Moalem et al. 2000).  
Finally, the work of Michal Schwartz and associates in the past two years has 
displayed the ability of T cells to protect against glutamate neurotoxicity.  Excessive 
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activation of neurons and/or glutamate release by activated cells such as microglia 
can result in such toxicity, and the potential of T cells to lessen glutamate toxicity 
based damage is another potential mechanism by which these cells are capable of 
providing protection following CNS damage.  The mechanism of action for this 
protection appears to be two fold.  In response to neuronal damage associated with 
glutamate toxicity, self-specific T cells directly decrease damage following glutamate 
exposure.  This is attributed to the neuroprotective capabilities of autoreactive T cells 
as discussed above. Secondly, regulatory T cells reduce cytotoxic-type microglial 
activation, reducing neuroinflammatory damage associated with such activation 
(Schwartz et al. 2003). 
These findings seem to imply an important, direct route by which T cells 
typically associated with inflammation in the CNS are actually important in 
combating damage under appropriate conditions.  The damage and associated 
neuroinflammation present in AD may thus also be regulated and counterbalanced by 
the same T cell subsets which might otherwise be involved in propagating 
neuroinflammatory events.  As has been illustrated earlier, microglia associated with 
neuritic plaques in the AD brain are known to instigate neuronal damage if left 
unchecked due to phagocytic frustration.  However, microglia have been shown to be 
capable of acting as Aβ APCs for T cells,  indicating a mechanism by which Aβ-
sensitive T cells may be reactivated local to these plaques (Monsonego et al. 2003).  
In 2003, Farkas et al. reported that Aβ mediated break-down of the BBB followed by 
infusion of activated T cells resulted in migration of these cells into the brains of male 
Wistar rats.  Based on these results, it is reasonable to assume that in murine AD 
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models, peripherally infused Aβ-sensitive T cells would migrate across the BBB into 
the brain, allowing them to associate with microglia in amyloid containing regions of 
the CNS.   
Microglia express MHC-II in order to interact with T cells, allowing microglia 
to participate in T cell activation, and thus indirectly in neuroprotection.  Suppresed 
expression of MHC-II is thought to be present in AD and may prevent early actions 
of microglia in clearing amyloid plaques, and it has been suggested that localized TH1 
cells may be able to stimulate such expression at an earlier time point (Schwartz et al. 
2003). In the presence of inflammatory factors released by damaged neurons, and 
following co-stimulation with microglia, these T cells may then be stimulated by the 
same mechanisms outlined above to both reduce local gliosis and counteract neuronal 
damage associated with Aβ deposition.  As a caveat, it should again be noted that TH1 
subset cells have been implicated in playing a major role in neuroinflammation in AD 
and other CNS disorders (Furlan et al. 2003).  Interestingly, however, it appears that 
microglia and T cell co-activation in the CNS results in upregulated production of 
anti-inflammatory cytokines such as IL-10 by T cells, resulting in decreased 
production of neuroinflammation-inducing cytokines and other inflammatory factors 
by microglia and TH1 cell lines (Chabot et al. 1999).  Mallat et al. (2003) produced 
results emphasizing the potential benefit to be gained via this mechanism.  It was 
shown that adoptive transfer of ovalbumin-specific Tr1 subtype T cells (which are 
capable of downregulating Th1 cells) reduced development of atherosclerosis in 
Apolipoprotein E knockout mice.  Injection of these cells along with ovalbumin in 
complete Freund’s adjuvant resulted in activation of infused lymphocytes and a 
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significantly reduced overall Th1 response (based on cytokine profiles).  It was 
suggested that this bias against a cellular based immune response resulted in 
decreased inflammation, which is thought to play a major role in development of 
atherosclerosis in these ApoE KO mice (Mallat et al. 2003).  Importantly though, this 
study focused on overall Th1 subset activities, not on the potential for specific 
autoreactive Th1 subsets on the CNS side of the BBB. 
Th2 subsets may also be capable of playing a neuroprotective role.  Benner et 
al. (2004) demonstrated that Cop-1 (a Th2 phenotype specific stimulator) activated 
immune cells adoptively transferred into MPTP-intoxicated mice (a model for 
Parkinson’s disease) are capable of migrating into the inflamed nigrostriatal 
dopaminergic regions of these mice.  Once localized to the site of inflammation, these 
cells were shown to be capable of suppressing microglia actions and of stimulating 
production of neuroprotective products such as glial cell line-derived neurotrophic 
factor (GDNF) by astrocytes to result in significant neuronal protection (Benner et al. 
2004).  Thus, without serving to reduce Aβ pathology, infused Aβ autoreactive T 
cells, including both Th1 and Th2 subsets, may be capable of protecting against Aβ 
associated damage if they too are able to produce neuroprotective agents and to 
combat neuroinflammation. 
Perhaps the most persuasive study indicating the potential for T cell therapy in 
AD was conducted in 2004 by Avidan et al.  This study reported that T cells specific 
to neuronal self antigens are capable of reducing damage associated with neurotoxic 
properties of Aβ.  Intraocular Aβ1-40 injections in C57BL/6J mice resulted in 
significant death of retinal ganglion cells.  In mice immunized prior to Aβ injection 
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with interphotoreceptor retinoid-binding protein (antigen specific cells in the eye), 
loss of neurons was significantly less.  To verify that this reduction was T cell 
induced, interphotoreceptor retinoid-binding protein and S-antigen specific T cells 
were passively transferred into C57BL/6J mice immediately following Aβ intraocular 
injections, resulting once again in retinal ganglion cell protection.  Further findings by 
Avidan et al. (2004) would seem to downplay the potential for neuroprotection 
following infusion of Aβ-sensitive T cells in APP transgenic mice.  It was noted that 
T cells specific to non-aggregated Aβ1-40 are capable of inducing only slight 
reductions in Aβ-induced retinal ganglion cell loss.  This was attributed to a lack of 
microglial capacity for expressing MHC-II in response to aggregated Aβ1-40 exposure 
based on unpublished results by Butovsky et al.  However, the authors do suggest that 
memory T cells specific to self antigens should be capable of activation and down-
regulation of cytotoxic microglia actions.  This is more in agreement with findings by 
Monsonego et al. (2003) which indicate that presentation of Aβ and direct activation 
of Aβ specific T cell subsets by activated Microglia can occur.  Furthermore, 
additional findings published by Monsenego et al. demonstrate the presence of Aβ-
sensitive T cells in AD patients, and it is suggested that processing of Aβ in the CNS 
by APC cells followed by migration of APCs to lymph nodes leads to eventual 
peripheral activation of Aβ reactive T cells (Monsonego et al. 2003-2).  The potential 
for Aβ-sensitive T cells to be activated via MHC-II presentation is thus established in 
both murine systems as well as in humans. 
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There appears to be potential for adoptive T cell transfer to serve as a 
therapeutic for neurodegenerative diseases.  The pathways by which such protection 
may occur in AD, as discussed above, are outlined in Figure 2.  The first pathway is 
based on the ability of certain T cells to stimulate the immune system early in Aβ 
pathology development via either a cellular (stimulation of microglial phagocytosis of 
Aβ) or humoral (stimulation of anti-Aβ antibody production) based response.  In 
addition, there is the potential for T cells to provide protection against neuronal 
damage resulting from development of Aβ pathology later along the course of the 
disease via both production of neurotrophins and down-regulation of glial-based 
neuroinflammation.  This form of protection may also extend towards prevention of 
glutamate based neurotoxicity.  No studies to date have established the behavioral 
effects of T cell infusions into a neurodegenerative disease model, nor have the 
pathological effects of such infusions been explored in a model of Alzheimer’s 
Disease.  Elucidation of the actions of various T cell subsets once within the CNS of 
AD models may provide insight into the potential for T cell therapy in AD.   
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Figure 2.  Mechanisms of T cell based neuroprotection.  Following re-activation in 
the CNS via interactions with APCs such as microglia, infused auto-reactive T cells 
sensitive to Aβ may act therapeutically in the AD brain via three mechanisms:  1)  
Early activation of the immune system to promote both humoral and cellular based 
immune responses to soluble and deposited Aβ (red).  2)  Suppression of “frustrated” 
cell (microglia, astrocytes, etc.) actions in the region of Aβ mediated neuronal 
damage to prevent excessive neuroinflammation and associated glutamate toxicity 
(blue).  3)  Production of neurotrophic factors which promote neuronal health and 
help protect against neuronal loss/dysfunction while also protecting against glutamate 
neurotoxicty (green). 
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Specific Aims 
 
The specific aims of this thesis are: 
1) To isolate, culture, and prime with human Aβ1-42 peptide, spleenocytes 
isolated from young, Aβ1-42 immunized wild-type mice, and to inject 
these activated, multi-subset, T cell enriched spleenocytes into AD 
transgenic mice. 
2) To determine the effects of Aβ-sensitive T cell enriched spleenocyte 
infusion on cognitive performance in Radial Arm Water Maze, Platform 
Recognition, and Y-maze tasks compared to placebo-infused transgenic 
and wild-type mice. 
3) To determine post-mortem the pathologic effects of Aβ-sensitive T cell 
enriched spleenocytes within the CNS of AD transgenic mice through 
analysis of Aβ burdens and distribution/activation levels of microglia and 
T cells therein. 
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4) To determine effects of Aβ-sensitive T cell enriched spleenocyte infusions 
on blood cytokines levels, specifically with regards to levels of pro and 
anti-inflammatory cytokines. 
5) To perform correlation analysis to determine if behavioral task 
performance measures correlate to any specific pathologic or biochemical 
measures. 
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Materials and Methods 
 
Animals 
To obtain the APPsw+PS1 mice used in this investigation, male heterozygous 
APPK670N,M671L transgenic (APPsw) mice were crossed with female, homozygous PS1 
mice of the 6.2 transgenic line.  Female heterozygous PS1 transgenic offspring were 
then crossed with APPsw males of the parental generation to obtain the non-
transgenic and heterozygous APPsw+PS1 mice used for this investigation.  Mouse 
backgrounds for this generation consist of a 56.25% C57, 12.5% B6, 18.75% SJL and 
12.5% Swiss Webster heterogeneous background.  Mice were genotyped after 
weaning, and then singly housed throughout the course of the study in standard 12-
hour light-dark cycle conditions, with free access to water and rodent chow.  
Behavioral assessment and immune cell infusions occurred during the light phase of 
the circadian cycle. 
General Protocol 
As indicated in the Timeline in Fig. 3, baseline cognitive performance for 10 
non-transgenic and 15 APPsw+PS1 mice was established via a 12 day administration 
of the RAWM task for working memory at eight months of age.  Transgenic mice 
were then divided into two groups balanced in RAWM performance based on overall 
latency and error averages so that pre- vs. post- infusion comparson could be made 
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between groups.  Seven transgenic mice were designated as recipients for Aβ-
sensitive immune cells, and 8 transgenics (as well as all 10 non-transgenics) were 
designated as controls, to be given PBS.  To generate Aβ-sensitive immune cells, 3 
additional congenic non-transgenics were repeatedly immunized with Aβ1-42 at 3-4 
months of age.  Spleenocytes and lymphocytes isolated from these animals were then 
cultured for 4 days prior to infusion into immune cell recipient mice.  Infusion of 
immune cells into these mice along with injection of PBS into both control groups 
occurred two days following completion of RAWM testing (Fig. 3).  After a one 
month delay, mice underwent additional behavioral assessment consisting of RAWM, 
Platform Recognition, and Y-maze task administrations (9, 4, and 1 days 
respectively).  A neurological assessment battery was also used to test for motor 
and/or neurological deficits prior to sacrifice.  Plasma samples and brains were taken 
at sacrifice.  Plasma cytokine levels were evaluated via immunoassay, and half brains 
(bisected mid-sagitally) were coronally sectioned and used for quantification of brain 
Aβ deposition levels via direct Thioflavin S staining, as well as by 6E10 
immunostaining.  Finally, statistical analysis was conducted to determine group 
differences in cognitive task performances, plasma cytokine levels, and Aβ load 
determinations.  Correlation analyses, factor analysis, and discriminant function 
analysis were also be used to evaluate overall group differences across these 
measures. 
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Figure 3.  General protocol time line for the adoptive transfer study. 
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Immune Cell Infusion Protocol 
Three non-transgenic mice from the same generation as the study cohort were 
vaccinated with human Aβ1-42 to elicit an immune response.  One day prior to 
injection, the site of injection on the backs of these mice was shaved.  The following 
day, 3 separate endodermal injections of human Aβ1-42 peptide (Bachem) in 
complete Freund’s adjucant (CFA) were administered to each mouse following 
isofluorane anesthesia.     Each mouse received a total of 250 µg of non-fibrillar, 
soluble Aβ in 100µl of adjuvant divided equally over the three injections to induce 
proliferation of Aβ sensitive immune cells.  Each mouse then received additional 
injections of 200 ng pertussis toxin 1 and 3 days post-immunization.  Mice were 
monitored for signs of distress and paralysis for these 3 days and for 7 days thereafter.  
Following this 10 day period, these mice were sacrificed for harvest of spleen tissues 
and lymph node fluids. Tissues from all 3 mice were pooled and homogenized with a 
loose fitting 15 mL dounce, followed by filtration through a 70µm sieve filter, 
centrifugal pelleting, and resuspension in red blood cell lysis buffer.  After five 
minutes, cells were again gently pelleted, then resuspended in full media and counted.  
Cells were then cultured in full media containing 8-10 µg/mL Aβ1-42 and for 4 days.  
After culturing, cells were once again pelleted, resuspended in phosphate buffered 
saline (PBS), and viable cells were counted by trypan blue exclusion. Immune cell 
recipient APPsw+PS1 mice were then administered approximately 2x107 viable 
immune cells in 0.5 mL PBS by tail vein injection. Control transgenic and non-
transgenic mice received tail vein injections of 0.5 mL PBS. All animals were then 
monitored daily for signs of discomfort or paralysis.  
   
113 
 
Behavioral Assessment 
Radial Arm Water Maze 
The RAWM task for working (short-term) memory was administered for all 
mice at two time points as indicated on the study timeline.  Testing occurred in a 
100cm diameter pool of water divided by an aluminum insert which establishes 6 
evenly spaced radial arms surrounding a central open area.  Each arm was 30.5 cm in 
length and 19 cm wide, while the central circular swim area was 40 cm in diameter.  
A transparent 9 cm diameter platform at a 1.5 cm depth was used as an escape 
platform for mice placed in the maze, and was placed approximately 15 cm away 
from the end of the randomly assigned goal arm of the maze each day of the task.  
Numerous visual cues surrounded the pool to provide spatial references for 
navigation of the maze.  For each trial of the task, mice were placed in the water at 
the entrance of a novel start arm of the maze for that day, facing the central swim 
area.  The start arm was never the arm containing the submerged escape platform, and 
both start arm sequences and goal arm location were semi-randomly changed each 
day.  The mouse was allowed to navigate the maze freely until fully entering an arm 
of the maze.  If the arm selected by the animal did not contain the escape platform, an 
error was recorded and the animal was pulled gently back to the start location for that 
trial.  This procedure, including counting of an error, was also used if no arm 
selection was made within 20 seconds.  If after 60 seconds, an animal did not find the 
escape platform, it was guided gently to it.  Latency to find the platform up to 60 
seconds and number of errors were recorded for each trial.  The RAWM task 
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consisted of five daily trials, the first four of which were administered with only a 30 
second delay between them during which the mouse was left on the escape platform.  
The fifth trial was administered 30 minutes later, and the animal was returned to its 
cage during this delay interval.  For animals which did not make at least 3 choices 
during a trial and did not find the escape platform, a penalty error was recorded for 
that trial.  The penalty error was calculated by averaging trial one errors for the first 
three days of testing for animals which did not find the escape platform but did make 
at least three arm choices during these trials. 
Platform Recognition 
The platform recognition task was administered following completion of the 
RAWM task to determine the ability of the mice to recognize a visible platform 
placed at various locations in an open, 100cm diameter pool.  This required a strategy 
switch, as the RAWM task required that the animals search for a submerged platform 
hidden in a divided pool based on orientation of visual cues around the pool, whereas 
the platform recognition task only requires identification of the visible escape 
platform.  Thus, this task also tested the ability of these animals to adapt to a new 
escape strategy.  For this task, a 9 cm circular platform with a conspicuous 10 x 40 
cm black and white conical visual cue attached was used, with the surface of the 
platform raised .8 cm above the water’s surface.  Mice were placed in the same 
location in the pool for each of 4 daily trials.  For each trial of a given day, the visible 
platform was moved to a central part of one of four established quadrants in the pool.  
The mice were allowed 60 seconds to find the platform before being guided to it 
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during each trial, and a 30 second stay on the platform was allowed between each 
trail.  Latency up to 60 seconds for each trial was recorded for 4 days of testing.  
Y-maze 
Mice were given 5 minutes to explore a black, three-armed Y-maze in order to 
test both general activity (based on total number of arm entries) and basic mnemonic 
processing (based on spontaneous percent alternation).  Mice were placed facing the 
center of the maze at the opening of the maze arm designated arm two.  During the 
five minute test period, the number and sequence of are choices was recorded.  
Percent alternation was calculated by subtracting two from the total number of arm 
entries and dividing this value into the total number of spontaneous alternation events 
(consecutive choice of each of the 3 Y-maze arms, without re-entry into a previously 
chosen arm) for each animal. 
Neurological Battery 
19 sensorimotor measures were taken from a neurological battery derived 
from the Irwin Test (Irwin 1968).  Qualititative assessment ratings of the following 
were obtained for each mouse:  transfer arousal after placement in a new 
environment, ataxia, hypotenic gait, pelvic elevation (while walking), tail elevation 
(while walking), palpebral closure, approach to Q-tip (novel object), withdrawl from 
invasive Q-tip, response to touch, response to audible startle stimulus, corneal reflex, 
righting reflex, visual placing (reaching for paw hold while hanging), grip strength 
(while hanging), recognition of visual cliff, response to toe pinch, and response to tail 
pinch.  Quantitative measures were also obtained for the following:  latency to move 
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to the edge of an elevated platform and number of head pokes over the edge of an 
elevated platform in one minute. 
Brain Collection and Sectioning 
Two days following behavioral testing all study mice were anesthetized with 
Nembutal (1 mg/10 gm body weight).  Blood (.2 ml) was collected from the heart, 
mixed with .5M EDTA, and centrifuged.  Plasma and red blood cells were then 
separated, flash frozen, and stored at -80°C.  Following blood collection, all mice 
were pericardially perfused with .9% saline.  Brains were excised and halved mid-
sagitally. The left half was fixed in 4% paraformaldehyde for 24 hours at 4°C, 
followed by graded sucrose solutions (10, 20, and 30% (w/v) sucrose in 0.1× 
Sorenson's phosphate buffer) prior to sectioning. Frozen 25 µm coronal sections were 
then collected on a sliding microtome and stored in PBS.  These sections were 
immunostained with 6E10 antibody (for diffuse Aβ) or stained with Thioflavin S (for 
compact Aβ deposition).  
Plasma Cytokine Level Measurements  
Relative cytokine level determinations were obtained using a custom RayBio 
Mouse Cytokine Antibody Array.  Briefly, provided membranes bearing ten separate 
anti-mouse-cytokine antibodies were treated with blocking buffer and then incubated 
with 1 ml of 1:10 diluted plasma samples for one hour.  The membranes were then 
incubated with 1x secondary biotinylated antibodies diluted in blocking buffer for one 
hour, followed by a two hour incubation with 1,000 fold diluted labeled-strepavidin in 
blocking buffer to complete the conjugated secondary antibody complex.  The 
membranes were washed following each incubation with provided 1x wash buffer 
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solutions.  Detection signals for each membrane were detected using Fujifilm AR x-
ray film following a seven second incubation with provided detection buffers.  Back-
lit photographs were taken of the developed film with a Kodak DC290 digital camera.  
Mean signal intensities minus background signal intensity for duplicate readings were 
determined using Kodak 1D Image Analysis Software and standardized to a zero to 
one scale based on minimum and maximum mean intensity readings for each 
cytokine.  This was necessary because of the naturally occurring large variability 
(100x-1000x) in levels (based on signal intensities) among various cytokines.  
Resultant standardized signal intensities were then used for relative cytokine level 
comparisons among animal groups.  
Αβ Deposition Determinations 
6E10 Immunostaining   
6E10 immunostaining was performed on mouse brain sections at the level of 
the dorsal hippocampus.  Three 25µm coronal sections spaced approximately 600-
700µm apart were used to analyze diffuse Aβ deposition in sections of the dorsal 
hippocampus and overlaying parietal cortex.  Sections were floated in 10% ethanol 
and mounted on pre-treated slides.  For the following steps, all incubations were 
carried out at room temperature on a rotating platform shaker unless otherwise noted.  
In order to induce epitope retrieval, slides were first placed in a 85ºC 25mM citrate 
buffer (pH 7.3) bath for five minutes, washed at room temperature in PBS, placed in 
88% formic acid for five minutes, and then washed under low pressure running de-
ionized water for 10 minutes.  Slides were then incubated at room temperature with 
pre-mixed DAKO blocking solution [49.5% DAKO (catalog #X0909; Dako, 
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Carpinteria, CA), 49.5% PBS, .3% H2O2 by volume] for 15 minutes to block 
endogenous peroxidase activity, with M.O.M. anti-mouse IgG antibody for 60 
minutes to block non-specific binding, with a Triton X solution (.4% by volume) in 
two 2.5-minute PBS baths to induce permeability, and with protein concentrate 
solution for 5 minutes to further block non-specific binding.  Slides were placed in 
PBS baths for 5 minutes following both DAKO and Triton X applications.  Slides 
were then incubated with 6E10 primary antibody overnight at 4ºC.  Following this 
incubation, slides were placed in three successive PBS baths at 60ºC for 3.5 minutes 
each.  Slides were then incubated with secondary IgG antibody in PBS with Triton X 
and protein concentrate.  Slides were then incubated for 30 minutes with ABC 
complex solution from a NovaRed (Vector) substrate kit, which was pre-mixed and 
allowed to incubate for approximately 30 minutes prior to application.  Three 3-
minute PBS baths were done following both incubation steps.  Slides were then 
incubated with NovaRed detection reagent mixture for three minutes, followed by a 
five minute water bath.  Slides were then washed in 45%, 60%, 80%, 95%, and 100% 
ethanol baths for approximately 20 seconds each or until no colors from Nova Red 
staining ran.  A final, four second xylene bath followed by immediate application of 
cytoseal and coverslipping completed the staining procedure. 
Thioflavin S Staining  
Thioflavin S staining was used to detect compact Aβ plaques in the same 
brain regions used for 6E10 immunostaining.  Slides were immersed for five minutes 
in 1% Thioflavin S in 50% ethanol.  The same graded alcohol washes and xylene 
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wash scheme used for 6E10 protocol was applied, followed by application of cytoseal 
and coverslipping. 
Image Analysis   
All 6E10 and Thioflavin-s stained sections were analyzed on a Nikon Eclipse 
E1000 microscope at either 4x (Thioflavin S) or 10x (6E10) magnification with Plan 
Four objective lenses.  A Retiga 1300 CCD with QImaging RGB LCD-slider was 
used to capture images of these sections.  A Nikon BV-2B fluorescence fliter cube 
was used for thioflavin S staining.  Image Analysis was performed using customized 
software written in Visual Basic 6.0 (Microsoft) that used Auto-Pro function calls to 
segment and quantify images according to the established protocols used by Costa et 
al (2004).  Aβ deposition was quantified as a percent of area of interest (=Area 
stainedtotal/Area Measuredtotal). 
Statistical Analysis 
Behavioral Statistical Analysis   
Inter- and Intra-group comparisons in pre/post infusion RAWM performance 
(errors and latency) and post infusion Platform Recognition (latency) and Y-maze (% 
alternation and arm entries) performances were obtained using standard one-way 
ANOVAs.  Two-way repeated measure ANOVAs were also used to compare groups 
in multi-day tasks (RAWM and Platform Recognition).  Daily averages over 4 days in 
Platform Recognition were used for this measure, and three 3-day block averages 
were used for RAWM.  Using the Fisher LSD test, pos-hoc pair-by-pair differences 
between groups (planned comparisons) were then obtained.  Swim speed in RAWM 
was approximated for each animal by dividing overall Trial 4 + Trial 5 average errors 
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into overall Trial 4 + Trial 5 average latencies.  Non-performers (e.g. repeated circlers 
etc.) for a given task were not used for statistical analysis in that task.  16 of the 19 
sensorimotor tasks comprising the Neurologic Screen were analyzed non-
parametrically using the Kruskal–Wallis test and Mann–Whitney U-test.  The 
remaining 3 measures (visual cliff, head poke latency, and number of head pokes) 
were analyzed using ANOVA. 
Pathological/Histochemical Statistical Analysis   
Standard one-way ANOVAs were used to determine group differences for Aβ 
load determinations (6E10 and Thioflavin S) and relative cytokine signal intensities.  
Using the Fisher LSD test, pos-hoc pair-by-pair differences between groups (planned 
comparisons) were then obtained for each measure.   
Correlation Analysis   
To determine if a direct relationship existed between behavioral and 
pathological measures, correlation analysis was performed using Systat software. A 
correlation matrix was established between 18 RAWM behavioral measures and 4 Aβ 
histochemical measures, as well as between these same behavioral measures and 10 
plasma cytokine measures.  Finally, Y-maze % alternation and arm entry measures 
were correlated to Aβ histochemical measures. 
Factor Analysis 
Factor Analysis (FA) was performed using Systat software to group 
behavioral measures into common, distinct factors.  Each factor corresponds to a 
discrete component of behavior or cognition such as sensory motor function or 
working memory. This allows for the relationship between behavioral measures to be 
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determined, and also indicates how individual task performances may correlate with 
other task performance levels.  FA was performed for 13 behavioral measures 
obtained. 
Discriminant Function Analysis 
Discriminant function analysis (DFA) was performed using 11 similarly 
loading measures from FA analysis as well as with all 13 behavioral measures used 
for FA analysis to determine if experimental animal groups (Tg+/T cell, Tg+/PBS, 
and NT) could be distinguished from one another behaviorally.  All DFA analyses 
were performed using Systat software using both direct entry and stepwise forward 
DFAs.  The direct entry method attempts to discriminate between groups using all 
behavior measures available, while the stepwise-forward method sequentially selects 
measures based on their variance contribution to best discriminate between the three 
groups. 
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Results 
 
Behavior 
RAWM 
Pre-Infusion Testing.  In pre-infusion RAWM testing (Fig. 4), 
transgenic (Tg+) mice were significantly impaired in working memory, as evidenced 
by an overall group effect for average combined Trial 4 and Trial 5 errors over 4 
blocks of testing [F(1,23)=6.6823, p<.02].  After completion of pre-infusion testing, 
animals in the Tg+ group were divided into two groups for infusion of Aβ-sensitive 
immune cells (Tg+/T cell group) or PBS (Tg+/PBS group).  Pre-infusion RAWM 
performance of these two sub-groups were identical prior to infusion (data not 
shown). 
Post-Infusion Testing.  Looking at overall post-infusion RAWM 
performance, Tg+/PBS mice made significantly more Trial 4+5 errors than Tg- mice ( 
p<.05), while Tg+/T cell errors were not significantly different from either Tg- or 
Tg+/PBS mice (p=n.s.).  Thus, overall Tg+/T cell animals performed at a level 
between that of Tg+ and Tg- control groups in RAWM working memory.  Looking at 
individual blocks, Tg+/PBS mice maintained high Trial 4+5 errors during block 1 of 
post-infusion testing (Fig. 5), whereas Tg+/T cell mice made significantly fewer Trial 
4+5 errors (p<.05) and performed identically to Tg- mice (p=n.s.).  No group  
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Figure 4.  Pre-infusion overall working memory performances.  Tg+ mice 
averaged significantly more errors in overall Trial 4+5 testing than Tg- mice prior to 
their division into treatment groups, indicating a clear transgenic impairment in 
working memory.  * = significant difference between Tg- and Tg+ groups (p<.02). 
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Figure 5.  Post-infusion Block 1 RAWM errors.  In contrast to Tg+/T cell mice, 
which performed similarly to Tg- mice, Tg+/PBS mice averaged significantly more 
errors in Block 1 Trial 4+5 post-infusion testing.  * = significant difference between 
Tg+/PBS and both Tg+/T cell (p<.05) and Tg- mice (p<.02).
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differences were evident on the semi-random Trial 1 (Fig. 5).  Additionally, no group 
differences were noted for Trial 1 or Trial 4+5 errors in either block 2 or 3 of testing 
(data not shown).  For Block 3 post-infusion testing (Fig 6) however, both Tg+/T cell 
mice (p<.05) and Tg- mice (p<.05) were able to significantly reduce their combined 
Trial 4+5 errors from Trial 1 “naive” performance levels, whereas Tg+/PBS mice 
were not (p=n.s.).  Neither Tg+/T cell nor Tg+/PBS mice were able to improve Trial 
1 vs. Trial 4+5 performance in Block 1 and Block 2, whereas Tg- mice showed 
improved Trial 1 vs. Trial 4+5 performance for all 3 blocks of testing (data not 
shown).   
To ensure that post-infusion performance differences were not attributable to 
differences in time taken by animals to navigate the RAWM apparatus, an average 
number of seconds per arm choice in overall Trial 4+5 was calculated for each group 
by dividing overall Trial 4+5 latency by overall Trial 4+5 errors.  No group 
differences in number of seconds per choice were noted for this measure (Tg+/T cell: 
10.9 ± 1.2, Tg+/PBS: 9.8 ± 1.1, Tg-: 11.2 ± 1.0 sec.). 
Pre-Infusion vs. Post-Infusion Testing.  To further determine the 
effects of immune cell infusion on working memory performances in Tg+ mice, a 
block by block comparison of pre-infusion vs. post-infusion performances in the 
RAWM task was performed for all groups (Fig. 7).  It was determined that Tg+/PBS 
mice did not significantly lower their number of errors for any individual block of 
testing (p=n.s.).  In contrast, Tg+/T cell mice did significantly lowered their number 
of errors from Block 1 pre-infusion testing to Block 1 post-infusion testing (p<.01) as  
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Figure 6.  RAWM during post-infusion Block 3 Trial 1 vs. Trial 4+5.  Both Tg+/T 
cell and Tg- mice were able to significantly reduce their number of Trial 4+5 errors 
compared to Trial 1 “naive” performances.  In contrast, Tg+/PBS mice failed to 
obtain a significantly lower number of errors for Trial 4+5 compared to Trial 1.  * = 
significantly lower Trial 4+5 errors compared to Trial 1 errors (p<.05).
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Figure 7.  RAWM pre-infusion vs. post-infusion comparisons for Trial 4+5 
combined errors by group.  Tg+/PBS mice did not significantly lower their errors 
for any block of post-infusion testing.  In contrast, Tg+/T cell mice were able to 
significantly lower their errors for both Block 1 and Block 2 of post-infusion testing 
compared with Trial 4+5 error averages for these blocks from pre-infusion testing.  
Tg- mice maintained relatively low errors throughout and thus also lacked significant 
improvement post-infusion.  * = significantly lower Trial 4+5 error in post-infusion 
testing vs. pre-infusion testing (p<.05 or higher level of significance).  
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well as from Block 2 pre-infusion testing to Block 2 post-infusion testing (p<.05] but 
did not show this error reduction for Block 3 performance (p=n.s.).  Tg- mice did not 
show significantly decreased errors for any block comparison, most likely due to 
relatively good pre-infusion performance levels.  Comparisons of Trial 4+5 errors 
during the final block of pre-infusion testing vs. the first block of post-infusion testing 
showed that Tg+/PBS mice became significantly worse (p<0.05) during initial post-
infusion testing (Fig. 8). By contrast, Tg+ mice that received T cell infusions 
maintained their final pre-infusion performance level, as did Tg- controls, on the 
initial post-infusion block (Fig.8). 
Y-Maze 
Post-infusion performance in the Y-maze task revealed a significant overall 
effect indicating a direct treatment effect on basic pneumonic processes 
[F(2,18)=6.8962; p<.01] (Fig. 9).  Tg+/PBS mice demonstrated significantly lower 
percent spontaneous alternations than Tg+/T cell mice (p<.01) or Tg- mice (p<.005).  
In sharp contrast, Tg+/T cell mice performed identically to Tg- mice.  No group 
differences were noted in number of Y-maze arm entries (data not shown). 
Platform Recognition 
Analysis of average latencies for individual days and over all 4 days of 
Platform Recognition testing found no group differences in performance for this task 
(Fig. 10).  There was a highly significant day effect [F(3,66)=7.02; p<.0005), 
indicating that all animals collectively improved their performances across the 4 days 
of testing. 
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Figure 8.  RAWM Trial 4+5 performance for pre-infusion (final block) 
vs. post-infusion (first block).  Tg+/PBS mice significantly worsened their working 
memory performance from pre- to post-infusion testing, whereas Tg+/T cell and Tg- 
animals maintained lower levels of errors in post-infusion testing.  * = significantly 
higher post-infusion RAWM errors compared to pre-infusion performances (p<.05, 
paired t-test).  
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Figure 9.  Post-infusion Y-maze spontaneous percent alternation performances.  
Tg+/PBS mice displayed significantly lower percent alternations compared to Tg- 
animals, whereas Tg+/T cell mice performed identically to Tg- controls.  * = 
significantly lower percent alternation compared to Tg- and Tg+/T cell mice (p<.01 
or higher level of significance). 
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Figure 10.  Post-infusion Platform Recognition latencies by day.  No group 
differences were noted for any day or overall in Platform Recognition 
performance. 
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Neurologic Battery 
While no group differences were noted between Tg+/T cell and Tg+/PBS 
groups for the 19 measures of our Neurologic Battery (data not shown), direct 
comparison between these groups and Tg- animals did elicit group differences.  
Tg+/PBS animals showed significantly decreased transfer arousal upon placement 
into a novel environment compared to Tg- mice [p<.05].  Tg+/Tcell mice showed 
decreased transfer arousal as well [p<.05], and also scored significantly lower in 
evaluation of pelvis [p<.01] and tail elevation [p<.05] compared to Tg- animals.  
Finally, Tg+/T cell mice showed an increased score for hypotonic gait qualifications 
compared to the Tg- group [p<.01].  The lack of differences between Tg+/T cell and 
Tg+/PBS groups may indicated that infusion of T cells did not result in any 
deleterious neurologic effects in Tg+ mice. 
Pathology 
Brain Aβ Deposition Quantification 
6E10 Immunohistochemistry/Thioflavin S Histochemistry.  Tg+/T cell 
and Tg+/PBS mice showed no group differences in % area Aβ plaque deposition, 
staining either for diffuse deposits (6E10) or compact deposits (Thioflavin S) (Fig. 
11).  Comparisons were made between groups for both hippocampal and parietal 
cortex Aβ burdens; no significant differences were noted for either brain region 
(p=n.s). 
Plasma Cytokine Analysis 
For the ten cytokine measures taken (Fig. 12), there were no group differences 
between Tg+/Tcell and Tg+/PBS mice or between Tg+/PBS and Tg- mice (p=n.s).   
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Figure 11.  Quantification of 6E10and Thioflavin S Aβ burdens.  No group 
differences between Tg+ groups were noted for either Aβ burden measure in either 
hippocampus or parietal cortex. 
.
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Figure 12.  Standardized mean signal intensities for 10 plasma cytokines.  Tg+/T 
cell mice showed significantly lower levels of plasma IL-10, TNF-α, and GM-CSF 
compared to Tg- mice.  * = significantly lower mean signal intensity compared to Tg- 
animals (p≤.05). 
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However, the Tg+/Tcell group did display significantly lower plasma cytokine levels 
than Tg- mice for GM-CSF ( p≤.05), IL-10 ( p<.05), and TNF-α (p≤.05).  Thus, T 
cell infusion into Tg+ mice did not result in a sustained, global increase in plasma 
pro-inflammatory cytokines. 
Multi-metric Statistical Analysis 
Correlation Analysis 
RAWM vs. Aβ Burdens.  A correlation matrix comparing Aβ 
deposition quantifications in hippocampus and parietal cortex vs. RAWM 
performances uncovered numerous correlations between these measures.  All 
correlations were positive unless otherwise noted (e.g. higher RAWM errors/latency 
associated with higher Aβ deposition).  For all 15 Tg+ animals combined (Table 1), 
these correlations were found exclusively between 6E10 hippocampal measures and 
the following 8 RAWM working memory measures:  overall Trial 4 errors (p≤.05), 
Block 1 Trial 4 errors (p<.01), Block 1 Trial 4+5 errors (p<.01), overall Trial 4 
latency (p<.05), overall Trial 4+5 latency (p≤.05), Block 1 Trial 4 latency (p≤.001), 
Block 1 Trial 5 Latency (p<.05), and Block 1 Trial 4+5 Latency (p≤.005).  No 
correlations were found between Thioflavin S burdens in either brain area and 
working memory.  Thus, lower hippocampal levels of diffuse Aβ deposits correlated 
with improved working memory. 
A strong correlation was noted between RAWM Trial 4+5 errors for Block 1 
of post-infusion testing and hippocampal 6E10 burdens when considering all Tg+ 
mice (p<.01).  This correlation is of particular interest because Block 1 performance 
for Tg+/T cell mice was identical to that of Tg- mice, while Tg+/PBS mice made  
Table 1.  For all Tg+ animals, a correlation matrix of RAWM error and latency measures vs. 6E10/Thioflavin S measures of 
Aβ plaque burdens in the parietal cortex and hippocampus. 
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         RAWM Errors 
 Overall Trial 4 
Overall Trial 
5 
Overall Trial 
4+5 
Block 3 Trial 
4 
Block 3 Trial 
5 
Block 3 Trial 
4+5 
Block 1 Trial 
4 
Block 1 Trial 
5 
Block 1 Trial 
4+5 
6E10:  Cortex r     
p 
0.092   
0.745 
0.166     
0.554 
0.134     
0.635 
-0.199   
0.477 
0.261     
0.347 
0.022     
0.939 
0.218     
0.436 
0.243     
0.382 
0.248     
0.373 
6E10:  
Hippocampus 
r     
p 
0.512   
0.051 
0.422     
0.118 
0.502     
0.057 
0.135     
0.631 
0.272     
0.326 
0.236     
0.398 
0.713     
0.003 
0.497     
0.059 
0.665     
0.007 
Thioflavin S:  
Cortex 
r     
p 
-0.133   
0.637 
-0.001   
0.997 
-0.078   
0.783 
-0.091   
0.748 
0.089     
0.751 
-0.006   
0.982 
-0.226   
0.418 
-0.042   
0.882 
-0.154   
0.583 
Thioflavin S:  
Hippocampus 
r     
p 
0.238   
0.393 
0.076     
0.789 
0.175     
0.533 
0.11       
0.698 
0.45       
0.092 
0.319     
0.247 
-0.017   
0.951 
-0.028   
0.922 
-0.024   
0.933 
          
RAWM Latency          
 Overall Trial 4 
Overall Trial 
5 
Overall Trial 
4+5 
Block 3 Trial 
4 
Block 3 Trial 
5 
Block 3 Trial 
4+5 
Block 1 Trial 
4 
Block 1 Trial 
5 
Block 1 Trial 
4+5 
6E10:  Cortex r     
p 
0.19     
0.497 
0.094   
0.738 
0.15     
0.594 
0.048   
0.864 
0.24     
0.389 
0.162   
0.565 
0.309   
0.263 
0.232   
0.405 
0.287   
0.299 
6E10:  
Hippocampus 
r     
p 
0.589   
0.021 
0.384   
0.158 
0.51     
0.052 
0.379   
0.163 
0.337   
0.219 
0.394   
0.146 
0.772   
0.001 
0.515   
0.049 
0.687   
0.005 
Thioflavin S:  
Cortex 
r     
p 
-0.027   
0.924 
-0.156   
0.578 
-0.093   
0.743 
-0.024   
0.932 
0.025   
0.929 
0.001   
0.996 
0.028    
0.92 
-0.093   
0.741 
-0.029   
0.919 
Thioflavin S:  
Hippocampus 
r     
p 
0.287   
0.299 
0.182   
0.517 
0.246   
0.376 
0.151   
0.591 
0.396   
0.144 
0.305   
0.269 
0.169   
0.546 
0.238   
0.394 
0.211   
0.451 
   Correlations (bold font) were noted between 6E10 diffuse plaque burdens in the hippocampus and several overall and Block 1 RAWM measures of working 
memory.  Most of these correlations were also noted when looking at only Tg+/T cell animals, however none were found when considering Tg+/PBS animals 
(data not shown), indicating the Tg+/T cell animals as the driving force behind correlations between working memory and diffuse Aβ depostion.  r = Pearson 
product-moment correlation coefficient.  p = probability.
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significantly more errors than either group.  Looking at the graph for this 
comparison (Fig. 13), it is apparent that Tg+/T cell mice are driving the correlation 
between working memory performance and hippocampal diffuse Aβ burdens.  
Interestingly, it appears that this correlation occurs as a result of segregation of the 
Tg+/T cell group into two subgroups.  Of the seven total Tg+/T cell mice, a group of 
four mice maintained low errors in Block 1 and displayed low diffuse Aβ burdens in 
the hippocampus, whereas the remaining three Tg+/T cell mice made a high number 
of errors in testing and displayed high hippocampal burdens.  In contrast, seven of 
eight Tg+/PBS mice displayed high errors and diffuse Aβ burdens.  This stark 
difference between Tg+/T cell and Tg+/PBS animals clearly illustrates not only how 
Tg+/T cell animals are driving correlations between RAWM and 6E10 measures, but 
would also seem to indicate that a treatment effect is apparent in the majority of 
Tg+/T cell animals.  It should also be noted that even the remaining three Tg+/T cell 
animals with higher Block 1 RAWM errors were able to reduce their errors by Block 
3 of testing, indicating that good working memory performance was not limited to 
only a portion of the Tg+/T cell animals.  
When considering only T cell recipient mice (n=7), correlations were also 
exclusive to hippocampal 6E10 burden when compared to the following measures:  
overall Trial 4 errors (p<.05), Block 1 Trial 4 errors (p<.05), Block 1 Trial 5 errors 
(p<.05), Block 1 Trial 4+5 errors (p<.05), Block 1 Trial 4 latency (p<.05), and Block 
1 Trial 4+5 latency (p<.05).  The lack of correlations between Tg+/PBS mouse 
RAWM measures and hippocampal 6E10 measures once again indicates that it is the 
Tg+/T cell mice which are driving these correlations for all Tg+ mice combined.  
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Figure 13.  For all Tg+ mice, a correlation between RAWM Block 1 Trial 4+5 
Errors and Hippocampal 6E10 burden.  A strong correlation between diffuse 
hippocampal Aβ burden and working memory impairment in Tg+ mice is apparent.  This 
correlation is clearly driven by the Tg+/T cell group, which show a distinct segregation 
into two subgroups, one with good working memory performance and low Aβ burdens 
(left side of the graph), and one with poor working memory performance and high Aβ 
burdens (right side of the graph).    
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 This is especially true for 6E10 vs. overall and Block 1 measures where correlations 
were found when considering all Tg+ mice as well as Tg+/T cell mice alone, but not 
when considering Tg+/PBS mice alone.  When considering PBS recipient transgenic 
mice only (n=8), correlations noted were between hippocampal Thioflavin S burdens 
and the following behavioral measures:  Block 3 Trial 5 errors (p<.05), Block 3 Trial 
5 latency (p<.01), and Block 3 Trial 4+5 latency (p<.05).   
Y-maze and Platform Recognition vs. Aβ Burdens.  No correlations 
were observed between Aβ burdens in the hippocampus and parietal cortex vs. Y-
maze percent alternations for Tg+/T cell mice or for all Tg+ mice combined (p=n.s.).  
Similarly, no correlations were noted between Aβ burdens and Day 4 or overall 
Platform Recognition Latencies for these groups of animals.  
RAWM vs. Plasma Cytokines.  A correlation matrix between plasma 
cytokine levels and RAWM performance measures was established for all mice, for 
Tg+ mice combined, and for both PBS recipient Tg+ mice and T cell recipient mice 
alone.  All correlations noted were negative (e.g. higher plasma cytokines associated 
with less RAWM errors).  For all mice combined, 9 negative correlations were found, 
including one between Block 3 Trial 5 errors and plasma GM-CSF levels (p≤.05).  
Negative correlations were also found between IL-1β levels and the following 
measures:  overall Trial 4 errors (p<.05), overall Trial 4+5 errors (p<.05), Block 1 
Trial 4 errors (p<.05), and Block 1 Trial 4+5 errors.  As for IL-1β correlations, the 
same negative correlations were also noted for plasma TNF-α levels:  overall Trial 4 
errors (p<.01), overall Trial 4+5 errors (p<.05), Block 1 Trial 4 errors (p<.005), and 
Block 1 Trial 4+5 errors (p<.05).   
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For all Tg+ mice combined, only 2 negative correlations were noted:  between 
IL-4 levels and overall Trial 5 errors (p<.05) and between IL-1β and Block 1 Trial 5 
errors (p<.05).  When considering only PBS recipient Tg+ mice, the only (negative) 
correlation noted was between IFN-γ and Block 1 Trial 5 errors (p<.05).  In sharp 
contrast, numerous negative correlations (13) were noted between levels of plasma 
cytokines in T cell recipient Tg+ mice and RAWM measures (Table 2).  IL-1α was 
found to correlate negatively with Block 3 Trial 5 errors (p<.05).  IL-1β was found to 
correlate negatively with overall Trial 4 errors (p≤.05) and Block 3 Trial 5 errors 
(p<.05).  IL-2 was found to correlate negatively with Block 3 Trial 4 errors (p≤.001).  
IL-4 was found to correlate negatively with overall Trial 4 errors (p<.05), as well as 
with Block 1 Trial 5 (p<.05) and Block 1 Trial 4+5 (p<.05) errors.  IL-12 was found 
to correlate negatively with both overall Trial 4 (p<.05) and Block 1 Trial 5 errors 
(p<.05).  Finally, TNF-α was found to correlate negatively with overall Trial 5 errors 
(p<.005), overall Trial 4+5 errors (p<.05), and Block 1 Trial 4+5 errors (p<.05). 
The strong negative correlations noted between RAWM measures and both TNF-α 
and IL-1β when considering all animals as well as T cell animals alone were not 
noted when looking at all Tg+ animals alone.  This would seem to indicate that both 
T cell and Tg- mice are driving these negative correlations, implicating plasma IL1-β 
and TNF-α levels as being particularly important in terms of RAWM performance.  
Other cytokines such as IL-4, IL-1α, and IL-12, which were only negatively 
correlated to RAWM performance when considering Tg+/T cell animals, may also 
have an impact.  However, the lack of such correlations for all animals combined  
   
Negative correlations (bold font) were noted for numerous measures when considering Tg+/T cell animals alone; correlations which did not exist when 
considering Tg+/PBS mice alone, or both groups of Tg+ mice together. (data not shown).   
 
 
 
 
 
 
 
 
 
 
 
 Overal Trial 4 Overall Trial 5 
Overall Trial 
4+5 
Block 1 Trial 
4 
Block 1 
Trial 5 
Block 1 Trial 
4+5 
Block 3 Trial 
4 
Block 3 
Trial 5 
Block 3 Trial 
4+5 
GM-CSF r    p 
0.057        
0.915 
0.345   
0.503 
0.203       
0.699 
0.456    
0.363 
0.239   
0.648 
0.452       
0.369 
-0.337   
0.514 
-0.354  
0.492 
-0.374    
0.466 
IL-12 r    p 
-0.613       
0.195 
-0 883   
0.020 
-0.765      
0.076 
-0.147   
0.781 
-0.858   
0.029 
-0.750      
0.086 
-0.170   
0.747 
-0.533  
0.276 
-0.393    
0.441 
IFN-γ r    p 
-0.234       
0.655 
-0 556   
0.252 
-0.402     
0.429 
0.369    
0.471 
-0.695  
0.125 
-0.322      
0.533 
0.108    
0.838 
-0.414  
0.415 
-0.183    
0.729 
IL-10 r    p 
-0.48         
0.335 
-0.582   
0.225 
-0.544     
0.264 
0.390    
0.444 
-0.692  
0.128 
-0.307      
0.554 
0.450      
0.37 
-0.273      
0.6 
0.071     
0.894 
IL-1α r    p -0.581       0.227 
-0.735   
0.096 
-0.674     
0.142 
0.185    
0.726 
-0.732   
0.098 
-0.458      
0.361 
-0.434     
0.39 
-0.820   
0.046 
-0.690    
0.129 
IL-1β r    p -0.806       0.053 
-0.681   
0.137 
-0.763     
0.077 
-0.307   
0.554 
-0.798  
0.057 
-0.797      
0.058 
-0.618   
0.191 
-0.813  
0.049 
-0.780    
0.067 
IL-2 r    p 
-0.515       
0.296 
-0.454   
0.366 
-0.497     
0.316 
-0.433   
0.391 
-0.411   
0.418 
-0.572      
0.236 
-0.972   
0.001 
-0.762  
0.078 
-0.929    
0.007 
IL-4 r    p 
-0.688       
0.131 
-0 854   
0.030 
-0.790     
0.062 
-0.278   
0.594 
-0.844  
0.035 
-0.815      
0.048 
-0.566   
0.242 
-0.761  
0.079 
-0.723    
0.104 
IL-6 r    p 
-0.235       
0.353 
-0.439   
0.384 
-0.464     
0.354 
0.499    
0.314 
-0.680  
0.137 
-0.235      
0.654 
0.367    
0.474 
-0.377  
0.461 
-0.031    
0.954 
TNF-α r    p -0.827       0.060 
-0 950   
0.004 
-0.892     
0.017 
-0.369   
0.471 
-0.790  
0.061 
-0.827      
0.042 
-0.437    
0.386 
-0.643  
0.169 
-0.591    
0.217 
Table 2.  Correlation matrix for RAWM errors vs. plasma Cytokine measures for Tg+/T cell animals.   
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would seem to indicate that they are not universally associated with behavioral 
performance in this task. 
Factor Analysis 
Factor Analysis of 13 post-infusion behavioral measures from RAWM, Y-maze, 
and Platform Recognition was performed to determine the underlying relationships 
between these measures/tasks (Table 3).  FA involving all 13 behavioral measures 
resulted in 11 of those measures loading on a common first factor, which accounted for 
58.2% of the total variance (a measure was considered “significant” for loading on a 
factor if it’s component loading value exceeded 0.65 for that factor).  Factor 1 was thus 
considered the primary cognition-based factor, as nearly all cognitive measures 
contributed to it.  The two Platform Recognition measures used in this analysis co-loaded 
in factors 1 and 2.  Only one RAWM measure (Block 1 Trial 5 errors) and Y-maze 
percent alternations did not load in the cognition-based factor 1.  Block 1 Trial 5 errors 
did not load in any factor, where as Y-maze percent alternations loaded alone in factor 4. 
Discriminant Function Analysis 
DFA was utilized to determine if behavioral performances of the three groups 
(Tg-, Tg+/PBS, and Tg+/T cell) could distinguish the groups from one another during 
post-immune cell infusion testing.  Both “direct entry” and “stepwise-forward” DFA 
methodologies were employed.  The direct entry method included all behavioral 
measures evaluated, while the “stepwise-forward” selects behavioral measures from the 
total number evaluated based on their contribution to the variance.  For each 
methodology, all 13 measures used in Factor Analysis were included.  Additionally, both 
   
Table 3.   Factor loadings of behavioral measures.   
 
Factor 
Variance 
(%) Post-Infustion Behavioral Measures 
RAWM: 
Overall Trial 4+5 Errors 
Overall Trial 4 Errors 
Overall Trial 5 Errors 
Block 1 Trial 4+5 Errors 
Block 1 Trial 4 Errors 
Block 3 Trial 4+5 Errors 
Block 3 Trial 4 Errors 
  Block 3 Trial 5 Errors 
Y-maze: 
  Arm Entries 
Platform Recognition: 
Overall Latency 
1 (58.2) 
  Day 4 Latency 
2 (12.3) Platform Recognition: 
Overall Latency 
    Day 4 Latency 
3 (9.6)  None 
Y-maze: 4 (8.7) 
  Percent Alternations 
RAWM: Did not 
load: 
- 
  Block 1 Trial 5 Errors 
 
 
 
 
 
 
 
 
 
 
 
Eight of nine RAWM measures loaded with Y-maze entries and two Platform Recognition measures in 
factor 1- the primary cognitive factor.  Both Platform Recognition measures co-loaded in factors 1 and 2.  
Only Y-maze alternations loaded in a separate factor (factor 4), whereas Block 1 Trial 5 RAWM errors did 
not load in any factor.  Percent of total variance explained by a given factor is indicated in bold type within 
parentheses. 
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 forms of DFAs were run using only the 11 measures that loaded on factor 1 of  Factor 
Analysis.  Results of these DFA’s are summarized in Table 4.  Direct entry DFAs, both 
for all 13 measures and factor 1 measures only, could not discriminate between the three  
groups based on their behavioral performance (p=.19; p=.48, respectively). In sharp 
contrast, the stepwise-forward DFA method (for both behavioral measures sets) was very 
effective in discriminating between Tg+/PBS mice and the other 2 groups.  When all 13 
behavioral measures were analyzed, RAWM Block 1 Trial 4+5 errors and  Platform 
Recognition Day 4 latencies were retained in step-wise forward DFA.  86% of Tg+/PBS 
animals were correctly classified by this analysis, whereas only 50% of Tg+/T cell mice 
and 60% of Tg- mice were correctly classified.  A similar pattern was noted for step-wise 
forward analysis of factor 1 behavioral measures, for which RAWM Block 1 Trial 4+5 
errors was retained.  88% of Tg+/PBS animals were correctly classified by this analysis.  
In contrast, only 48% of Tg+/T cell and 50% of Tg- mice were correctly classified by this 
procedure.  Thus, while step-wise forward DFAs were capable of discriminating between 
Tg+/PBS groups and the other 2 groups, this analysis could not effectively discriminate 
between Tg- and Tg+/T cell groups, indicating that behavioral performances in these 
latter two groups were too similar for distinction between them to be made. 
 
 
   
Table 4.  Summary of discriminant function analyses. 
 
Direct Entry Stepwise Forward Measures 
Significance: Significance: Measures Retained: 
All 13 *p < .01  RAWM Block 1 Trial 4+5 Errors 
  
N.S. 
  PR Day 4 Latency 
Factor 1 N.S. *p < .05  RAWM Block 1 Trial 4+5 Errors 
   
 
 
 
 
p-values are from Wilks’s λ.  * = significant for Tg+/PBS vs. both Tg+/T cell and Tg- groups. 
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Discussion 
 
General Summary 
 In the present study, we evaluated the behavioral and pathological effects of 
adoptive transfer of Aβ-sensitive immune cells into AD transgenic mice.  These cells 
consisted of spleenocytes and lymphocytes taken from Aβ-immunized, congenic wild-
type  mice. The cells were cultured to enrich for T cells prior to infusion into recipient 
animals. We determined that such an infusion of T cells led to reversal of working 
memory impairment and also improved basic mnemonic processing at a 1-1½ month 
post-infusion time point.  While overall no reductions in brain Aβ deposition were found, 
strong correlations between diffuse hippocampal deposition and RAWM working 
memory performances in T cell infused mice were noted, indicating that cognitive benefit 
was likely Aβ dependent.   
It is also important to note that cognitive benefit in immune cell infused animals 
was not accompanied by increases in plasma pro-inflammatory cytokines.  This would 
seem to indicate that a systemic inflammatory response was not evoked by adoptive 
transfer of immune cells into AD transgenic mice.  Results of our Neurologic Battery 
would seem to confirm this, with no differences noted between transgenic controls and T 
cell recipient mice.  Considering the lack of differences between transgenics noted in the 
Neuorologic Battery, as well as the presence of cognitive benefit extending over several 
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domains following only one immunotherapeutic infusion of T cells, such adoptive 
immunotherapy shows great promise for future human application in treating AD.  
Behavioral Results 
Immunotherapeutic techniques directed against Aβ have been tested in AD 
transgenic mice since 1999, however only a handful of these studies incorporated 
comprehensive behavioral testing of treated animals.   In 2000, Morgan et al. found that 
repeated immunizations with Aβ1-42 in Freund’s adjuvant over an 8 month period 
resulted in protection against impairment in the RAWM task for working memory, 
though the 15 month old APPsw+PS1 mice tested did take more trials to learn the task 
than non-transgenic controls. In 2003, Austin et al. found that short term (4 biweekly 
injections) administration of this same vaccine to aged APPsw+PS1 mice did not result in 
reversal of impairment in the RAWM task..  In a longitudinal study, Jensen et al. 2005 
reported that APPsw+PS1 mice immunized with Αβ1-42 from 2-16.5 months of age were 
protected against impairment in RAWM testing performed at both 5 and 16 months of 
age.  Thus it has been established that protection against impairment in RAWM can be 
incurred via active Aβ immunization in APPsw+PS1 mice.  However, it is also clear that 
repeated administrations over an extended time period are necessary to establish this 
behavioral benefit.  In the current study, we show that a single immunotherapeutic 
administration of Aβ-sensitive T cell results in improved RAWM performance at a 1 
month post-infusion time point.   
In pre-infusion RAWM testing, Tg+ mice were clearly impaired in working 
memory performance compared to Tg- mice, making significantly higher Trial 4+5 errors 
overall.  In post-infusion RAWM, Tg+/PBS mice maintained a poor level of working 
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memory performance, with significantly higher Trial 4+5 errors overall compared to Tg- 
mice.  In contrast, Tg+/Tcell mice were not significantly different from either Tg- or 
Tg+/PBS mice for this measure, indicating an overall improvement in working memory 
performance to a level between that of Tg- and Tg+ controls.  Indeed, for Block 1 of 
testing, Tg+/T cell mice performed identically to Tg- animals in Trial 4+5 errors, while 
Tg+/PBS mice made significantly more errors than either group.  Further demonstrating 
that improvement in working memory performance was present in Tg+/T cell animals, it 
was noted that these mice showed a significant learning effect from Trial 1 to Trial 4+5 
during the final block of RAWM testing.  This effect was not noted for Tg+/PBS mice for 
any block, whereas Tg- mice showed a significant learning effect for each block of post-
infusion testing. 
To further demonstrate the level to which Tg+/T cell animals were able to 
improve their working memory performances from pre-infusion levels, a block by block 
comparison of pre- vs. post-infusion RAWM errors was performed.  This analysis 
revealed an inability of Tg+/PBS animals to improve their performance for any block.  In 
contrast, Tg+/T cell animals did show significant improvements in this measure for both 
Block 1 and Block 2 of post-infusion testing.  One final analysis of the RAWM task 
comparing final block pre- vs. first block post-infusion also demonstrated this effect.  
Tg+/PBS animals significantly worsened their working memory performance following 
PBS infusion and a 1½ month hiatus from testing, whereas Tg+/T cell animals as well as 
Tg- animals maintained significantly low levels in post-infusion testing.  Post-infusion 
and pre-vs. post-infusion analysis revealed that overall and for each block of post-
infusion RAWM testing, Tg+/T cell animals displayed either an improvement in working 
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memory performance from pre-infusion performances, and/or an ability to perform at a 
level greater than that of Tg+/PBS controls.  In many cases, this performance level was 
identical to Tg- animals.  This benefit was most prominent during the initial phase of 
post-infusion testing, but was evident throughout the entire post-infusion treatment 
period.  Thus, post-infusion analysis confirms the potential for a single Aβ-sensitive 
immune cell infusion to reverse cognitive impairment in transgenic animals.  Trinchese et 
al. (2004) found impairment in APPsw/PS1 mice in RAWM at as early as 3-4 months of 
age, while our laboratory has found impairment at as early as 5.5 months (Jensen et al. 
2005) but has found no impairment at a 3 month time point (unpublished observation).  
These findings combined with pre- vs. post-infusion analysis from the current study 
confirm that the treatment effect noted above was a reversal of cognitive impairment, 
specifically in the domain of working memory. 
In the Y-maze task of spontaneous alternations, Tg+/PBS animals displayed 
significantly lower alternations than both Tg+/T cell and Tg- animals.  Therefore, it can 
be said that T cell infused animals were clearly protected against basic mnemonic 
processing impairment found in un-infused transgenic controls.  Thus Y-maze, which is a 
relatively insensitive task, was still capable of eliciting a treatment effect in 10 month old 
mice.  The results demonstrate how both working memory (RAWM) and basic 
mnemonic processing (Y-maze) benefited from T-cell infusion in Tg+ mice.  In early Y-
maze studies, Holcomb et al. (1998; 1999) found decreased Y-Maze alternations in 3-4 
month, 6 month, and 9 month old APPsw/PS1 mice, whereas other studies did not find 
impairment at multiple time points through 16 months (Arendash et al. 2001, Jensen et al. 
2005).  Thus, the direct treatment effect observed confirms that T cell infusion promotes 
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improved performance in the Y-maze task, but does not provide insight into whether this 
is due to prevention or reversal of impairment.  In 2004, Wilcock et al. showed that 3 
monthly infusions of anti-Aβ antibodies were required to see behavioral improvement in 
the Y-maze task in 22 month old Tg2576 mice.  The improved performance noted for this 
task in the current study occurred one month post-infusion of a single dose of Aβ-
sensitive T cells.  This again underscores the potential of this immunotherapeutic 
technique to provide cognitive benefit without numerous administrations. 
No differences were noted between treatment groups in Platform Recognition 
performance.  The relatively poor performance of all 3 groups compared to prior studies 
(Arendash et al. 2001, Jensen et al. 2005) may have resulted from Platform Recognition 
testing immediately following post-infusion RAWM.  All groups may have had difficulty 
adjusting to the new, working memory-independent strategy of this task.  However, it 
should be noted that, for all groups collectively, there was an overall learning effect, with 
significantly improved latencies from first to last day of testing.  
Importantly, no differences were found when comparing the Neurologic Battery 
results of Tg+/PBS and Tg+/T cell animals.  This would seem to indicate a lack of EAE 
(Experimental Allergic Encephalomyelitis) in T cell animals, which can occur following 
adoptive T-cell transfer (Kipnis et al. 2002).  However, differences noted between Tg+/T 
cell animals and Tg- animals may indicate potential for some hind-leg motor control 
difficulties in T cell animals, beyond those found in control Tg+ mice.  Future studies 
must look further into the effects of adoptive immunotherapy on neurological function to 
determine if these effects are consistent and, if so, to identify their cause. 
 
   
151 
 
 
Pathology 
No group differences were noted for 6E10 or Thioflavin S burdens in the 
hippocampus or parietal cortex, indicating no overall reduction in diffuse or compact 
(insoluble) Aβ depostion following T cell infusion into APPsw/PS1 mice.  Potential does 
exist for reductions in soluble Aβ levels, which would go a long way in explaining the 
behavioral improvement noted in Tg+/T cell animals.  Previous immunotherapeutic 
studies in AD models have found improved behavior associated with reduced insoluble 
Aβ levels (Janus et al. 2000, Wilcock et al. 2004).  Additionally, it has been noted in 
several studies that behavioral improvement can be independent of overall reductions in 
Aβ deposition (Morgan et al. 2000, Arendash et al. 2001, Jensen et al. 2005) following 
immunotherapy, as noted in the current study.  This may be due to reductions in soluble 
Aβ levels, as other immunotherapeutic studies have reported reductions in soluble Aβ 
levels in the CNS following immunization (Sigurdsson et al. 2001, Sigurdsson et al. 
2004).  Future studies must be conducted to analyze soluble forms of this peptide, most 
importantly the Aβ1-40 and Aβ1-42 isoforms, to determine if reduced soluble amyloid 
levels contribute to the cognitive improvement noted in Tg+/T cell animals. 
The lack of significant difference between Plasma cytokine levels in Tg+/T cell 
and Tg+/PBS groups suggests that T cell infusion into Tg+/T cell mice did not result in a 
sustained, global immune response.  Thus, cognitive benefit associated with such an 
infusion was found to occur independently of an enhanced systemic immune response, 
although strong correlations were evident between plasma cytokines and cognitive 
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performance (see below).  However, it should be noted that these cytokine measurements 
are for plasma only, and may not be indicative of regional brain cytokine profiles.  Future 
studies must be conducted to analyze brain specific cytokine levels to determine if this 
trend for reduced cytokine levels is carried over into the CNS following infusion of Aβ-
sensitive T cells.  Compared to Tg- mice, there was a trend for Tg+/T cell mice to display 
reduced plasma cytokine levels, with significance noted for IL-10, TNF-α, and GM-CSF 
vs. Tg- controls.  This reduction in cytokine levels may indicate an overall immune 
system inhibition by immune suppressive regulatory T cells (T regs), or down regulation 
of specific immune cell types by T helper cell subsets.  The lack of significance between 
cytokine levels in Tg+/PBS and Tg- animals suggests no overt immunological response 
to Aβ in Tg+ animals.  This may be indicative of an established immune tolerance to this 
human peptide, as would be expected for any peptide produced endogenously at high 
levels throughout the life of these mice.  In 2002, Town et al. found that APPsw mice 
immunized with Aβ1-42 displayed decreased IFN-γ and increased IL-10 plasma cytokine 
levels.  Levels of IL-2 and IL-4 were deemed immeasurable in this same study.  Based on 
these findings, the authors proposed that Aβ1-42 immunization elicited a Th2 biased 
response in APPsw mice.  Microglia and astrocytes are known to display increased 
expression of IL-1β, TNF-α, and IL-6 in the brains of Tg2576 animals, however this is 
not necessarily indicative of plasma levels of these cytokines (Benzing et al. 1999, 
Melhorn et al. 2000). 
Correlations 
Correlations to RAWM measures were limited specifically to hippocampal 6E10 
diffuse brain Aβ burdens when considering all Tg+ mice.  The majority of these 
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correlations were shown to be driven by the Tg+/T cell group however, as strong 
correlations also exist when considering only these animals.  Analysis with Tg+/PBS 
animals only showed correlations with hippocampal Thioflavin S compact brain Aβ 
burdens exclusively.  Thus it is clear that hippocampal Aβ burdens do have an impact on 
cognition, and diffuse hippocampal burdens seems to play the most important role 
following infusion of Aβ-sensitive T cells into AD transgenic mice.  Without such 
infusion, compact plaques seem to take on a more important role in determining level of 
impairment.   
Perhaps the best example of the overall correlation effect involved correlation 
data between Tg+ animals in RAWM Block 1 Trial 4+5 errors vs. hippocampal 6E10 Aβ 
burdens.  Clearly, Tg+/T cell animals drove this correlation, with 4 animals displaying 
low errors and low burdens, and 3 animals display higher errors and higher burdens.  In 
contrast, all but 1 Tg+/PBS animal displayed high errors with high Aβ burdens.  This 
correlation may also demonstrate one mode of action for T cell adoptive immunotherapy.  
Clearly the four Tg+/T cell animals with lower RAWM errors displayed decreased Aβ 
burdens, and it may be possible that these infused animals benefited behaviorally due to 
clearance of hippocampal diffuse Aβ, thus explaining why this measure was of particular 
importance.   
We have previously demonstrated that cognitive performance in a number of 
tasks can correlate with brain Aβ burdens in AD transgenic mice (Leighty et al. 2004, 
Gordon et al. 2001, Arendash et al. 2001b), though these correlations are not always 
present (Jensen et al. 2005).  When  present, correlations often involve the RAWM task, 
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although they can also involve Morris Water Maze and Platform Recognition (Leighty et 
al. 2004).  RAWM is a task for working memory, thus performance in this task is heavily 
hippocampus dependent.  This directly explains the cognitive benefit noted during Block 
1 of post-infusion testing in 4 out of 7 Tg+/T cell animals.  What these correlations do 
confirm is that both diffuse and compact Aβ burdens in the hippocampus can contribute 
to cognitive impairment in Tg+ animals, and also that modest reductions in diffuse 
hippocampal Aβ burden are associated with improved performance in the RAWM task. 
Several correlations were noted between RAWM measures and plasma cytokine 
levels when considering all animals.  Higher plasma cytokine levels correlated with better 
cognitive performance.  All but one of these correlations were between either IL-1β or 
TNF-α and RAWM measures.  These and several other correlations were also found 
when looking at Tg+/T cell animals alone, but not when looking at Tg+ animals 
combined or Tg+/PBS animals alone.  Clearly then, these negative correlations are being 
driven by both Tg- and Tg+/T cell animals.  These correlations were all negative (e.g. 
higher plasma cytokines with lower RAWM errors).  Therefore, it would seem that 
despite a trend for decreased plasma cytokine levels in Tg+/T cell animals, higher levels 
of individual cytokines (especially IL-1β and TNF-α) may play a role in improving 
cognitive performance capabilities.  It is interesting that the two key cytokines driving 
these correlations are pro-inflammatory cytokines which have been found to be over-
expressed by microglia local to Aβ plaques in transgenic models of AD (Benzing et al. 
1999, Akiyama et al. 2000).  In humans with AD, CSF levels of both cytokines are 
increased (Cacabelos et al. 1991, Tarkowski et al. 1999).  However, several lines of study 
suggest that while these cytokines are involved in the neuroinflammatory cascade of AD, 
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under situations of appropriate immune activation they may actually act beneficially in 
the CNS to reduce inflammatory damage (Correale and Villa, 2004). This may indicate 
that the actions of certain cytokine producing cells may be important in determining 
extent of behavioral improvement.  Once again, this emphasizes the importance of 
analyzing brain cytokine levels, and perhaps also quantifying levels of activated immune 
cells such as microglia, astrocytes and T cells that would contribute to production of 
these cytokines in the brain. 
Factor Analysis/Discriminant Function Analysis 
All but one RAWM measure loaded in Factor 1 of FA, as did both PR measures, 
indicating this factor as cognitively-based.  Stepwise forward DFA results for all 
behavioral measures as well as Factor 1 measures alone indicate that Tg+/T cell animal 
performances could not be separated from Tg- performances, whereas Tg+/PBS animal 
performance levels were poor enough that they were clearly distinguished from the other 
two, better performing groups.  Our laboratory has shown in the past that “stepwise 
forward” DFA analysis is capable of distinguishing not only between transgenic 
treatment groups and wild-type mice, but also between different strains of transgenic 
mice (Jensen et al. 2005, Leighty et al. 2004).  Thus, the lack of discrimination between 
Tg+/T cell animals and Tg- animals when applying this methodology across multiple 
cognitive measures strongly emphasizes the similar performance levels of these two 
groups.  This reinforces the hypothesis that infusion of Aβ-sensitive immune cells leads 
to normalization of Tg+ animal performances in RAWM to that of Tg- levels. 
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Proposed Mechanisms of Aβ-Sensitive T Cell Mediated Cognitive Improvement in 
APPsw/PS1 Mice 
Although the current literature is limited with regards to application of adoptive 
immunotherapy in neurodegenerative diseases, it is possible to speculate as to the 
mechanisms by which infused T cells could act therapeutically in a mouse model for AD.  
It has been shown that immuno-tolerance to Aβ is present in APP transgenic mice 
(Monsonego et al. 2001), and it is therefore necessary to administer Aβ vaccinations in 
adjuvant designed to activate the immune systems to elicit an effect.  One mechanism of 
action for Aβ-sensitive T cells infused into such an immuno-tolerant environment could 
be to break this tolerance and initiate an immune system-based clearance of Aβ from the 
CNS.  Neuroinflammation is thought to be a major contributor to the progression of AD, 
and is present to a large extent in AD mouse models.  A second mechanism for T cell 
action could be for regulatory T cells and/or Th2 cells to down-regulate this type of 
cellular-based neuroinflammatory response.  Finally, it is possible for T cells and the 
cells they activate (astrocytes, microglia etc.), provide neuroprotection via a number of 
mechanisms.   
Stimulation of the immune system against an endogenous ‘self’ peptide, Aβ   
T helper cells play a central role in determining the type of immune response elicited 
against a given immunogen.  Depending on the major sub-type of T cell involved in 
stimulating such an immune response against Aβ, it is likely that one of two reactions, 
either cellularly or humorally based, would be elicited against this peptide.  If Th1 T 
helper cells were the major contributor towards developing this reaction, a phagocytic 
immune cell activation would be anticipated.  This would potentially result in clearance 
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of deposited amyloid via phagocytic mechanisms, a mechanism of clearance found to be 
present in several active immunization studies in AD models (Das et al. 2003a, Das et al. 
2003b).  In the CNS, the primary phagocytic cells are the microglia, and thus such a 
reaction would most likely be associated with increased microglial activation in the areas 
of Aβ plaques (Wilcock et al. 2001).  While correlation data from the current study 
suggests that decreased diffuse hippocampal Aβ may mediate RAWM improvement in 
some T cell infused mice, no overall reductions in Aβ pathology were noted, indicating 
that this effect was not widespread in Tg+/T cell mice.  In futures studies, it will be 
important to determine to what extent microglia and other components of the cellular 
immune system are activated in the CNS of T cell infused mice. 
If following T cell infusion a Th2 biased response was elicited, in contrast to the 
cellular based response to Aβ promoted by Th1 cells, a humoral response would be 
anticipated instead.  This would be mediated by the ability of Th2 subset cells to 
stimulate B cells to produce antibodies, in this case antibodies specific to Aβ.  Based on 
the results of passive immunizations studies in models of AD (DeMattos et al. 2001, 
Wilcock et al. 2004), it is likely that such a humoral based immune response would also 
trigger the clearance of insoluble as well as soluble Aβ from the CNS via standard 
clearance mechanisms for antigen-antibody immune complexes.  A down-regulation of 
cellular immunity present in Th1-biased immune reactions would also be expected in a 
Th2-biased response, perhaps leading to decreased neuroinflammation as discussed 
below.  To determine if these effects were present in T cell animals, it may be beneficial 
to look at antibody titers and regional brain cytokine levels in future studies. 
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Overall down-regulation of the immune system, or of specific immune cells which 
may contribute to neuroinflammation.  
As previously mentioned, microglia and other cellular components of the CNS 
immune system may be down-regulated by the Th2 subset of T helper cells.  This would 
be especially beneficial in the Tg+ animal brain paradigm, in which immune cells such as 
microglia are perpetually activated by Aβ and Aβ associated neuronal damage.  Without 
the influence of regulatory cells, this form of activation may result in a state of “frustrated 
phagocytosis”, which results in production of neuroinflammatory mediators involved 
both in inappropriately activating other cells (such as astrocytes) and in directly causing 
damage/dysfunction in adjacent neurons (Streit et al. 2004, D’Andrea et al. 2004).  Th2 
subset cells could down-regulate such activation, blocking perpetuation of the AD 
neuroinflammatory cascade.  Regulatory T cells may also be involved in this process, 
down-regulating numerous immune cell types indirectly via de-activation of T-cells or 
directly via interactions with microglia and other components of the cellular immune 
system (Avidan et al. 2004).  Again, in future studies, looking at regional cytokine 
profiles would be beneficial to determine if such an effect was present.  Analysis of 
activated immune cell levels in the CNS would also be extremely beneficial in 
determining the exact actions of adoptively transferred T cells. 
Neuronal protection   
The potential for T cells to enhance neuronal health and protect against neuronal 
damage has been established in the current literature (Moalem et al. 2000, Benner et al. 
2004, Avidan et al. 2004).  This could involve a down-regulation of immune cells which 
instigate neuroinflammation (and resulting neuronal damage) as described above, or a 
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direct production and/or induced production of neuroprotective agents by astrocytes. 
Whether cells in the Aβ-sensitive T cell populations infused into Tg+ animals possess 
this potential is unknown, and analysis of either neurotrophic factor levels in the CNS 
would indicate if this is a viable method by which T cells provide cognitive benefit in 
these animals.  
Clinical Implication of T cell Study Findings and Proposed Future Investigations 
As with all immunologically based protocols, special care must be taken before 
application of such protocols in humans.  Further investigation into the potential for Aβ-
sensitive immune cells to promote EAE or other deleterious auto-immune type reactions 
is of the utmost importance, especially in lieu of the adverse effects resulting from 
clinical application of active Aβ immunotherapy (Orgogozo et al. 2003).  Additionally, to 
help elucidate the exact mechanism of cognitive improvement/protection provided by 
immune cell infusion, it may be beneficial for futures studies to look at the effects of 
infusion of specific T cell subsets into transgenic animals.  Analysis of the effects of 
these subsets on behavior and pathology, as well as added analysis of brain cytokines, 
activated immune cell (such as microglia) stains, and neurotrophic factor levels may 
provide insight into the mechanisms by which Aβ-sensitive immune cells improve 
cognitive-based performances in these AD transgenic mice.  In addition, a comparison of 
neuronal health and activity, especially in the hippocampus, in treated vs. untreated Tg+ 
animals may elucidate the exact mechanism by which cognitive performances in tasks 
such as the RAWM are being improved.  These and additional studies would be desirable 
before application of this procedure in humans is initiated.   
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From a methodological standpoint, Aβ-sensitive T-cells could be isolated from an 
AD patient’s blood, or even spleen, expanded in vitro and returned to the patient on a 
periodic basis.  While invasive, this process is not unprecedented and has been used in 
donor lymphocyte infusion protocols for many years (Kolb et al. 1995).  Only one 
infusion of T cells into AD transgenic mice was necessary to observe cognitive 
improvement 1-1½ months later in this study.  Future studies would be necessary to 
determine if these effects would continue without additional infusions.  If such follow-
ups were unnecessary or could be spaced far apart, this immunotherapeutic approach may 
prove to be less invasive than other immunotherapeutic approaches to AD (specifically 
active and passive immunization therapies against Aβ), which require regular injections 
of either Aβ in adjuvant or anti-Aβ antibodies.  Both of these forms of treatment have 
potential for side effects as elucidated by studies both in animal models of AD and, for 
active immunotherapy, in humans.  Both active and passive immunotherapeutic 
approaches have been shown to induce meningoencephalitis (Lee et al. 2005) due to 
excessive immune system activation.  This form of inflammation may not be present 
following a single infusion of Aβ-sensitive T cells independent of adjuvant.  Findings of 
reduced levels of cytokines in the plasma of T cell infused mice would seem to suggest 
that inflammation such as that noted in human active Aβ immunization trials is not 
present, though further work will confirm or refute this hypothesis.  Thus, adoptive 
immunotherapy may provide a means of providing long term cognitive benefits in AD, 
with decreased potential for negative side-effects. 
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